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TERMS AND ABBREVIATIONS
M enopause:
Perim enopause:
Postm enopause:
Postm enopausal:
Estrogen:
Progesterone:
Ovariectomized:
Sham:
Luteal phase: 
Follicular phase: 
Estrus:
Diestrus
Proestrus:
Metestrus:
Negative allesthesia: 
Hyperphagia:
Hypophagia:
Hyperplasia:
TERMS
cessation of the m enses
begins at age 35 with declining estrogen levels
years beyond m enopause
no menstrual period for 12 months
female sex hormone dominant in follicular phase of 
menstruation
female sex hormone dominant in luteal phase of 
menstruation
surgical removal of the ovaries
surgery without the removal of the ovaries
12-14 days following ovulation
12-14 days prior to ovulation
recurring period of maximum sexual receptivity in 
most female mammals
interval between periods of estrus
period immediately following estrus
period following estrus and preceding diestrus
hunger or appetite
hunger or increase in appetite and food 
consumption
satiety or decrease in appetite and food 
consumption
build-up of the endometrial lining
x
ABBREVIATIONS
BW: Body weight
OV: Ovariectomized
S: Sham surgery
E: Estrogen or Estradiol
P: Progesterone
H Hormone
PRO: Protein
CHO: Carbohydrate
C: Chocolate
FAT: Fat
g: Grams
BMI: Body Mass Index: weight in kilograms divided
height in meters (squared)
kcal: Kilocalories
HDL: High density lipoproteins
Choi: Cholesterol
LH: Luteinizing hormone
FSH: Follicle stimulating hormone
GnRH: Gonadotropin-releasing hormone
HRT: Hormone replacement therapy
CHD: Coronary heart disease
A B ST R A C T
Hormone replacement therapy (HRT) is chosen by a growing segm ent 
of the postmenopausal population. Mid-life body weight gain is perceived to 
increase further with exogenous HRT. To examine hormonal effects on caloric 
intake (Cl), carbohydrate (CHO), FAT, protein (PRO), chocolate and body 
weight (BW) in a  female model, Sprague-Dawley postbreeder (n=55) rats (10 
mos., 10 litters of pups) were ovariectomized (OV) and implanted with 17 p 
estradiol (E) and/or progesterone (P), or placebo in three separate studies 
(phases) of 10 days each. Uterine weights (p=.0001) and radioimmunoassay 
confirmed hormonal bioactivity. The sham (S) group with placebo implant was 
used for comparison.
In phase I, 3 food cups containing CHO, FAT, and PRO were presented 
ad libitum to all treatments. Estrogen decreased the rate of body weight gain 
(p=.001) compared to OV, P, and S with no significant differences in caloric 
intake (trend of estrogen p=.052). In phase II, all except S received 4 food 
cups; 2 CHO choices, (sweet, AIN 76 and nonsweet AIN 93), FAT and PRO. 
The body weight of the P and S groups compared to OV (p=.009) in phase II 
adapted and did not continue to increase. OV produced a  carbohydrate 
appetite for both SW & NSW (p=.007), E&P chose 3 times more SW than NSW 
(p=.001). For phase III 4 caloric levels of chocolate were added (except for S). 
Chocolate was consumed at 40% to 53% of total caloric intake with or without 
HRT with reduced nutrient dense macronutrient consumption. Thus access to 
chocolate eliminated both the reduced rate of weight gain caused by E (phase 
I) and the body weight adaptation by P in phase II. Variations in % fat intake 
(40% to 60%) did not result in treatment differences in body composition
(p=.0945). The OV group which consumed the most calories from 
carbohydrate (p=.001)t gained the most overall BW (p=.001). The rats 
consuming the most fat (S 57%) gained the least amount of body weight 
(p=.001). Caloric conversion ratios (weight gain/by caloric intake x 1000) 
varied among treatments (p=.003). Additional research on the metabolism of 
the postm enopausal female taking hormone replacement therapy is needed.
CHAPTER 1: INTRODUCTION
There are 470 million women aged 50 years and older living in the 
world today (World Health Organization [WHO]: World Health Statistics 
Annual, 1990). These women are older than the average age of natural 
m enopause throughout recorded history. Only 50 years ago, even in 
developed countries the average woman did not live to be 50 years of age. 
On a global basis, there are large populations of women for whom the risks of 
estrogen deficiency are undefined. The largest potential benefit of estrogen 
replacement therapy is the prevention of heart disease, the major cause of 
death in the female. In countries with a relatively high risk of heart d isease, 
current studies suggest that estrogen reduces that risk by 50% (WHO, 1990). 
Due to recently reported clinical trials showing the cardioprotective effects of 
hormone replacement therapy, a  large number of women in the USA and 
other developed countries may be prescribed extended estrogen replacement 
therapy (HRT) to reduce cardiovascular disease (The Writing Group for the 
PEPI Trial, 1995). Very little is known about the effects of exogenous 
hormones on energy balance in women. The common perception is that they 
may increase body weight (personal interviews with OB/GYN physicians).
Between puberty and menopause, serum estrogen and progesterone 
levels vary throughout the menstrual cycle. The follicular phase is estrogen 
dominant with high concentrations of estrogen and low progesterone levels. 
During the luteal phase, the progesterone levels rise to a degree that neither 
hormone is dominant. During pregnancy, levels of estrogen and progesterone 
rise steadily until they reach a  plateau weeks before delivery. Circulating 
estrogen levels begin to decline in the perimenopausal years. At m enopause,
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the level of estradiol, produced primarily by the ovary, falls and is replaced by 
a less active estrogen, estrone, produced primarily by conversion of 
androstendione in adipose tissue. After the m enopause there is little further 
decrease in endogenous estrogens with advancing age. Progesterone 
appears to decline at the sam e rate a s  estrogens. There is a  w idespread 
perception among women that this signal of m enopause is responsible for 
weight gain after age 50. This belief is held both by women who are already 
overweight when they reach menopause, as well a s  those whose weight is 
normal prior to menopause.
A recent report by Willett, et al., (1995) at the Nutrition Center at Harvard 
University School of Public Health is being debated for validity. They report 
that obesity is a  major risk factor for a variety of medical conditions: 
cardiovascular disease, hypertension, diabetes mellitus, reproductive cancers, 
arthritis, and kidney disease, and that if m enopause is found to accelerate 
weight gain among women who are already obese and at medical risk, then 
steps need to be taken prior to the m enopause to minimize its impact on 
weight gain among those who are most vulnerable. Body weight m aintenance 
to reduce risks is prudent however, often this kind of reporting can create 
negative health behaviors. The rates of anorexia nervosa and bulimia are 
increasing. We see  the impact of this concept in the fact that $33 billion is 
spent yearly on weight control in this country (Atkinson,1990). Low fat diets 
and body weight reduction in the female have become national obsessions.
Therefore, the issue of whether menopause, age or hormone 
replacement therapy provokes weight gain must be examined critically. It is 
important to know what effect hormone replacement has on food choices and
weight gain. Due to the current em phasis on thinness and low fat diets (Ley, 
et ai, 1992), the female often resists any involvement in exogenous agents that 
could cause body weight gain regardless of the potential positive effects.
Som e reports in the early 1990s on the effect of obesity on 
cardiovascular risk in women (n=115,886) show that after adjusting for age  
and smoking, the risk is 3.3 times higher in women with a  body m ass index 
(BMI) of >29.0 compared to a  BMI of <21.0 for non obese women. These 
authors have concluded that the risk of coronary heart disease (CHD) in 
middle-aged women increases even among those who were only moderately 
overweight (Manson, Willett, & Stampfer, 1995). The priority of body weight 
seem s to supersede all other concerns. Therefore, if the female feels that 
hormone replacement can cause body weight gain she may decline its use or 
fail to comply with the physician’s prescription. Recent reports have shown 
that compliance drops to 8% after three years and that 50% of the fem ales 
given the prescription for hormone replacement therapy (HRT) never have the 
prescription filled (Lerner, 1995).
Health implications surrounding body weight and HRT are also relevant 
because it is known that obesity increases the risk of breast cancer in 
postm enopausal women (Vatten, & Kvinnsland, 1990; Sellers, et al., 1992; 
Troisi, 1995). The dilemma of taking HRT is compounded if the perception 
also exists that the protective effect will be offset by the increased weight gain. 
M enopause is thought to be associated with a shift to upper body adiposity, 
which may be related to increased risk for cardiovascular disease, diabetes 
mellitus and breast cancer. Endometrial cancer has been strongly associated 
with obesity in postmenopausal women (Folsom, et. al.,1989). Unlike breast
cancer, it is linked to the amount rather than the distribution of fat stores. The 
issue of whether hormone replacement therapy initiates additional body 
weight gain should be scientifically measured and reported. At present, 
reports are not conclusive.
The positive effects of HRT are evident. However a recent report on the 
negative side effects of hormone replacement therapy stated that 50% of the 
women for whom hormone replacement medication had been prescribed had 
discontinued taking their medication in under 1 year. Earlier publications have 
cited a wide range of compliance problems, and the overall rate of 
discontinuation is surprisingly high. Among the list of negative side effects are 
persistent bleeding complications, severe mood changes and lack of 
adaptation and response to manipulation of therapy programs. Body weight 
gain and an increase in abdominal fat and enlarged breasts are often reported 
to physicians (Lemer, 1995). Many of the early complaints occurred when 10 
mg of progesterone was the accepted dosage to maximally decrease the risk 
of reproductive cancer. Current Food and Drug Administration (FDA) clinical 
trials are using 2.5 continuous or 5 mg cyclically of progesterone combined 
with .625 mg of estrogen. The 10 mg dosage is no longer recommended. The 
newest combined levels are being tested for effectiveness against 
osteoporosis, heart disease with maximum endometrial protection. These 
trials will provide the “Guidance of Clinical Evaluation of Combination 
Estrogen/Progestin-Containing Drug Products Used for Hormone 
Replacement Therapy of Postmenopausal Women.” The earliest reports by 
leaders in the field, state that in clinical trials the “new” drugs should (a) initially 
compare the rate of endometrial hyperplasia in the treated group to that in a
placebo group, (b) report the lowest progestin dose which is protective 
against endometrial hyperplasia, (c) establish the minimum effective dose of 
a  specific progestin for any given dose of a  specific estrogen (Grady & 
Cummings: 1995, Andrews, 1995, Gambrell, 1995, FDA HRT Working Group, 
1995). Perhaps these new guidelines will correct earlier misconceptions, 
decrease  negative physiological side effects, and ultimately increase 
compliance rates. However, when the perception of increased body weight is 
one of those side effects, the problem is often greater to overcome. More than 
vanity is at stake. According to the National Institute of Health, up to one third 
of all Americans are overweight, and they spend more than $30 billion per 
year in their efforts to trim the fat (Barinaga, 1995).
The current emphasis on dietary fat intake has created a  national 
paranoia regarding anything that might trigger a  fat appetite. Dietary fat intake 
may not be a s  strongly linked to a  number of nutrition-related disorders, 
including obesity, heart disease and cancer, a s  earlier believed. The 
consumption of fat may be related to its palatability, high energy density, and 
ultimately positive physiological effects. Additional research is needed to 
understand how the sensory qualities of fat and individual differences in 
preferences for dietary fat influence human food intake and body composition 
and health related implications (Rolls, 1992). Changes in food intake during 
aging may also change the nutrient intake patterns related to the process of 
aging, not debilitating d iseases (Kimura, 1992). Is there a  chance that the 
appetite can be trusted and that moderate amounts of fat intake daily could 
again be considered a healthy choice? Is there hope that compliance to a
cardiovascular regime would be followed if women knew the body weight 
consequences of HRT? This author believes more information is needed.
This study was designed to examine hormonal effects on macronutrient 
food choices reflected in caloric intake and body weight. The metabolic 
implications within an aging animal model in a  controlled environment may 
provide new information with potential implications for the mature human 
female. The purpose of this study was to examine patterns of caloric intake, 
macronutrient composition, and body weight gain in the female rat model 
(postbreeder) a s  affected by exogenous 17 (3 estradiol (E) and/or 
progesterone (P), following ovariectomy. These are the hormones most often 
prescribed by physicians to treat menopausal symptoms. It is hoped that the 
study will yield data and provide new information to help understand how 
ingestive behavior, specific appetites, hunger motivation and body weight vary 
in relation to female sex hormones, following hysterectomy or natural 
m enopause in mature women. This research design provides a  controlled 
method of examining the effects of female sex hormones E, E&P, and P on 
food intake and body weight through administration of exogenous estrogen 
and progesterone in the retired breeder female rat(s) following ovariectomy.
PURPOSE AND OBJECTIVES 
The overall purpose is to identify and quantify the effects of exogenous 
female sex hormones E, E&P, and P on food intake in ovariectomized 
postbreeder female rats. The specific objectives of the project are to:
1. Evaluate the effects of female sex hormones E, E&P, and P on total 
caloric intake and body weight gain.
2. Measure the effects of female sex hormones E, E&P, and P on nutrient 
composition (fats, carbohydrates [sweet and nonsweet] and proteins) of 
ad libitum food intake.
3. Measure the effects of female sex hormones E, E&P, and P on food 
choices of chocolate with high fat/high sugar, high fat/low sugar, low 
fat/high sugar and low fat/low sugar content.
4. Measure bioactivity of the hormones by assessing serum hormone 
levels of E, P and testosterone and m easure cholesterol, HDL 
cholesterol, organ weights, fat content of livers and total body 
composition.
CHAPTER 2: REVIEW O F LITERATURE
Human health is a  complex and multidetermined issue, influenced by a 
wide variety of factors: physiological, biochemical, nutritional, psychological, 
environmental, and social (Rodin & Salovey, 1989). Women’s  health is a  
priority of the 218t century. A number of health concerns are unique to women. 
Even for health issues that affect both women and men, most research has 
been limited to male subjects, leaving a  large gap in our knowledge b ase  
concerning women’s health.
The 1988 Surgeon General’s  Report on Nutrition and Health reports 
obesity to be the nation's number one nutritional problem (Public Health 
Service, 1988). The Healthy People 2000 (U.S. Printing Office, 1990)
document reports that for 2 out of 3 Americans who neither smoke nor drink, 
eating patterns may shape their long-term health prospects more than any 
other choice. Due to increased longevity, the average U.S. woman will spend 
one-third of her life a s  a  postmenopausal individual (Greendale & Judd, 1993). 
Recent census data from the U.S. indicates that in the 1990s the number of 
women above the age of 50 years will approach 40 million, and that a 50-year- 
old has a  30 year projected life-span. The quality of life during these years 
has been shown to be improved through hormone replacement therapy. 
Recently the results of the Postmenopausal Estrogen/Progestin Interventions 
(PEPI) study were reported revealing cardioprotective effects of hormone 
replacement therapy (The PEPI Writing Group, 1995). However, due to 
misconceptions regarding its implications to body weight gain many women 
are not choosing to take hormone replacement therapy and are therefore
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depriving them selves of the advantages provided by its cardiovascular 
protective effects (Barrett-Conner, Bush, 1991).
MENOPAUSE AND POSTMENOPAUSAL THERAPY
In the perimenopausal woman, estrogen and progesterone levels 
decrease  and luteinizing hormone (LH) and follicle stimulating hormone (FSH) 
becom e elevated, indicating the approaching m enopause. The ovarian 
follicles grow in response to FSH. The estrogen produced in turn decreases 
delivery of gonadotropin-releasing hormone (GnRH). The decrease of GnRH 
then suppresses FSH and LH. As the ovaries age during natural m enopause, 
the follicle store is depleted and estrogen production declines (Block, et al, 
1952). In postmenopause, the depleted follicular status is generally the sam e 
regardless of the age at which m enopause occurs. Without estrogen 
feedback, GnRH increases and, thus, FSH and LH rise substantially (Utian, 
1978). Levels of FSH increase 10-20 times and LH three times within 1 to 3 
years after m enopause. These high levels are conclusive proof of m enopause 
for a  woman of menopausal age. In the postmenopausal woman, the m ean 
daily level of estrogen production falls from 50-500 pg/d to 5-10 ng/d (for men, 
estrogen levels are  2 to 25 pg/day, equal to the urinary estrogens of a  woman 
during the first week of her menstrual cycle). These estrogens result from the 
conversion of adrenal steroids (such a s  androstenedione) to estrone and 
estradiol. Levels of androstenedione post-menopause, however, are only half 
those prior to menopause. Testosterone levels do not decline significantly and 
may even rise in the postmenopausal woman (Zichella, 1993).
Symptomatic menopausal women who experience hot flashes, night 
sweats, sleep disturbances, mood disturbances, impairment of memory and
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concentration, and muscle and joint pains with or without lower genital tract 
atrophy may actively seek hormone replacement therapy (Marsh & Whitehead, 
1992). The safety and efficacy of a daily combination of micronized estradiol 
(E2) (0.7-1.05 mg) and progesterone (200-300 mg) were evaluated in ten 
m enopausal women with moderate to severe vasomotor symptoms and/or 
vaginal atrophy over a  12-month study interval. Resulting evidence revealed 
symptomatic improvement, minimal side effects, an improved lipid profile, and 
am enorrhea without endometrial proliferation or hyperplasia in m enopausal 
women (Hargrove, et. al., 1989). The micronized form of progesterone is 
extracted from a  natural source such as soybean or yams and was shown in 
the PEPI investigation to be the most effective form of progesterone (The PEPI 
Writing Group, 1995). Currently, the most widely used exogenous female sex 
hormones by postmenopausal women are Premarin® and Provera®. The 
decision to utilize these or other exogenous forms of exogenous female sex 
hormones generally occurs during the perimenopausat period when 
symptoms can intensify and alter the quality of life a s  previously mentioned.
Physiologically following the perimenopause, menstrual cycles cease  
and the secretion of steroid hormones and gonadotropin changes. 
Postm enopausal levels of circulating estradiol are lower than levels seen  
during the menstrual cycle (Judd, Judd, & Lucas, 1974). The major source of 
estradiol becom es the peripheral conversion of estrone and testosterone. In 
contrast to the ratio seen in premenopausal women, postm enopausal estrone 
levels are higher than estradiol levels. Postmenopausal estrone is also 
derived from the peripheral conversion of androstenedione and testosterone. 
Small amounts of progesterone are made by the adrenal gland. After
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m enopause, androgens do not change uniformly. Androstenedione, the 
principal ovarian androgen, is reduced by about 50%. The adrenal gland 
contributes 80% of the postmenopausal androstenedione, while the ovary 
continues to produce 20% (Chang & Judd, 1981).
Monitoring endogenous production so that exogenous dosages can be 
individually prescribed would appear to contribute valuable information to the 
female and her physician. However, existing tests are expensive and can 
often be unreliable. Most postmenopausal hormone therapy is intended to 
increase the blood levels of estradiol. The hormone progesterone is not 
normally produced at all in postmenopausal women. When progesterone is 
given to menopausal women (mainly for women with an intact uterus) it is 
primarily used to protect the endometrium (Bass, Westhoff, & Bush, 1995).
Currently oral forms of estrogen and progesterone, Premarin® and 
Provera® in the form of tablets, are the most widely used exogenous female 
sex hormones. With Premarin® the standard human dose for estrogen 
replacement therapy is 0.625 mg daily. It protects against postm enopausal 
osteoporosis (Type I) and cardiovascular disease in the majority of 
postm enopausal women (Stanczyk, et. al, 1995). The annual rate of 
endometrial hyperplasia (excessive proliferation of normal cells) at this dose is 
estimated to be between 7% and 15%. With Provera®, the most widely 
prescribed human progestational agent for use in conjunction with estrogen 
replacement therapy dosages vary from 2.5 mg, 5 mg and 10 mg. The 
regimen that is most convincingly shown to prevent hyperplasia has been 10 
mg at days 13-28 of each cycle. This above described treatment is most
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generally prescribed by the physician following either surgical or natural 
m enopause (Grady & Cummings, 1995).
While these exogenous female sex hormones have positive 
cardioprotective effects, they have also been reported to increase 
macronutrient food intake and thus increase caloric intake (Wade and 
Schneider, 1992). More recently it has been reported that the addition of 10 
to 15 lbs. of body weight gain has been shown to occur when circulating 
estrogen levels begin to decline in the perimenopausal years (Wing, 1992; 
Troisi, et al, 1995). Physiologically, perimenopause is a  time of erratic 
menstrual periods prior to m enopause between the ages of 35 and 45. 
Estrogens have numerous actions on several biologic systems. Such systems 
include lipid metabolism, coagulation parameters, and blood pressure.
The effect of hormone replacement therapy on carbohydrate 
metabolism in menopausal women has been reviewed by Notelovitz and 
Tonnessen (1993). Early markers of negative effects were short term with no 
effects on body weight increase. Estrogen treatment was shown to have a bi- 
phasic effect; abnormal glucose tolerance with a  normal insulin level 
commonly found within 3 months of treatment, followed by normalization of the 
glycemia when treatment is extended beyond one year. Progestogens have 
adverse short-term effects on carbohydrate metabolism and on lipid and 
lipoprotein profile, lowering the ratio of high-density lipoprotein: low-density 
lipoprotein (HDLLDL) cholesterol compared to unopposed estrogen 
replacement therapy (ERT) (Gambrell, 1995).
Longer term trials of more than I year, including the recently published 
PEPI trial ( The PEPI Writing Group, 1995), indicate that time modifies these
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effects. The duration of treatment was concluded to be important. This w as 
first commented upon by diPaola, Robinson and Nicholson (1970), who noted 
that with estrogen treatment most of the abnormal glucose tolerance tests 
occurred between the first and third months of treatment and decreased  
thereafter until the ninth month, by which time normal blood glucose levels had 
returned. Therefore those who experience early appetite shifts may find that 
with time normalization occurs.
In extreme cases  the profile of endogenous female sex hormones can 
be monitored, however in the population dosages are generally based on 
symptomology provided through patient communication with her physician. 
Plasma levels of FSH, LH and estradiol were m easured serially in eleven 
prem enopausal patients before and after hysterectomy. One week after the 
operation an incremental dosage regime of conjugated estrogens in tablet 
form was commenced on the basis of two weeks of therapy with each dose 
interspersed with two weeks without therapy. FSH, LH and estradiol levels 
were measured at the end of each period with and without therapy. Estradiol 
levels fell within 24 hours of operation while FSH and LH levels rose 
gradually. In only one instance did conjugated estrogens succeed in reducing 
FSH to premenopausal levels, and that was at a  dosage of 2.5 mg. It should 
therefore be noted that usual conjugated estrogen treatment after surgical 
m enopause does not represent physiologic “hormone replacement therapy,” if 
defined a s  the dosage to maintain premenopausal circulating concentrations 
of reproductive hormones (Utian,1978; Lerner, 1995).
Additional physiological studies in postmenopausal women are 
needed. An early study by Notelovitz (1982) was conducted to examine blood
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pressure and body weight of postmenopausal women after one year of 
estrogen-progestin therapy. Twenty naturally menopausal women received 
either 0.625 or 1.25 mg conjugated estrogens with 10 mg 
medroxyprogesterone acetate for one year. Eighteen women of similar age 
and m enopausal status were followed for the sam e time period with no 
treatment. Blood pressure and body weight were a ssessed  at baseline, six 
months, and one year. No significant changes in blood pressure or body 
weight occurred in either group nor were there any treatment-related 
differences between the groups. More recent data (The PEPI Writing Group, 
1995) indicate preliminarily no significant differences in body weight gain in 
postmenopausal females taking hormone replacement therapy (n=875) over a  
three year study. This data is expected to be reported in detail in later 
publications.
Few studies have examined in-depth the implications of female sex 
hormones on food intake and body weight. Many of the earlier studies were 
conducted on normally cycling younger females. One such recent study 
examined the changes in dietary intake, urinary nitrogen and urinary volume 
across the menstrual cycle in women confined to a  metabolic unit, These 
subjects were maintained at a  constant activity level, and fed an ad libitum, 
rotating, staff-weighed diet. No significant changes in intakes of energy, 
protein, and fat occurred throughout the menstrual cycle (Fong & Kretsch, 
1986).
One of the few current reports on postmenopausal women utilized a 
written survey to examine body weight gain in m enopause (Wurtman, O’Leary,
& McDermott, 1992). This survey of free living subjects (n=490) asked for
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reports on changes in body weight, food intake and activity levels in the early 
postm enopause. The majority reported weight gain since the onset of 
m enopause, regardless of whether m enopause was natural or surgical, and 
whether the subjects were obese or nonobese prior to m enopause. This 
report revealed that weight gain occurred among 64% of the women who were 
normal weight prior to m enopause and among 96% of the women already 
obese prior to m enopause. The traditional perceived causes of weight gain: 
increased caloric intake, decreased activity, did not seem  related to weight 
gain in the women involved in the study. Women who were not obese prior to 
m enopause gained an average of 10-15 lbs; women who were obese gained 
an average of 21-23 lbs. The National Health and Nutrition Examination 
Survey (NHANES III) study does not currently report body weight param eters 
in this segm ent of the population. A $625 million study entitled “The Women’s 
Health Initiative” is presently being conducted charting body weight changes 
over a  15 year period. These results should provide much of the missing 
information (Healy, 1993). The measurement of fat intake and body weight is 
included in the experimental design. Reports should be available in 2010.
A research study on body weight increase in 290 women w as recently 
conducted (Wing, 1992). The study reported that age, and not m enopausal 
status, w as shown to be the cause of body weight increase. Other literature 
confirms that the hormonal changes in m enopause, are associated with 
changes in body composition and fat distribution. With time, the 
postm enopausal female decreases in lean body m ass and increases in fat 
m ass (Young, et. al., 1963). Ley and colleagues (1992) investigated the 
differences in body composition and regional fat distribution among men and
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pre-and postm enopausal women. Using dual-energy X-ray absorptiometry 
(DEXA), they found that postmenopausal women had 20% greater fat m ass 
than prem enopausal women. An increase in the percentile of abdominal fat 
during early m enopause also was reported (Haarbo, et al., 1991). However, 
the latest information (Troisi, et al., 1995) shows a  change in distribution to be 
more pronounced than percentage of body fat changes, and that waist to hip 
ratios were significantly lower in postm enopausal women taking exogenous 
female sex hormones.
The National Research Council Committee on Diet and Health: 
Implications for Reducing Chronic D isease Risk, reports that these  shifts in 
body fat distribution in extreme degrees of obesity increase the risk of coronary 
heart disease. Shifts in upper body fat has been shown to be an indicator of 
the predisposition to cardiovascular disease and diabetes in the female. A 
more important fact which involves a  greater percent of the mature population 
are the modest degrees of overweight, and the implications on risk 
assessm ent. The issue of moderate body weight gain has been distorted by 
the popular press and has been used synonomousiy with obesity. It should be 
noted that moderate body weight gain has also been associated with 
increased immunity and longevity (Bouchard, 1995).
HORMONAL IMPLICATIONS ON HEALTH AND DISEASE
The issue of body weight, fat intake, longevity and subsequent 
implications on morbidity as reported in the current media has caused national 
concern. Dr. Richard Atkinson, president of the American Society for Clinical 
Nutrition stated in a  recent report that $33 billion dollars were spent on weight 
loss in this country last year. Research surrounding the segm ent of the
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population incurring these expenses should be conducted. This manipulation 
of the public in the U.S. is not seen  globally. A French study showing higher 
national levels of fat consumption but lower incidences of heart disease is one 
example (Criqui & Ringel, 1995). The mission statement of the newly formed 
Office of Research on Women’s  Health shows that research surrounding 
prevention, diagnosis, and treatment of illness and disease conditions in 
women should be conducted. These studies may reveal a  very different profile 
than is currently perceived in this country.
Current reports correlate increased fat intake and implied increased 
body fat stores with disease states. These may not be confirmed in future 
research. Age and genetics may be the primary reasons for body weight 
increase. The transition from prem enopausal to postm enopausal status has 
been related to an increase in coronary heart disease risk. An additional fact 
often not mentioned in mortality studies Is that “reason for death” on coroner’s 
reports in the past only included 4 categories, and heart disease was listed 
first. Mortality records in this country may reflect skewed bias in favor of heart 
disease for this reason. The effect of weight changes on coronary d isease  risk 
factors in a  population-based sample of 485 middle-aged women spanning 
three years (Wing, et al., 1991) revealed that weight gain was significantly 
associated with increases in blood pressure and levels of total cholesterol, 
low-density lipoprotein cholesterol, triglycerides and fasting insulin. However, 
it should be noted that these increases were associated primarily with age. 
Aging and m enopause are natural phenomena which should be considered 
and correlated statistically a s  these results are reported. These physiological 
param eters are not surprising.
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The correlation between weight change and coronary heart d isease  
(CHD) in women was recently presented (Willett, et al., 1995). The 
researchers assessed  the validity of the 1990 U.S. weight guidelines for 
women. The results show that in a  follow-up of the Nurses Study (total of 
115,818 women 30 to 55 years of age without a  history of coronary heart 
disease), that only (1,292) 12% cases of coronary heart d isease were 
ascertained. These data which were analyzed after controlling for age, 
smoking, menopausal status, postmenopausal hormone use, and parental 
history of CHD, revealed that the women who gained weight within the BMI 
range of 18 to 25 kg/m2 from 18 years of age were strongly predicted to 
develop CHD. Willett, et al. report that higher levels of body weight within the 
“normal” range, a s  well a s  modest weight gains after 18 years of age, appear 
to increase risks of CHD in middle-aged women. These data are currently in 
question. National averages show that only 12% of the population is presently 
affected, and that baseline data calculated from body weight at the age at 18 
may not reflect meaningful information.
Further, Willett et al. reported that current recommended weight 
guidelines may be falsely reassuring to that segment of the population of 
women older than 35 years who fall within those guidelines. The report states 
that som e risks of CHD could be avoided if body weight guidelines were 
lowered. This report may cause unwarranted alarm, and create the mental 
stimulation for the astronomical $33 billion spent on weight loss a s  mentioned 
earlier by Dr. Atkinson. Further increases in anorexia nervosa and bulimia 
may be seen  as the result of the information reported by Willett, et al. In all 
fairness, it should also be noted and reported that 88% of the women did not
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suffer from the reported cardiovascular weight related implications. The 
pattern of alarming 100% of the population when 10-15% suffer from a  health- 
related problem has become the norm in this country and is often used to 
market high cost food items. This form of marketing can be termed a 
manipulation of the health conscious aging American and has become a 
major source of income for vendors. The scientific accuracy upon which these  
claims are m ade should be questioned and examined further.
The Center for Science for the Public Interest may be the source of the 
current perceptions and misconceptions on fat which are being m anipulated 
and used for marketing ploys in the U.S. population. Recently a report 
revealed the self-selected contents of the refrigerator at the Center a s  being 
high in fat for its employees. Clearly the body fat issue needs definitive and 
conclusive evidence not currently in place in the literature a s  it relates to 
health param eters and disease states. These human eating behavior 
param eters are the focus of this research.
The question of hormonal effects on food choice and future impact on 
health param eters is not known. Female sex hormones are an obvious choice 
to examine since increasing numbers in the female population are choosing a 
supplemental form to address health related implications. The most recent 
data suggest that estrogen therapy reduces heart disease (The PEPI Writing 
Group, 1995). These reports show that exogenous estrogen suppresses 
hepatic lipase activity, thereby raising the level of high-density lipoprotein 
cholesterol (HDL). Barrett-Conner and Bush (1991) noted that between 25% 
and 50% of the beneficial action of estrogen on coronary heart disease risk 
could be ascribed to changes in HDL-cholesterol and LDL-cholesterol.
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Hormone replacement therapy (HRT) is currently accepted for relief of 
m enopausal symptoms, and for the reduction in risk for osteoporosis and 
cardiovascular disease. With increasing numbers of females choosing HRT, 
long term unknown health concerns should be addressed. One fact seem s 
very clear: preliminary clinical and laboratory work-up prior to hormone
replacement therapy in postmenopausal women (Pardo, et. al., 1992) should 
consist of mammography test for malignancy exclusion, confirmation of 
m enopause by FSH and estrogen, and also the confirmation of normal lipid 
metabolism. Baseline data is essential to the strength of reported results.
Additionally, the assessm ent of dosages may be an area of concern for 
postm enopausal women considering hormone replacement therapy. It should 
be noted that it is rare that investigators have included biologic m easures of 
serum female sex hormones before, during or after drug administration. 
Without such data, dosages administered and the classification of pre-, peri-, 
or postm enopausal status provide only a  rough yardstick with which to 
evaluate subject or treatment characteristics. One such study revealed the 
effects of estrogen-progestin replacement therapy in postmenopausal women 
(Ortega, Cuadros, Gonzalez, & Ruiz, 1993). Serum levels of LH, FSH, 
estradiol and progesterone were measured. M easurements were collected 
before and after four different estrogen-progestin replacement therapies. The 
results showed that serum levels of LH and FSH dropped significantly in all 
four groups, that estradiol levels increased in all groups but that progesterone 
levels remained relatively unchanged.
New studies on micronized progestins (the natural form found in such 
food sources as soybeans and yams) as opposed to medroxyprogesterone
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are providing evidence of decreased side effects (which affect compliance) 
with micronized progestins (The PEPI Writing Group, 1995). Negative side 
effects can be premenstrual syndrome, bloating, depression, weight gain and 
uncontrolled eating bouts. The micronized progesterone used in the PEPI trial 
w as produced by Schering Plough, Kenilworth, NJ. Synthetic progesterone 
produces different more pronounced side effects than the natural plant 
sources (Hargrove, et al., 1989). However, micronized progestin 
bioavailability may be lower and dosages may therefore need to be increased. 
Progesterone receptor site levels are significantly lower in postm enopausal 
women (Becker, et al., 1990). Side effects may directly correlate to 
compliance rates in the postmenopausal female. Additional research showing 
endogenous levels prior to administration of dosages and comparisons with 
medroxyprogesterone (Provera®) are needed in the human postm enopausal 
female. More specifically, mechanisms and physiological implications of all 
sources of exogenous female sex hormones should be investigated.
The varieties in the mode of presentation of exogenous sex hormones 
has increased recently: oral, suppositories, vaginal creams, patches and 
subdermal implants given cyclically, continuously or at 3 to 6 month intervals. 
The dosages that provide the greatest degree of cardioprotection with
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minimum side effects should be investigated. An earlier study of 
postm enopausal women given exogenous esterified sources of estrogen 
0.625 mg (Estratab), esterified estrogen 0.625 mg plus 1.25 mg 
methyltestosterone (Estratest H.S.), or conjugated estrogen 0.625 mg 
(Premarin®), showed no significant differences among treatment groups 
(Jurgens, et. al.,1992). Serum levels of estradiol remained unchanged. There
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are often correlations between estrogen receptors and estradiol in 
postm enopausal women which provide biomarkers for cancer and 
cardiovascular disease (Perez-Lopez, et al., 1993). The demand is increasing 
as cardioprotection studies are released and osteoporosis prevention is 
further investigated. In the absence of serum tests for steroid levels, the current 
method of m easurement requires verbal feedback from the patient to the 
physician. And very often hormone replacement is discontinued before the 
physician is contacted.
Much of the current popular interest in exogenous female sex hormones 
com es from the effect on a  disease state such a s  CHD or osteoporosis. 
Although the initial decision often surrounds compensating for negative 
m enopausal symptoms, the continuation of exogenous female sex horm ones 
may have other less obvious reasons and compliance is abandoned. The 
implications of body weight gain as affected by varying dosages of HRT in the 
healthy female who chooses hormone therapy have not been thoroughly 
investigated. Higher levels of progesterone often prescribed for women with a  
family history of breast cancer may initiate a  fat appetite which can further 
compound the problem (Rolls personal communication, 1993, (Ob/Gyn. 
physicians personal communications, 1994).
A recent study conducted at the University of Vienna, Department of 
Obstetrics and Gynecology, shows that after long term therapy with estrogen 
implants, a 13% increase of prolactin was reported (Metka, et al., 1994). This 
increase seem s to be dose related. Further work is needed to examine body 
weight implications. Another related study by Bennet and Ingram (1990) w as 
designed to investigate the possible mechanisms by which dietary fat may
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influence the development of breast cancer by influencing the concentration of 
female sex hormones. They investigated the effect of the type of fat consum ed 
on concentrations of female sex hormones in serum. They found that when 
nutrient consumption was correlated with hormone concentrations, prolactin 
was directly associated with fat consumption, and sex-hormone-binding 
globulin was inversely associated with fat consumption (particularly 
cholesterol consumption), and that the proportion of nonprotein-bound 
estradiol was directly associated with complex carbohydrate consumption.
Currently, a  laboratory in Boston is reducing prolactin levels and 
altering body weight without altering caloric intake. Cincotta and Meier (1986) 
have shown that altering circadian rhythms can create desirable metabolic 
outcomes on body weight and diabetic states. Reductions of prolactin 
secretion by bromocriptine treatment for 24 days reduces fat stores in 
ham sters by 25-49% compared with control animals. However, body weight 
and food consumption were not affected. These results document the 
important role for prolactin in regulation of fat metabolism and indicate that 
bromocriptine might be used to decrease fat stores. More recently, a  report 
from this laboratory has shown a  600% decrease in caloric intake in the 
OB/OB mouse with a return to normal body weight following a state of obesity 
(Dr. A.H. Meier, personal communication, 1995). Their work takes us beyond 
the current findings in the female rat and may in the future provide answers to 
the perplexing questions surrounding body weight gain and various d isease  
sta tes such as diabetes mellitus.
There appears to be a growing body of evidence that hormonal profiles 
affect food intake choices. The clinical analysis of hormonal levels prior to
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dosage determination and prescription in the human may be appropriate in 
the future for a  variety of reasons.
The management of the peri- or postmenopausal woman, whether 
symptomatic or asymptomatic, involves a careful assessm ent of the problems 
and expectations. The effects of the physiological implications of m enopause 
and treatment on immediate and long-term health must be taken into account. 
This may involve aspects of medical topics a s  diverse as physiology, 
gynecology, endocrinology, nutrition, psychology, oncology and cardiology. 
Although the benefits of estrogen therapy are well established, the response to 
therapy must be carefully monitored, seeking out adverse effects both in 
individuals and populations.
HORMONAL EFFECTS ON ENERGY BALANCE
Although very little information is available from the human studies, 
many scientists have m easured the effects of both endogenous and 
exogenous fluctuating levels of gonadal hormones in animal models. The 
most descriptive work was reported by Wade and Gray in the 1970s. Much of 
the earlier research to m easure control of body weight (e.g. food intake and 
voluntary exercise) w as conducted in the albino rat (Wade & Zucker, 1969; 
W ade & Gray, 1979; Wade, Gray, & Bartness, 1985; Wade and Blaustein, 
1978). In female rats estrogens decrease food intake, body weight, and 
adiposity, while progestins increase these param eters (Wade and Schneider, 
1992). In the male rat adiposity is suppressed by testosterone in a  wide range 
of diseases. In female rat studies, the age of the rat is often not reported. Due 
to reproductive four day estrus cycles and gestational patterns, this information 
appears relevant to progesterone levels and research results.
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While W ade’s  research in the animal has provided a  great deal of 
information on the basic endocrinology of body weight as affected by female 
sex hormones, very little is known about the physiological or biochemical 
mechanisms by which ovarian and testicular hormones act to influence body 
weight, total body composition and behavioral food choices in the human. In a 
theoretical review Wade and Gray (1979) reported selected aspects of sex 
hormone actions on body weight and composition, metabolism, and behaviors 
in the rat. This work is needed in the human to show empirically the 
investigations conducted in the rat, female sex hormone effects on adiposity 
and the relationship to eating behavior and food choices. If the results of 
earlier work in the animal can be applied to the human, then gonadal steroids 
may be shown to influence adiposity by direct action on a few peripheral 
adipose tissues which control triglyceride storage with subsequent metabolic 
implications. If this is true, changes in macronutrient food choices and caloric 
regulation may be altered by varying levels of circulating hormones with 
resulting metabolic benefits overtim e (Jorgensen, et. al., 1994).
Behavioral and physiological controls of macronutrient choices and 
energy balance vary with reproductive condition in female rats. Experimental 
manipulations of circulating hormone levels (ovariectomy and hormone 
replacement therapy) indicate that the regulatory changes that are seen  over 
estrus cycles are due in large part to fluctuations in levels of estradiol and 
progesterone (Wade, 1976; Wade & Gray, 1979). Estradiol acts both centrally 
and peripherally to induce a  coordinated array of changes in the procurement, 
ingestion, metabolism, storage, and expenditure of metabolic fuels. In young
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rats, estradiol decreases the intake and increases the expenditure of energy, 
thereby decreasing body fat stores.
In general, progesterone reverses nearly all of the effects of estradiol 
and, thus promotes fat storage in rats. In the younger model, it has been 
suggested that body weight changes are somehow related to estradiol- 
induced shifts in a  hypothetical body weight setpoint. That is, changes in 
voluntary exercise and metabolic expenditure persist only until body weight is 
brought into line with a  new regulated level. A recent release in the New 
England Journal of Medicine conducted by scientists at Rockefeller University 
reported dynamic effects of setpoint in both obese and non-obese subjects 
(Leibel, Rosenbaum, & Hirsch, 1995). Earlier reports by Fantino and C abanac 
(1984) have shown hoarding behavior a s  an indicator of food deprivation 
effects on set point in body weight studies.
In adult female rats, withdrawal of ovarian hormones by ovariectomy 
induces a hyperphagia (hunger) and weight gain which lasts for approximately 
one month (Wade & Gray, 1979). Then the hyperphagia subsides, and body 
weight is maintained at 20-25% above the level of sham -operated controls 
(Gentry & Wade, 1976; Salhanick, et al., 1969). Running wheel activity is 
permanently suppressed by ovariectomy (Wang, 1923). The effects of the 
ovariectomy can be reversed by treatment with estradiol alone. Treatment of 
ovariectomized rats with physiological doses of estradiol produces a  transient 
hypophasia (satiety) and decline in body weight. Body weights of estradiol 
treated rats are lower than, as  well as parallel to, the ovariectomized controls 
(Mook, et al., 1972; Wade, 1975). As long as estradiol is given, running wheel 
activity remains elevated (Wade, 1975). Leshner and Collier (1973) found that
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ovariectomy doubled carcass fat content in weanling female rats. Treatment 
with estradiol has been shown to reverse the increase in adiposity caused by 
the ovariectomy (Roy & Wade, 1977; Salans, et al, 1971).
Earlier studies have shown that progesterone has no effect on food 
intake, voluntary exercise, body weight, or carcass composition in 
ovariectomized rats (Galletti & Klopper, 1964; Hervey & Hervey, 1967; Rodier, 
1971; Ross & Zucker, 1974). However, in the presence of estradiol (in cycling 
fem ales or in ovariectomized female rats given estradiol), treatment with high 
doses of progesterone (5 mg/day) increased body weight and food intake. 
The hyperphagia and increased body weight gain during progesterone 
treatment are transient, just a s  after the ovariectomy (Hervey & Hervey, 1967; 
Roberts, et al., 1972). During pregnancy and pseudopregnancy, when plasm a 
progesterone levels are elevated, eating (Hashimote, Hendricks, Anderson, & 
Melampy, 1968), weight gain, and fat depositions are also elevated (Knopp, 
Saudek, Arkey, & O’Sullivan, 1973; Slonaker, 1924; W ade & Zucker, 1969), a s  
they are during exogenous progesterone treatment.
C arcass analyses indicate that the weight gain during progesterone 
treatment in the presence of estradiol is due primarily to the increase of fat 
tissue (Galletti & Klopper, 1964; Hervey & Hervey, 1967), similar to that seen  
with ovariectomy. It should be noted that the age of these animals is not in 
evidence in all cases, and that no studies are reported in the postbreeder rat.
Sexual and hormonal variables have been shown to significantly affect 
the rat’s  preference for sweet taste. Taste tests in rats have been conducted in 
water bottle fluid consumption flavored with quinine (bitter) and sw eet 
(saccharin). The decrease in fluid consumption was proportionately greater
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for intact than ovariectomized females when the water supply was adulterated 
with quinine sulfate. Quinine acceptance by ovariectomized rats was 
unaffected by treatment with estradiol benzoate or progesterone alone. In 
combination, these hormones were effective in decreasing intake of the bitter 
solution. In intact females, estrogens and progestins appear to act 
synergistically to increase reactivity to the aversive taste stimulus. The 
decrease in fluid consumption attributable to the quinine, perhaps is due to 
the decrease  in estradiol and increase in progesterone secretion in pregnant 
and pseudopregnant females compared to unmated females. It is further 
suggested that the decrease in sweet effect is due to the decrease in estradiol 
and increase in progesterone secretion and subsequent bioactivity 
characteristics of these endocrine states. Possible neural m echanism s 
account for these different effects (Wade & Schneider, 1992).
Behavioral change has been widely assum ed to be the contributing 
factor in the changes in body weight and fat depositions which follow 
fluctuations in ovarian hormones. The action of ovarian hormones in the brain 
which could alter food intake and voluntary exercise might then influence fat 
deposition and body weight gain. In the normally cycling rat, there is an 
excellent correlation between changes in body weight, food choice and level 
of activity. During estrus cycles (when estrogen levels are high) the decrease  
in body weight occurs a s  a  result of increased voluntary exercise and a  
decrease in food intake (Brobeck, Wheatland, & Strominger, 1947).
However, there are several lines of evidence that suggest that no 
simple causal relationship exists between sex hormones, behavior, and fat 
deposition. Fluctuations in food intake and hormonal levels correspond quite
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closely but running wheel activity is permanent as long as the exogenous 
hormonal levels remain constant. The changes in activity persist long after the 
changes in body weight gain have subsided (Mook, et al., 1972).
Hormone induced changes on body weight are not always 
accompanied by changes in food intake. Hervey and Hervey (1967) found 
that progesterone treatment significantly increased body weight in cycling 
female rats even when the normally-occurring excess food intake patterns 
were prevented by restricting their food intake to pre-treatment levels. In fact, 
Roy and Wade (1977) found the ovariectomized females had to be restricted to 
80% of their normal consumption to prevent the castrated weight gain. Thus 
excess intake of calories is not necessary for either progesterone or 
ovariectomy induced body weight gain and leading to obesity.
A number of studies, mainly conducted in genetically obese and 
overfed rodents (Rothwell & Stock, 1979; Trayhurn, 1984) have shown that 
brown adipose tissue may play an important role in the regulation of energy 
balance. Edens and Wade (1983) also have suggested that brown adipose 
tissue might be involved in the regulation of energy balance in rats treated with 
ovarian hormones. A reduction in brown fat thermogenesis is usually 
accompanied by a reduction in energy expenditure, which in turn leads to a 
positive energy balance. This hypothesis needs to be examined more carefully 
before it is assum ed to be true in the aging female rat model.
These past studies do not provide evidence of human correlations and 
have not been continued. The correlation to human health param eters needs 
to be addressed in future research.
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HORMONAL EFFECTS ON FOOD INTAKE IN 
THE HUMAN FEMALE
Hormonal effects on food intake have not been extensively investigated 
in the human female. Currently the only macronutirent body weight data are 
reported in the younger cycling female model during reproductive years. The 
effects of exogenous female sex hormones in the postmenopausal woman 
taking hormone replacement therapy have not been investigated and 
reported. It should be noted that endogenous and exogenous female sex 
hormones may not be valid comparisons. Chemically, these are not the sam e, 
the natural rhythm of secretion release, and the binding of endogenous 
hormones has not been mimicked by exogenous treatment. The comparison 
merely provides a  point of departure for further investigations in the 
postm enopausal female taking hormone replacement therapy. It is likely that 
the two comparisons may not reflect parallel applicable information. With that 
disclaimer the following information will be examined.
Systematic shifts in energy intake, corresponding to different phases of 
the menstrual cycle, have been described (Barr, Janelle, & Prior, 1995; 
Lissner, Stevens, & Levitsky, 1988; Manocha, Choudhuri, & Tandon, 1986; 
Oram, 1987; Dalvit-McPhillips, 1981, 1983; Abraham, Beaumont, Argali, & 
Haywood, 1981; Gong, Garrel, & Calloway, 1989; Gallant, et. al., 1987; Pliner 
& Fleming, 1983). Several studies have shown that in the younger cycling 
female the menstrual cycle affects caloric intake and energy expenditure, 
however a s  earlier stated, no such research studies are found in the literature 
in postm enopausal women with intake of exogenous female sex hormones. 
One such well controlled trial of college age females shows that women
31
consum ed about 500 kcal more per day for the 10 days following ovulation 
(luteal phase) than the 10 days preceding ovulation (follicular phase) (Dalvit- 
McPhillips, 1981). This was supported in later work by Dalvit-McPhillips 
(1983) and Manocha et al. (1986); both observed elevated energy 
consumption during the 10 days before menstruation (luteal phase) when 
compared with the 10 days after the onset of menstruation (follicular phase). 
However, Abraham et al. (1981) found that energy intake was at its minimum 
level around the onset of menstruation (late luteal phase). Several authors 
have recommended additional research investigating women’s  health by 
examining in greater detail food selection or nutrient intake (Dalvit-McPhillips, 
1983; Tomelleri & Grunewald, 1987). Pliner and Fleming (1983) found that 
both body weight and reported food intake were significantly higher during the 
luteal phase than during the follicular phase in menstruating women. They 
further report that caloric intake from sw eetness (sucrose) preferences 
declined in the luteal phase when (progesterone levels were elevated) with an 
absence of such a  decline in the follicular phase. Some have suggested that 
a  better understanding of the food intake patterns and body weight gain in 
women may aid in understanding related diseases and illnesses affected by 
obesity (Bush, 1990).
Smith and Sauder (1969) stated that in collecting their human data, 
85% of those who craved chocolates also included themselves in the group 
that craved sweets. In a  report by G.E. Abraham (1984), a  premenstrual 
tension syndrome subgroup reported cravings for sweets, “mainly chocolate." 
Because many chocolate foods are high in both sugar and fat content, one 
cannot conclude that women in previous studies were necessarily craving
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sweets. They may have also been craving fatty foods or they may have been 
craving a  combination of sweet/fatty foods. It is also possible that som e 
subjects may experience a craving for chocolate flavor interacting with the 
sugar and/or fat content of the food. Others may experience cravings for 
chocolate independent of the sugar and fat content. Therefore, the present 
investigation was designed so that phase III of the study would m easure 
various fat and sugar levels of chocolate in the female rat model.
Caloric intake can be largely determined by the taste or palatability of 
food, and many highly palatable foods (including most chocolate foods) are 
high in sugar and fat content (Weiffenbach, 1977; Rodin, 1980). O bese 
hum ans find oral stimuli with a  higher fat content (Drewnowski, et al., 1985) or 
a  higher sugar content (Rodin, Moskowitz, & Bray, 1976) more palatable than 
do normal-weight subjects. Increased taste responsivity to sw eets and oral 
responsivity to fats have often been cited as important factors in overeating 
and in the development and maintenance of obesity.
The ways in which foods may increase willingness to eat or to satisfy 
the desire for further food is also an issue of great theoretical significance. 
Products in which palatability has been raised in order to promote 
consumption may have the potential for causing overnutrition. In addition to 
the new types of foods, additives are injected into the food supply on a  regular 
basis. Little is known about the effects of these additives on appetite. It could 
be of great value to have tables showing the energy-satiety ratio of all the 
common foods to indicate their potential for causing overnutrition (Heaton, 
1981). The study of the mechanisms of appetite is another dimension of this
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area of research which is beyond the scope of this paper. But it is of profound 
interest and applicability to this study and future research.
As earlier stated, to extrapolate data shown in the younger female 
during ovulatory menstrual cycles to the effects of exogenous female sex 
hormones in the postmenopausal female may not be accurate. However, it 
does provide a  view of the implications of energy intakes in the luteal a s  
opposed to the follicular phase in younger cycling females. Specifically, Barr, 
Janelle, and Prior (1995) compared energy and macronutrient intakes across 
the menstrual cycle in 42 regularly cycling vegetarians and nonvegetarians. 
Temperature records were quantitatively analyzed to determine whether 
cycles were ovulatory, and if so, the date the luteal phase began. Analysis 
was based on diet records matched with temperature analysis results. Higher 
caloric intake was observed during the luteal phase. The contribution m ade 
in this data suggests that 30% of the cycles may be anovulatory or have a 
short luteal phase, and that energy intake of women differ between menstrual 
cycle phases when the menstrual cycle is normally ovulatory. They 
recommend that in cross-sectional studies, failure to consider menstrual cycle 
phase could have important implications, especially if small numbers of 
subjects are studied. They further recommend that the time of ovulation must 
therefore be documented because energy intake differs only when cycles are  
ovulatory. It should be noted that this study may provide evidence of the 
conflicting reports seen in earlier literature such as Abraham and his 
colleague’s  (1981) who reported energy intake at a  minimum just before 
menstruation.
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To examine estrogen and progesterone effects separately is not 
possible in the younger human model. Progesterone levels are elevated 
during the luteal phase but not to the exclusion of estradiol (Becker, et al., 
1990). Animal work provides the strongest body of evidence, which indicates 
greater caloric intake and body weight gain when progesterone levels alone 
are elevated (Wade & Schneider, 1992). Evidence from recent reports 
indicates a greater caloric intake, snack food consumption, and body weight 
during several premenstrual days compared with the postmenstrual period 
(Barr, Janelle, & Prior, 1995; Dalvitt-McPhillips, 1981; Dalvitt-McPhillips, 1983; 
Pliner & Flemming, 1983; Lissner, Stevens, & Levitsky, 1988; Lyons, et al., 
1989; Gong, et. al., 1989) in contrast to the follicular phase when estrogen 
levels are elevated. These studies provide interesting information to those 
interested in investigating the effects of exogenous female sex hormones, 
estrogen and progesterone in the postm enopausal female. Hormonal effects 
on food intake, body weight and the set point surrounding the timing of these  
biological processes should be investigated further in the human 
postm enopausal model. New information is appropriate on this growing 
segm ent of the population which has previously not been studied.
HORMONAL EFFECTS ON APPETITE. TASTE AND PALATABILITY
Positive hedonic judgment or p leasantness of food taste such as 
sw eetness in chocolate can lead to a preference for consumption and 
increased intake of a particular food group (Drenowski, et al., 1985). Appetite 
and tastes may be influenced by both endogenous and exogenous female sex 
hormones. The timing and sequence of events leading to subsequent food 
consumption and body weight increase has not been determined (Friedman,
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1990). Further, the impact of hormonal effect on food choice to the exclusion 
of other more nutrient dense foods and subsequent effects on total health in 
the female should be critically examined.
The question of increased palatability influencing food choice in the 
face of a  deprivation of essential vitamins and minerals necessary to maintain 
bone density in m enopause could provide additional research questions in the 
aging female. Do eating patterns in aging cause the physiological markers of 
degeneration with subsequent disease states and high cost health care in the 
aging segm ent of the population? If the answer is yes, then (a) what is 
causing the alterations in appetite and (b) what can be done to improve the 
health status and correct nutrition related disease implications. Again, that is 
beyond the scope of this paper but could ultimately affect future research and 
the preventive medicine and wellness picture a s  m anaged health care is 
implemented. Scientists involved in brain research as it controls systemic 
responses are providing the most interesting current results.
However, knowledge of the mechanisms which control food intake and 
body weight has been surprisingly meager. Recent work at the University of 
North Carolina School of Medicine in this area  has shown that the surface of 
the gastrointestinal tract may be more than the site of absorption of nutrients; it 
may be a  preabsorptive reservoir of signals which would be released by 
contact with ingested food (Whitehead, personal communication, 1995). 
These preabsorptive signals would then act to control meal size, regulate 
length of meal intervals or both. This concept has been strengthened by 
continuing chemical discoveries of neural and hormonal gastrointestinal 
peptides which might serve a s  satiety signals. The fact that many of these
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sam e peptides and their receptors are also present in brain tissue has 
generated acceptance of the idea that brain stores of certain peptides might 
exert direct actions of feeding behavior, unrelated to any peripheral effects.
The classic small intestinal hormone cholescystokinin (CCK) when 
administered systematically can cause a reduction in food intake in rats. 
When it is released by food ingestion, it functions a s  a  negative feedback 
signal to limit meal size. This inhibitory action has been observed in many 
animal species, including sub-human primates, across a wide variety of test 
conditions (Gibbs, Young, & Smith, 1973). The action is strongly dose-related 
and is behaviorally specific. Although a large amount of evidence has been 
established, the fact that exogenous CCK reduces short-term food intake is 
evident. The m echanisms of endogenous CCK for the normal termination of 
eating have not been clearly determined but the CCK hypothesis is emerging 
a s  an established finding.
The hormone-releasing action of CCK is believed to elicit satiety. This 
conclusion was drawn from surgical and chemical lesion studies which have 
demonstrated that afferent, capsaicin-sensitive neurons of the abdominal 
vagus are required for the satiety action of CCK injected peripherally. The 
entry into the brain through afferent neurons of the vagus have their first 
synaptic relay in the hindbrain (Gibbs & Smith, 1982). Brain sites and 
pathways involved in processing food intake signals is the specific research 
focus of many scientists investigating ingestive behavior. Clearly, all the 
answers are not in place. The following is a  summary of m echanisms relating 
to ultimate food choice.
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Pancreatic glucagon was the first peptide tested for a  possible effect of 
food intake signals. Intravenous dosages of glucagon small enough to mimic 
the rise in plasma glucagon normally seen within twenty minutes after the 
completion of a  meal were shown to reduce test meal size by about 20%. 
Geary and Smith (1982) reported the efficacy of systematically administered 
glucagon in producing satiety in a  wide variety of animal and avian species. 
Like exogenous CCK, exogenous glucagon is strongly dose-related, rapid in 
onset, and transient. Unlike CCK, the effect of glucagon appears quite 
sensitive to environmental conditions, deprivation states and circadian 
rhythms. Mildly deprived or nondeprived rats are refractory to the satiety 
influence of glucagon around the time of dark onset, but quite responsive two 
or three hours later, or during the mid-light period (Martin & Novin, 1977).
The liver is the major target organ for metabolic actions of glucagon. 
Novin and his colleagues tested the effects of infusions directly into the hepatic 
portal vein (Martin, Novin, & VanderWeele, 1978). By this route, glucagon 
produced a  rapid and dose-related reduction in food intake. It appears that 
afferent fibers of the hepatic vagus are the key element supporting this 
behavioral effect. These results constitute persuasive evidence that circulating 
glucagon has a  physiological role in controlling food intake.
Bombesin is known to be distributed in mammalian gastrointestinal tract 
and brain. Intraperitoneal injections of bombesin produced large, dose- 
related reductions of food intake in rats. Several studies suggested that the 
inhibition of food intake reflected a  true satiety effect of the peptide which w as 
not simply secondary to malaise or generalized discomfort (Murrahainen, 
Kissileff, & Thornton, 1983). As with CCK, the satiety effect of peripherally-
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administered bombesin produced a  significant inhibition of food intake at test 
meals without producing significant side effects.
Insulin, administered peripherally in large doses, has long been known 
to provoke feeding in animals and elicit reports of hunger (Lovett & Booth, 
1970). In 1980 VanderWeele suggested that smaller doses of insulin closer to 
the physiological range would reduce food intake when delivered chronically 
to rats (VanderWeele, Pi-Sunyer, & Novin, 1980). Chronic reduction of insulin 
w as shown to be due to a  decrease in individual meal size. Woods and Porte 
(1977) have suggested that insulin may play an important inhibitory role in 
feeding behavior by acting directly on the brain. This places insulin not in the 
short-term control of individual meal size, but rather as a  long term monitor of 
the adipose tissue stores of the body. This hypothesis rests on several strong 
supports: (1) plasma insulin is well known to vary with the fat mass; (2) in turn, 
insulin levels in cerebrospinal fluid vary after a  lag period, with plasma insulin 
(Woods & Porte, 1977), (3) insulin and insulin receptors can be found within 
the brain, (4) infusions of small amounts of insulin directly into the 
cerebrospinal fluid of rats and primates reduces daily food intake and body 
weight, without raising plasma insulin levels, and (5) although plasma insulin 
levels are elevated in obesity, these investigators have found that 
cerebrospinal levels of insulin, brain levels of insulin and brain insulin binding 
are all low in rodent models of obesity, suggesting that the insulin signal from 
the adipose tissue m ass is not reaching its target sites in the brain (Baskin, 
Stein, & Ikeda, 1985).
It is of interest that this hypothetical mechanism for the regulation of 
long-term food intake and body weight appears to interact with at least one of
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the putative short-term satiety signals. Although the administration of a  very 
small amount of insulin into the cerebral ventricles failed to affect food intake 
by itself in rats and in primates, it potentiated a  sub-threshold dose of CCK, 
and the combination inhibited food intake (Woods & Gibbs ,1989).
Somatostatin, found in the gastrointestinal tract and brain appears to act 
a s  an inhibitor of multiple pancreatic and gut functions. Administered 
intraperitoneally to rats and baboons, it produced a  dose-dependent and 
behaviorally specific inhibition of food intake (Lotter, Krinsky, & McKay, 1981).
Oxytocin, which is synthesized in cell bodies of intra- and 
extrahypothalamic neurons, also has binding sites widely distributed in the 
brain tissue. Doses required to reduce feeding after peripheral administration 
were massive; intracerebroventricular administration of 10 ng/rat produced a 
marked suppression of food intake, accompanied by increased grooming. 
This effect was totally reversed by an oxytocin antagonist (Olson, et. al, 1989).
Calcitonin, which is released postprandially into the circulation, reduced 
food intake in rats and rhesus monkeys following subcutaneous administration 
and in rats after intracerebroventricular administration. Maximal inhibition 
occurred several hours following peripheral injection in rats, suggesting that 
the peptide is not directly involved in the regulation of meal size (Krahn, et. al, 
1986).
Corticotropin-releasing factor, a  41-residue peptide which stimulates 
pituitary ACTH and p endorphin release, also reduce food intake after injection 
into cerebral ventricles and the paraventricular nucleus of the hypothalamus 
(Krahn, Gosnell, & Levine,1984).
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Circulating pancreatic polypeptide levels rise dramatically at meals, and 
this peptide has been shown to reduce food intake and body weight after 
peripheral administration in lean and obese mice (Malaisse-Legae, 
Carpentier, & Patel, 1977). It failed to reduce food intake in rats (Gibbs, Gray,
& Martin, 1980) and has not been tested in other species.
Secretin and gastrin, two classical gastrointestinal peptide hormones, 
had no effect on food intake in rats, even when large doses were employed 
(Gibbs, Young ,& Smith, 1973).
Progress in uncovering the physiological mechanisms of food intake 
and body weight over the years is evident. The major element in this progress 
is the discovery of the key role of a small group of peptides which link the 
gastrointestinal tract and the brain. Enterostatin and Neuropeptide Y are two of 
the newest peptides reported to impact neural mechanisms of appetite and 
food choice (Bray, et al, 1990). Leptin (Halass, et al., 1995), is the most recent 
discovery and holds much promise in genetic implications of obesity research. 
The review of the entire scope of all the current investigations is beyond the 
scope of this paper.
In summary, certain appetite mechanism patterns seem  to be emerging.
It appears that several peptides have their initial action peripherally. Second, 
this initial action is relayed centrally by afferent nerves. A major role is played 
by the abdominal vagus. Third, the dorsal hindbrain is required for the full 
expression of meal cessation.
The recent development of highly potent and highly specific receptor 
antagonists and antibodies for several of these peptides has provided an 
indispensable tool for assessing the physiological meaning of effects on food
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intake produced by the agonists. The mechanisms of food intake and the 
safety of these biologically potent agents when given chronically are unknown 
and must be established (Bray et. al, 1990). The uncertainty of the health 
status of the female taking exogenous female sex hormones (which were not 
utilized exogenously for centuries) leaves many questions to be answered. 
However, it behooves the scientific community to address these relevant 
questions when such a large segment of the population is potentially affected.
The mechanisms reviewed and the way in which the m echanism s 
influence food choice and metabolic implications have currently not been 
correlated to the effects of endogenous female sex hormones. Hormonal 
effects on appetite, taste, and palatability in the human and the correlation to 
an animal model should be evaluated. To date, the most reliable systemic 
specific macronutrient food intake research has been conducted in animal 
models. The following is a  report of current and past work which may ultimately 
lead to the answers affecting knowledge surrounding hormonal influences on 
food intake and body weight. Reports from both animal and human studies 
will be included to provide a s  much information as is currently available in a 
concise form.
When receiving exogenous estrogen, the female rat shows an 
increased sugar preference and a  decreased fat preference. Also, sugar 
preference increases with increasing levels of estradiol. Geiselman, Martin, 
VanderW eele and Novin (1981) showed that when rats were behaviorally 
responsive to their elevated endogenous estradiol levels they not only showed 
a  significant increase in sugar intake, but they also showed a significant 
decrease  in fat consumption.
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In a  similar human study, Aaron (1975) reported greater p leasantness 
of the sweet taste in the follicular phase which lowered during the luteal phase 
when progesterone levels were higher and estradiol and estrone were lower. 
In an additional study across the menstrual cycle, Bowen and Grunberg (1990) 
reported increased sweet food consumption with higher preference ratings 
during the luteal phase, when progesterone levels are generally elevated. 
However, it should be noted that their “sweet” foods included combinations of 
fat and sweet such a s  chocolate, coffee cake, and gum drops analyzed 
together. Pliner and Fleming (1983) found that negative alliesthesia i.e., a 
decrease in sucrose preference typically reported from before to after a 
glucose load, occurs during the luteal phase but not the follicular phase. The 
importance of studying not only sugar preference but also fat preference in a 
controlled female rat model is further suggested by data showing that when 
endogenous estrogen levels are lower and progesterone is elevated, rats 
chose significantly more dietary fat (Geiselman, et al., 1981). There are only 
a  few anecdotal reports in the human literature of changes in fat preference 
across the menstrual cycle, with no evidence in the aging rat or 
postmenopausal female. It is important to understand the hedonics of specific 
appetites a s  affected by female sex hormones.
It is therefore important in this study to systematically examine both 
sugar and fat content in food choices as seen  in separate food cups containing 
nutritionally balanced sources of nutrients. This study was designed to 
specifically identify and quantify the effects of exogenous female sex 
hormones (estrogen, estrogen/progesterone, and progesterone) on 
macronutrient preferences, sweets, fats and chocolate in the ovariectomized
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retired breeder female rat to provide information and preliminary data for future 
human studies. Based on the physiological param eters currently being 
investigated in this specific study, the female Sprague-Dawley rat seem s to be 
an appropriate animal model.
The animal literature primarily reflecting data collected in the Sprague- 
Dawley rat strongly implicates female sex hormones in the control of appetite, 
food intake, and body weight. When female rats are ovariectomized, food 
intake and body weight both increase (Schemmel, et al, 1982). However, 
administration of small doses of estradiol reverses the body weight gain and 
returns food intake to normal (Wade, et al, 1985). A significant decrease  of 
food intake when estrogen is high with a significant increase in food 
consumption when estrogen is low was seen in the cyclic secretion of 
estrogen during the estrus cycle of the rat (Tarttelin and Gorski, 1971).
Later work by Tarttelin and Gorski (1973) with ovariectomized rats 
showed an increase in food intake and body weight which plateaued roughly 
one month after surgery. Daily injections of 1.5 fig estradiol benzoate initiated 
at that time significantly reduced both the food intake and body weight. When 
estrogen treatment is initiated at the time of ovariectomy, the increase in food 
intake and body weight is prevented. No influence of progesterone injection 
(either with estradiol benzoate or alone) was detected. These results suggest 
that estrogen, but not progesterone, is the ovarian hormone active in the 
regulation of intake param eters and body weight in the female rat (Tarttelin & 
Gorski, 1973). Fantino and Brinnel (1986) have shown a  direct fluctuation of 
the body weight setpoint with the ovarian cycle. The implications of this work 
have direct application to the concept of hoarding behavior a s  a  m easure of
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increased body fat stores and increased body weight in the ovarian cycle of 
the female rat. Hoarding has been shown to be a  direct correlate to increased 
body rat stores. Proestrus and diestrus m easures were taken. The diestrus 
period is equated to the luteal phase in the female when progesterone levels 
are elevated. Higher progesterone levels initiated increased hoarding 
behavior in the mature Sprague-Dawley female rat.
Another study in rats (Mandour, et al., 1977) demonstrated that 17 p 
estradiol had a marked suppressive effect on the alpha cells of the pancreas 
and a  minimal effect on plasma insulin release as measured in the portal vein. 
The invasive nature of this study is not appropriate in humans. However, if the 
data are extrapolated to the clinical situation, it could explain som e of the 
observed biochemical changes seen in women on estrogen therapy, a s  
evidenced by lowered fasting blood glucose levels (because of relative fasting 
hyperinsulinemia) and elevated triglycerides (Bush, 1990).
Short-term therapy with progestogens (less than 6 months) is not 
associated with alterations in glucose or insulin metabolism (Spellacy, et al., 
1970). However, later work by Notelovitz (1982) shows that time is a  strong 
indicator of effects and that early findings in the first 6 months may change with 
time. Therefore, the early appetite changes seen when hormone replacement 
therapy is initiated may not be long term. This fact should be explained to the 
postm enopausal female by her physician. Such information could affect the 
decision to begin hormone replacement therapy and the future level of 
commitment and compliance. However, that information is not currently 
available. That is a  contribution that this scientist hopes to make in the future
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in cooperative research with Dr. Notelovitz (Dr. Morris Notelovitz, personal 
communication, 1995).
Currently the most reliable research in a  mammalian model has been 
conducted in the primate at Bowman Gray School of Medicine (Dr. Thomas 
Clarkson, personal communication, 1995). Observations of rhesus monkey 
females indicate a  systematic relationship between levels of food intake and 
endogenous estrogen and progesterone levels. A positive correlation has 
been noted between the incidence of food rejection and levels of circulating 
estrogens (Czaja and Roy, 1975). Gilbert and Gillman (1956) showed a  sharp 
decline in primate food intake during the first 6 to 11 days and continued low 
intake throughout the follicular phase followed by a consistent and maintained 
rise after ovulation with a  peak of caloric intake being recorded between 2 and 
7 days before menstruation. Dr. Thomas Clarkson at the Bowman Gray 
School of Medicine, Department of Comparative Pathology, is currently 
measuring food intake involving phytoestrogens from soybean and the effects 
on body weight and cardiovascular disease in the primate. His earlier work 
provided the basis for the research design for the PEPI trial. Research in 
appetite, macronutrient intake and body weight with hormonal effects is 
needed (Clarkson, personal communication, 1994).
EATING BEHAVIOR: ENERGY BALANCE MECHANISMS
Aside from all the uncertainty surrounding mechanisms and biological 
mysteries, the body is a marvelous organism with built in homeostatic 
mechanisms. Body weight and food intake are carefully regulated in most 
laboratory animals, and humans by a  variety of physiological and behavioral 
control mechanisms (Balagura, et al, 1981; Code, 1967; Hervey, 1969;
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Morgan, 1965). Although short-term errors do occur in this regulation, long­
term regulation is amazingly accurate, and adults of most mammalian species 
gain weight only very slowly with age (Hervey, 1969).
However, although weight is carefully regulated, it should be noted that 
body weight setpoint is not immune to physiological and environmental 
fluctuations. A variety of factors, including diet palatability (Corbit & Stellar, 
1964), environmental temperature (Brobeck, et al, 1947), relative levels of 
various metabolic hormones (Woods and Porte, 1977), and the opportunity to 
exercise in running wheels (Leshner and Collier, 1973) affect body weight 
level in rats. Additionally, neurological damage may also raise or lower body 
weight setpoint (Hoebel & Teitelbaum, 1962; Powley and Morton, 1976). Of 
interest in this research, and increasingly more relevant are the effects of 
exogenous female sex hormones on caloric regulation. These female sex 
hormones should be added to the list of factors affecting behavioral and 
physiological regulation of body weight.
We have summarized what is known about the effects of ovarian 
steroids on energy balance and caloric conversion in younger rat models, and 
earlier human studies. This information and the principles derived from this 
earlier research have provided the basis to examine this hypothesis in 
postbreeder female rats. Eating behavior patterns in the ovariectomized 
postbreeder female rat may provide the model to investigate the effects of 
exogenous female sex hormones on food intake and body weight in the 
mature female of other species. Female sex hormones have important effects 
on behavioral and physiological controls of energy balance in a  wide range of 
mammalian species. Work with laboratory animals reveals that fluctuations in
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circulating estradiol and progesterone levels produce coordinated changes in 
ingestion, metabolism, storage, and expenditure of metabolic fuels. In rats, 
estradiol can act directly in the brain to alter food intake and voluntary 
exercise. Subsequent neuroendocrine m essages are then translated into 
actions in the adipose tissue, muscle, and liver to influence metabolism and 
the storage of metabolic fuels. The effects of estradiol on food intake are due, 
at least in part, to direct hormone actions in the brain (Wade and Schneider, 
1992). Early work using intracerebral hormone implants suggested that 
estradiol acted in the ventromedial nucleus of the hypothalamus (VMH) to 
decrease food intake (Beatty, et. al., 1975; Jandowiak & Stem, 1974; Nunez, et 
al., 1980; W ade & Zucker, 1970). However, more recent work indicates that 
the paraventricular nucleus (PVN) of the hypothalamus, rather than the VMH, 
is the principle regulator of estradiol on food intake (Butera & Beikirch, 1989; 
Czaja, Butera, & MacCaffrey, 1983; King & Cox, 1973; Butera, 1995, personal 
communication). These data seem  to indicate that estradiol can act to 
decrease food intake in rats, and that it plays an essential role in the effects of 
estradiol on food intake. Little else is known about the m echanisms of 
estradiol and other female sex hormones on food intake. The estrogen 
receptor may hold the answer in future investigations.
Very little is known about the effects of ovarian steroids on energy 
balance in women, although food intake and metabolism are known to vary 
with reproductive condition, including menstrual cycles, and m enopause. 
Virtually nothing is known about the macronutrient choices as affected by 
exogenous female sex hormones on energy balance and subsequent 
physiological outcomes in postmenopausal women. With recent evidence that
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hormone replacement therapy is cardioprotective in the postm enopausal 
female (The PEPI Writing Group, 1995), information regarding body weight 
param eters which could affect the rate of compliance is needed. Fluctuations 
in body weight over a  thirty day period represent hormonal influences on 
setpoint as Fantino and Brinnel (1986) have shown. Short term perceptions of 
luteal phase or progestin initiated body weight gain may not be related to total 
body weight over the life span but may be indicative of macronutrient choices 
with varying caloric conversion rates. The implications may be short term or 
long term depending on an array of variables yet unmeasured. The 
investigation seeking these answers will be a  continuing dimension to future 
research related to disease states.
SUMMARY OF THE IMPLICATIONS OF THIS RESEARCH 
The number of females in this country taking daily exogenous female 
sex hormones has increased for the past 30 years and is currently at an all 
time high (Notelovitz and Tonnessen, 1993; Wallis, 1995). The numbers are  
increasing daily as postmenopausal baby-boomers choose hormone 
replacement therapy during menopause. In earlier days of medical practice, 
hormone replacement therapy was simply called estrogen replacement 
therapy. When research revealed the predisposition to cancer in those 
fem ales who were taking “unprotected” estrogen, progesterone was added to 
the daily or monthly oral intake of exogenous hormones. "Currently, the variety 
of prescriptions used to treat menopausal symptoms has expanded to include: 
continuous low levels of both estrogen and progesterone taken 
simultaneously; and cyclical, whereby estrogen is taken for the first 10 to 14 
days of the month and then progesterone is added for the last 14 days. In
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addition to an array of patches, implants and injections, oral doses of 
Premarin® (estrogen) and Provera® (progesterone) are the most widely 
prescribed forms of hormone replacement therapy as earlier stated. The 
earlier levels of progesterone varied from 2.5 mg to 10 mg. Higher levels of 
progesterone have been shown to create premenstrual syndrome-like 
symptoms which often deter continuance and compliance. The evidence of 
this potential noncompliance may be initiated by nuisance side effects (such 
a s  edem a, breast tenderness, memory loss, mood swings, and food cravings) 
(Gambrell, 1995). The question that must be addressed by the physician and 
the female patient is: what levels of exogenous female sex hormones are 
cardioprotective and osteoporosis protective without negative premenstrual 
tension syndrome-like side effects? The physician needs scientific information 
based on peer reviewed research to prepare the patient, offer solutions, and 
help to put potential problems in proper perspective.
The most current research findings involving exogenous female sex 
hormones in the postm enopausal female do not provide these answers. The 
results of the first efforts to examine cardiovascular health implications of 
hormone replacement therapy were revealed at the Fall 1994 meeting of the 
American Heart Association. This first female clinical trial investigating 
hormonal effects on cardiovascular disease in the Postm enopausal 
Estrogen/Progestin Investigation (PEPI), reveals that estrogen only, or in 
combination with a  progestin, improves lipoprotein ratios and lowers 
fibrinogen levels without detectable effects on insulin and blood pressure. 
Unopposed estrogen is the optimal regimen for elevation of high density 
lipoprotein cholesterol (HDL-C), but the study reveals that a  high rate of
50
endometrial hyperplasia restricts the use of estrogen alone by women with a 
uterus. The design of the PEPI study was changed after 12 months of testing 
when endometrial biopsies revealed a  precancerous state in the uteri of a 
small percentage of the females taking estrogen only. The research did not 
focus on the effects of exogenous female sex hormones on caloric intake, 
body weight and subsequent affect on health status and longevity. The Block 
Questionnaire (Block, et al, 1986) was used to a sse ss  food intake patterns but 
w as only collected three times during the three year study. No direct 
m easures in changes of exercise patterns in the subjects were measured. The 
further analysis of the existing PEPI data base will provide only a brief 
indication of metabolic param eters affecting hormone replacement therapy 
(Dr. Trudy L. Bush, personal communication, 1995).
The current study which seeks to answer som e of these questions, is 
aimed at the interrelationships between exogenous female sex hormones, 
dietary intake, and specific food preferences (especially a s  it relates to sweets, 
fats, and chocolate) in the control of appetite, eating and body weight. The 
ovariectomized retired breeder female rat is used as a model to provide 
preliminary data and serve a s  a  guide for future studies measuring the sam e 
or similar param eters in postmenopausal women. This study allows 
identification of dietary and physiologic factors that vary with hormonal levels.
It is expected that the factors identified in this project will lead to a  better 
understanding of dietary and physiological implications involved in caloric 
regulation in the postmenopausal female taking exogenous female sex 
hormones.
CHAPTER 3: MATERIALS AND M ETHODS
EXPERIMENTAL CONDITIONS 
In order to establish hormone levels in a postmenopausal model, 
postbreeder female rats which were ovariectomized and then implanted with 
exogenous female sex hormones, were chosen for this study. Retired breeder 
Sprague-Dawley female rats (Harlan Sprague Dawley, Madison, Wisconsin) 
weighing 268.1g ± 3.1 g, which had been ovariectomized in Wisconsin before 
shipment, were housed individually in stainless steel hanging wire cages 
maintained on a  12:12 lighting schedule (lights on at 0700 hr, off at 1900 hr). 
A control group of sham surgically treated (ovaries were left intact) rats were 
observed to document food intake and body weight of animals at this aging 
status who were not manipulated by exogenous female sex hormones or 
novel food choices. A control group of ovariectomized rats of the sam e age 
reflected the normal body weight and food selections of this model with no 
hormone implants. (An additional group, sham receiving all food choices was 
originally included in the research design but a high death rate early in the 
study eliminated this group.) Three other ovariectomized groups were treated 
with exogenous female sex hormones which were packed into silastic tubing 
and implanted subcutaneously (Richard, 1986; Geary, et al, 1994; Butera and 
Beikirch, 1989; Richard, 1995, personal communication). The source of 
hormone was chosen to most closely replicate endogenous levels in rats and 
a s  a  reflection of the bioactivity of exogenous female sex hormones in the 
human. The rats were randomized so that each treatment group would 
contain a  mean body weight of 268.1g ± 3.1. This experimental design 
resulted in the following treatment groups:
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GROUP A Sham: Placebo (empty silastic tubing)
GROUP B OV: Placebo (empty silastic tubing)
GROUP C OV: 17(3-estradiol crystalline (15mg)
GROUP D OV: 17p-estradiol (15 mg) and progesterone
(200 mg) crystalline
GROUP E OV: Progesterone (200 mg) crystalline
ANIMALS
Sprague-Dawley female postbreeder rats which were 10 months old 
and had given birth to 10 litters of pups were chosen for the study. The rats 
were ordered four months prior to the study so that a homogenous group of 
females could be procured. Due to the stress of the two surgeries, the heat, or 
the age of the animals, five died prior to data collection. The animals were 
transported to the LSU laboratories by air-conditioned plane and truck.
In summary all materials and methods were designed to answ er 
questions posed in chapter I to test the stated hypotheses. The female rat 
model was chosen because the controlled laboratory environment allows 
more accurate m easures of body weight and food intake m easurem ents than 
can be obtained in free living subjects keeping dietary records. The 
application of animal data to human implications is sometimes questioned 
(Wade & Schneider, 1992). However, the rat model chosen for this study 
reflects many of the parameters shown in the literature to directly parallel the 
human female. The rats were ovariectomized for two reasons: a) to remove 
endogenous hormone production so that controlled levels could be implanted 
and documented, and b) to mimic the menopausal state in an animal model.
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SURGERY
The ovariectomy or sham surgery was performed by Sprague-Dawley 
prior to shipment. Sham surgery is typically used in research to induce the 
stress experienced by the other research animals but ovaries are left intact. 
Rats were anesthetized with ketamine (100 mg/ml) + xylazine, (20 mg/ml) 3 
parts ketamine to I part xylazine at 0.1 ml/100 g BW. The incision was on the 
upper hind quarter along the back and was secured by metal clamps until 
recovery. After an adjustment period the rats were weighed and assigned to 
treatment groups according to body weight. The second surgery to implant the 
hormones was performed 48 hours after arrival. After an incision was m ade 
behind the neck, implants packed with crystalline female sex hormones from 
Sigma were inserted and the incision was secured with silk thread.
HORMONE IMPLANTS 
Silastic tubing m ade by Dow-Corning was cut into single 15mm lengths 
for the estradiol and into two, 40 mm lengths to accommodate the 
progesterone. Silastic capsules were prepared from medical grade silicone 
tubing (1.5 mm i.d., 3.2 mm o.d.). The crystalline form of the steroids 17 13- 
estradiol or progesterone (Sigma Laboratories), was packed into the silastic 
tubing. The ends of the silicone tubing were sealed with a  wooden plug 
followed by Medical Adhesive (Silicone Type A, Dow-Coming, Midland, Ml) to 
prevent dispensation through the cut ends. The tubing was then soaked in a  
water bath overnight to begin the dispensation process. Thus, released  
hormone into the animal began immediately upon implantation. The osmotic 
flow through the walls of the silastic tubing has been shown to provide a 
reliable method of administering female sex hormones (Richard, 1986).
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Each rat received three implants: Sham and OV received a single 15 
mm placebo, plus two 40 mm placebo empty tubes. E received a single 
15mm estradiol and two empty tubes, E&P received a  single 15 mm of 
estradiol and two 40 mm tubes containing active progesterone. P received a 
single empty 15 mm and two 40 mm tubing filled with progesterone. Rats were 
allowed 2 days recovery time from the surgery before food intake data was 
collected. When the rats were sacrificed, the tubes were extracted from the 
neck area  to confirm that no tube was totally depleted of the hormone source 
(Richard, personal communication, 1995). Results confirmed that no tube was 
totally empty.
CONFIRMATION OF HORMONE DOSAGES 
Previous research has shown these 15 mg of estradiol and 200 mg. of 
progesterone in silastic tubing provides blood levels of estradiol within the 
normal physiological range. Dispensation of the hormones from silastic tubing 
w as confirmed at conclusion of study with radioimmunoassay of estradiol and 
progesterone in serum and bioactivity was verified by uterine weights 
(Abraham, 1977; Judd & Korenman, 1982).
WATER AND FOOD CUPS 
Tap water was placed in inverted water bottles with stoppers and metal 
drinking spouts and dispensed ad libitum. Food cups were small glass jars 
which adequately provided easy  access to the three food cups in phase I, four 
food cups in phase II (three for S) and the eight food cups in phase III (three for 
S). Food cups were secured with metal bracing to decrease the likelihood of 
spillage. Phase I food choices are seen  in Table 3.1, Phase II, Table 3.2 and 
Phase III, Table 3.3. Spills were collected in small plastic medicine cups and
TABLE 3.1 PHASE I - TEN (10) DAYS 
M ACRONUTRIENT C H O IC ES, SEPA R A TE FOOD C U P S  OF 
PROTEIN, FAT AND CARBOHYDRATES
Group A Group B Group C Group D Group E
12 Rats 10 Rats 12 Rats 11 Rats 10 Rats
Sham
Surgery
Ovariecto­
mized Surgery
Ovariecto­
mized Surgery
Ovariecto­
mized Surgery
Ovariecto­
mized Surgery
Control
Treatment
Control
Treatment
Estradiol
Treatment
Estradiol/
Progesterone
Treatment
Progesterone
Treatment
Protein 
Food Choice
Protein 
Food Choice
Protein 
Food Choice
Protein 
Food Choice
Protein 
Food Choice
Fat
Food Choice
Fat
Food Choice
Fat
Food Choice
Fat
Food Choice
Fat
Food Choice
Carbohydrate 
Food Choice
Carbohydrate 
Food Choice
Carbohydrate 
Food Choice
Carbohydrate 
Food Choice
Carbohydrate 
Food Choice
TABLE 3.2  PHASE II - TEN (10) DAYS 
CARBOHYDRATE ANALYSIS SW EET VS N ONSW EET
Group A Group B Group C Group D Group E
12 Rats 10 Rats 12 Rats 11 Rats 10 Rats
Sham
Surgery
Ovariectomized
Surgery
Ovariectomized
Surgery
Ovariectomized
Surgery
Ovariectomized
Surgery
Control
Treatment
Control
Treatment
Estradiol
Treatment
Estradiol/
Progesterone
Treatment
Progesterone
Treatment
Protein 
Food Choice
Protein 
Food Choice
Protein 
Food Choice
Protein 
Food Choice
Protein 
Food Choice
Fat
Food Choice
Fat
Food Choice
Fat
Food Choice
Fat
Food Choice
Fat
Food Choice
Carbohydrate 
Food Choice
(a) Sweet (a) Sweet (a) Sweet (a) Sweet
(b) Nonsweet (b) Nonsweet (b) Nonsweet (b) Nonsweet
TABLE 3 .3  PHASE III - TEN (10) DAYS SW EET FAT 
AND CHOCOLATE PRO FILE WITH FOUR 
CALORIC LEVELS O F CHOCOLATE
Group A Group B Group C Group D Group E
12 Rats 10 Rats 12 Rats 11 Rats 10 Rats
Sham
Surgery
Ovariecto­
mized Surgery
Ovariecto­
mized Surgery
Ovariecto­
mized Surgery
Ovariecto­
mized Surgery
Control
Treatment
Control
Treatment
Estadiol 
(15 mg) 
Treatment
Estradiol & 
Progesterone 
15mg/200mg 
Treatment
Progesterone 
200 mg 
Treatment
Protein 
Food Choice
Protein 
Food Choice
Protein 
Food Choice
Protein 
Food Choice
Protein 
Food Choice
Fat
Food Choice
Fat
Food Choice
Fat
Food Choice
Fat
Food Choice
Fat
Food Choice
Carbohydrate 
Food Choice
CHO
Food Choice
CHO
Food Choice
CHO
Food Choice
CHO
Food Choice
(a) Sweet 
Food Choice
(a) Sweet 
Food Choice
(a) Sweet 
Food Choice
(a) Sweet 
Food Choice
(b) Nonsweet 
Food Choice
(b) Nonsweet 
Food Choice
(b) Nonsweet 
Food Choice
(b) Nonsweet 
Food Choice
Chocolate (a) Choc HF/HS (a) Choc 
HF/HS
(a) Choc 
HF/HS
(a) Choc 
HF/HS
(b) Choc HF/LS (b) Choc 
HF/LS
(b) Choc 
HF/LS
(b) Choc 
HF/HS
© Choc LF/HS © Choc LF/HS © Choc LF/HS © Choc LF/HS
(d) Choc LF/LS (d) Choc LF/LS (d) Choc LF/LS (d) Choc LF/LS
Chocolate:
(a) High Fat/High Sugar
(b) High Fat/Low Sugar
(c) Low Fat/High Sugar
(d) Low Fat/Low Sugar
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TABLE 3 .4  MACRONUTRIENT SELECTION DIETS
Protein SW-CHO Nonsweet CHO Fat
gm % kcal gm % kcal gm % kcal gm % kcal
Protein 84.8 89.7 4.9 5.1 4.9 5.1 8.8 5.1
Carbohy­
drate
4.8 5.1 84.5 89.7 84.5 89.7 8.7 5.1
Fat 2.1 5.1 2.1 5.1 2.1 5.1 67.4 89.7
Total 91.1 100.0 91.6 100.0 91.6 100.0 84.9 100.0
kcal/gm 3.72 3.77 3.77 6.76
Ingredient gm kcal gm kcal gm kcal gm kcal
Casein, 80 
Mesh
875 3500 50 200 50 200 50 200
DL-
Methionine
13.1 0 0.75 0 0.75 0 0.75 0
Corn Starch 20 80 199.6g 692 559 2168 20 80
Maltodextrin
10
0 0 186 600 0
Sucrose 20 80 665.4g 2768 120 692 20 80
Cellulose,
BW200
50 0 50 0 50 0 50 0
Soybean Oil 22.2 199.8 22.2 199.8 22.2 199.8 22.2 199.8
Crisco 0 0 0 0 0 0366.7 3300.3
Mineral AIN 
Salt Mix 
S10001
35 0 35 0 35 0 35 0
Vitamin Mix 
V10001
10 40 10 40 10 40 10 40
Choline
Bitartrate
2 0 2 0 2 0 2 0
FD&C Red 
Dye #40
0 0 0 0 0.1 0 0.1 0
FD&C Blue 
Dye #1
0 0 0.1 0 0 0 0.1 0
FD&C Yel­
low Dye #5
0.1 0 0 0 0 0 0 0
Total 1047.4 3899.8 1035.05 3899.8 1035.05 3899.8 576.85 3900.1
Formulated by E.A. Ulman, Ph.D., Research Diets, Inc, 3/3/94
Chocolate selections are from powdered hot chocolate mix of 4 caloric levels
of varying fat and sugar.
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weighed back daily to achieve a more precise record of food consumed. The 
color coding of the powdered diets helped identify the source of spills.
DIETS
The formulas (Table 3.4) for individual macronutrient food cups which 
were nutritionaliy balanced were developed in the laboratories of Cornell 
University (Ulman, personal communication, 1994). These formulations of 
balanced essential nutrients are used in standard diets for ingestive behavior 
studies in animal models and have been analyzed for caloric value by bomb 
calorimetry (Ulman, 1994). The macronutrient choices were individually 
balanced with vitamin and mineral components so that rats could sustain life if 
only one food cup source was chosen. The diets were mixed at LSU with 
standard ICN Biochemical ingredients.
The materials and methods regarding diet selections in each phase 
were designed to m easure hormonal effects on caloric regulation and food 
choice. Therefore, in phase I the three macronutrient food choices, FAT, 
carbohydrate (CHO) and protein (PRO) were nutritionally balanced for 
essential vitamins and minerals (Table 3.1). In phase II the investigation of 
sw eet compared to nonsweet choices of carbohydrate sources (Table 3.2) was 
divided into sweet AIN-76 which was four times higher in sucrose levels in the 
non sweet AIN-93 (Reeves, Nielsen, & Fahey, 1993). The sweet food choice 
was designed to represent simple carbohydrates with a higher sucrose level. 
The nonsweet food choice was designed to represent complex carbohydrates 
with the addition of cornstarch, maltodextrin and cellulose (Table 3.4). In 
phase III the additional m easure of chocolate choices was added to the fat, 
protein, carbohydrate (sweet and nonsweet). The food cups contained
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chocolate sources of four caloric levels: High Fat/ High Sugar (HF/ 
HS), High Fat/ Low Sugar (HF/LS), Low Fat/ High Sugar (LF/LS), Low Fat/ 
Low Sugar (LF/LS) (Table 3.3). Chocolate sources were four caloric levels of 
Carnation® Hot Chocolate mix which were mixed with additional 
hydrogenated shortening and water to provide a non-spill consistency. Low 
Fat versions, which contained water were calculated for evaporation rates by 
weighing separate food cups kept on a shelf in the sam e room. The food cups 
with chocolate choices did not contain the essential vitamins and minerals that 
were included in the other macronutrient food cups. The HF/HS was 
designed to be equivalent to a  typical chocolate bar with 33% fat. Carnation 
Hot Chocolate Powder Mix was used a s  chocolate source. The Rich 
Chocolate (HF/HS) was mixed with fat to constitute 5.56 calories per gram. 
The Sugar Free(HF/LS) was mixed with fat which and was 5.17 calories per 
gram. The 70 Calorie Mix(HS/LF) was combined with water to form a  paste to 
yield 2.65 calories per gram. Diet Hot Chocolate mix (LF/LS) was mixed with 
water to yield 1.19 calories per gram. Statistical data was reported in calories 
not grams.
The diets were mixed in bulk and stored in the freezer until use during 
the 30 day study. The powdered diets were color coded to more easily detect 
the source of spills for maximum accuracy in food intake data collection. 
Liquid food coloring was blended with small amounts of the diet and then 
incorporated into the bulk mixture. The acceptability of the diet consistency 
and formulation and four different forms of chocolate were tested in a  pilot 
study.
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DATA COLLECTION 
Body weight gain was determined daily, and, percentages of body 
weight were calculated over the 30 day study. Body weight gain and 
percentage of body weight gain were calculated within phases to show effects 
of macronutrient choice effects. Food cups were weighed and calculated for 
mean caloric intake daily, over each 10 day phase and at the conclusion of the 
30 day study. Data were collected on an Excel spread sheet with Balance Link 
by Mettler.
Data collection began in phase I (Day 1) with diets of carbohydrate, fat 
and protein sources (Table 3.1) available ad libitum in separate food 
containers, with 10-12 animals per hormone treatment group. In phase II 
(Table 3.2) all groups of rats except the sham group were allowed continuous 
ad libitum access to four macronutrient choices, protein, fat and carbohydrates 
(sweet and nonsweet). Food intake was m easured to the nearest g betw een 
1000 am and 1100 am daily by weighing food dishes: spillage was caught on 
paper towels and weighed. In phase III (Table 3.3) the rats, except the sham  
group, were given four caloric levels of chocolate in addition to the four 
macronutrient choices (protein, fat, carbohydrate- sweet and nonsweet).
BLOOD SAMPLES 
Feeding param eters were followed for a  total of 30 days, ten days for 
each diet phase. Over the next 5 days the rats were fasted 24 hours and then 
removed from their cages one at a  time and sacrificed. Three rats per day 
were randomly selected from each hormone treatment group to ensure that 
rats from all groups were randomly sacrificed throughout the entire time 
period, a  total of fifteen rats per day. Rats were anesthetized with ketamine +
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xylazine, 3:1 (100 mg/ml, 20 mg/ml), 0.1 ml/100g body weight. Blood sam ples 
were taken by cardiac puncture and blood volume recorded. Blood was 
allowed to clot at room temperature. Sample tubes were spun in centrifuge 
tubes to separate the serum, which was then pipetted into labeled Eppendorf
tubes and immersed in ice for later storage at 4° C or -80° C.
Blood sam ples were analyzed using radioimmunoassay for 125l 
estradiol, 125l progesterone and 125l testosterone using Diagnostic Products 
Corporation Coat-a-Count tubes and reagents (Sitteri & Febres, 1979). The 
purpose of this analysis was to verify serum hormone levels for documentation 
of bioactivity. The procedure is based on the competitive inhibition of binding 
radioactively labeled hormones to a  specific antibody. Concentrations of 
hormones in the 10 -1 2  picogram range can be m easured by this technique. 
Cholesterol and HDL cholesterol m easurements were determined using 
Sigma Kits for colorimetric methods (Perkin-Eimer Lamba 1 UV Vis 
spectrophotom eter) ( Friedewald, et al, 1972).
CARCASS COMPOSITION
At the conclusion of the study the rats were sacrificed according to the 
protocol of the animal care committee (LSU Internal Review Board 
Regulations, 1986). The hearts, livers and uteri were harvested, weighed and 
frozen for further analysis.
Carcass composition of the five treatment groups was determined and 
reported in terms of percentage of carcass weight of lipid, protein, and water 
(Maggio, et al., 1984). Eviscerated carcasses, autoclaved under pressure, and 
homogenized using the Brinkman polytron/3500. Aliquots of the carcass 
hom ogenates were analyzed for the determination of nitrogen according to the
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micro-Kjeldahl method, lipid according to the ether extraction method and 
moisture by drying to a  constant weight at 100 degrees C. Weights and 
composition of the excised samples were used in the final calculations. 
Additionally, fat extraction procedures were used to analyze fatty contents of 
the livers using the sam e method described in total body composition analysis. 
The Soctex Instrument made by the Tecator Subsidy of the A Powerstep 
Analytical Co. Indianapolis, Indiana was used in the fat extraction analysis. 
Moisture analysis was conducted in a drying oven made by Sanyo 
Corporation, Sussex, England. Micro-Kjeldahl m easures for protein were 
conducted on the autoanalyzer model BD-20 (Technicon Instruments Corp.) 
according to procedure 976.06 in the Official Methods of Analysis of the 
Association of Official Analytical Chemists, (1990).
STATISTICAL METHODOLOGY
Prior to implantation, rats were randomly divided into five groups. There 
were no significant differences in starting body weights between rats assigned 
to the five treatment groups and no significant difference between groups. 
Hormone implants were surgically implanted in random order. The m ean 
body weight of the group of 55 rats was 268.1 ±3.1 on the day the data 
collection began. However, groups did not weigh the sam e after the two day 
recovery period when the first body weight and food intake data were collected 
and recorded. On day one of the data collection the beginning mean body 
weights were: S: 272±8.2, OV: 266±7.7, E: 258±5.9, E&P: 266.2±6.5, P:
277±3.5.
For analyses of food intake (caloric, macronutrient and chocolate), the 
experiment was divided into three, ten day periods of each diet protocol for a
64
total of 30 days. The food intake and body weight data were divided into three 
phases. For each of these periods, one-way analyses of variance were used 
to determine hormone treatment effects on food intake and body weight data. 
One-way analysis of variance was also used to determine hormonal effects on 
different caloric macronutrient intake. Scheffd’s  multiple comparison 
procedure w as used to determine the differences among the treatments. 
Additionally, linear group contrasts were used to determine the differences 
between the four ovariectomized groups (E, E&P, and P) vs nonhormone (OV), 
between estrogen (E, E&P) vs nonestrogen (OV, P) and between 
progesterone (E&P, P) vs nonprogesterone (OV, E) in clusters of treatments. 
Phase I and phase II differed only by the inclusion of the sweet/nonsweet 
investigation of the carbohydrate macronutrient group.
In Phase III, 4 caloric levels of chocolate were added to the food 
choices. In the analysis of caloric intake, foods were first converted from 
weight consum ed (in grams) to caloric value. From those calculations, 
conversion ratios (CR) of body weight gained per 1000 calories consum ed 
were determined (CR = grams of body weight increase divided by caloric 
intake X 1000). Conversion ratios were calculated for each phase and over the 
30 day period.
One way analysis of variance was utilized to determine the effects of 
hormone treatments on total body weight gain, % body weight gain, total 
caloric intake, % of caloric intake from individual macronutrients and total 
individual macronutrient intake, food intake (macronutrient and chocolate 
choices), body composition, cholesterol, serum hormone levels, liver, heart 
and uterine weights, weight to length ratios, fat content of livers, and caloric
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conversion ratios. Data were collected with the use of Microsoft Excel 
spreadsheets and analyzed with Superanova Statistical software, Abacus 
Concepts (Gagnon, 1989). One way ANOVA with contrasts and ANOVA 
factorial analysis with two independent variables (level of estrogen and 
progesterone) were used. ANOVA percentages were used to statistically 
compare the data obtained as percentages. Phase I analysis was conducted 
on all five groups since they received the sam e food choices. Phase II and III 
were analyzed by including the four ovariectomized groups receiving all food 
choices. Data for the total study reflected all three phases in combined and 
separate analysis. Both four and five group treatments (S for comparison) 
were included in statistical analysis.
PILOT STUDY
A pilot study was conducted to test macronutrient mixtures and 
chocolate (chocolate syrup, chocolate chips, chocolate bars and chocolate 
paste m ade from hot chocolate mix) for palatabiiity and form of presentation to 
minimize spillage and loss (Ulman, personal communication, 1994). The 
chocolate paste w as found to be the most acceptable form to the rats. The 
surgical administration of the hormone by silastic tubing implant was also 
piloted (Richard, 1986). This procedure provided continuous hormone release 
without injections (Smith and Walsh, 1976). All laboratory procedures and 
statistical modeling were examined and evaluated during the pilot testing 
period and by consulting scientists directly involved in endocrinology and 
eating behavior research.
CHAPTER 4 RESULTS AND D ISCU SSIO N
In this section, specific p values for statistical comparisons will be found 
in tables or appendixes (denoted by page number). Statistical techniques 
used for data mentioned in the text will also be denoted in parentheses. In 
Phase I, data in the tables are based on ANOVA with five treatment groups 
and five group ANOVA percentages. Analyses other than five treatment group 
ANOVA are shown in the appendixes, for example four group ANOVA, 
percentages, group contrasts and factorial analysis. Phase II and III are based 
on 4 group ANOVA, excluding the sham. The sham treatment group should be 
judged a s  a  comparison group which was maintained on the three 
macronutrients throughout the study. Abbreviations for treatments are as 
follows: ovaries left in tact (sham), S; ovariectomy with no hormone treatment, 
OV; estradiol, E; estradiol and progesterone, E&P; progesterone, P; all 
endogenous (S) and exogenous hormone treatments, H. All summary figures 
appear in Appendix F (p208-224). Any statement of significance (reported in 
3 digits) m ade in the text m eans that p was less than 0.05. Actual computer 
generated numbers in tables are reported (p=) for the purpose of conversion to 
relative risk ratio calculations for use in future medical and physiological 
publications.
RESULTS OF PHASE I: OVERVIEW
In Phase I, three choices of macronutrients were presented: fat, 
carbohydrate and protein in all five treatment groups.
BODY WEIGHT
Body weight gain (total & %) among groups was affected by hormone 
treatment but caloric intakes were not (Table 4.1 A, Figure 1.0 p208 and 4
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TABLE 4.1 A PHASE I - BODY WEIGHT GAIN 
AND TOTAL CALORIC INTAKE
Treatment Sham Ovariec-
tomized
OV+17B
Estradiol
OV -+* 1713 
Estradiol 
+ Proges­
terone
OV +
Proges-
terone
ANOVA 
p value
Number of
Animals
(n=)
Original 
Weight of 
Animals
12
272»
10
264
11
258
12
271
10
275 p=.388
Total 
Weight 
Gain (g)
20.7± 3.1
(a)
24.4± 2.3
(a)
6.4±2.0
(b)
14.7± 2.7 
(a,b)
27.6± 5.0 
(a)
p=.001
% of gain 7.8% (a) 9.2% (a) 2.6% (b) 5.5%(a,b) 10.0%(a) p=.001
Total
Caloric
Intake
831 ± 
42.0
898 ± 
47.8
773 ± 
35.5
831 ± 
50.5
883 ± 
40.2
p=.314
% of total 38.7% 32.1% 31.0% 31.4% 32.2%
Caloric
Conversion
Ratio*
24.6±3.5
(a)
27.8±2.8
(a)
8.8±2.8
(b)
17.0±2.9
(a.b)
29.8±4.5
(a)
p=.001
• Initial mean body weight of the five groups on day one of data collection was 
268.1.
Values are m eans ± SE. Means in the sam e row with the different superscripts 
are significantly different from each other by Scheffd’s  S procedure for post- 
hoc comparisons.
% of gain is for this 10 day period
% of total caloric intake shows percent of caloric total (phase I, II, III) consumed 
in phase I
* Caloric conversion ratio formula (CR): Grams of body weight increase 
divided by caloric intake X 1000.
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ANOVA p192). OV treated animals implanted with E gained less weight than 
the S, OV, and P {total & % Table 4.1 A). The progesterone treated animals 
were the only hormone group significantly higher than the estrogen group 
(total & % Table 4.1 A), initial body weight differences were examined by 
ANOVA at the beginning of the study. There were no significant differences 
(Table 4.1A ANOVA initial body weight p 193). Group contrasts showed that 
OV animals gained more weight (total & %) than the hormone treated animals 
and E was significantly lower by 59% than NonE (4 group ANOVA p192 total 
& % Table 4.1B). The estrogen effect on decreased body weight gain(4 group 
ANOVA factorial p193) was greater than E&P or P.
CALORIC INTAKE
There was a trend (p=0.052) for decreased caloric intake for the E 
animals compared to Non E animals (Total Table 4.1 B). A trend (p=.054) was 
also shown (4 group ANOVA factorial p193) with four group analysis.
CALORIC CONVERSION RATIO
The conversion of calories consumed into body weight gain w as 
significantly lower for the E group compared to S, OV and P (Total Table 4.1A 
Total 4 group ANOVA p193, 4 group ANOVA factorial p194). Hormone 
treatm ents significantly lowered caloric conversion ratios compared to the OV 
animals with no hormone in group contrasts and E significantly lowered caloric 
conversion ratios compared to Non E (4 group ANOVA p194).
TOTAL FAT
When the distribution of macronutrients consumed (Table 4.1C) w as 
examined there were no significant among treatment differences in
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TABLE 4.1 B PHASE I - G RO U P CO N TRA STS TOTAL 
WEIGHT GAIN AND TOTAL FOOD INTAKE
Tmt n Total
Weight
Gain*
p value Total Caloric 
Intake (kcal)*
p value Caloric
Conversion
Ratio
p value
% 9 %
9 Wt. % kcal
S
vs
12 20.7 7.8 
±3.1 ±1.3
p=.211 831.0 
±42.0
37.9
±1.2
p=.971 24.6
±3.5
p=.756
H 33 15.8
±3.3
5.9
±.9
%p=.191 827.6
±42.1
31.4
±.6
18.4
±3.4
OV
vs
10 24.4
±2.3
9.2
±.8
p=.035 898.0
±47.8
32.2
±.9
p=.194 27.8
±8.9
p=.025
H 33 15.8
±3.3
5.9
±.9
%p=,029 827.6
±42.1
31.4
±.6
18.5
±3.4
E
vs
23 10.7
±1.9
4.1
±.7
p=.001 803.5
±31.3
31.1
±.7
p=.052 12.9
±2.8
p=.001
Non
E
20 26.0
±2.7
9.6
±1.
%p=.001 890.7
±30.4
32.2
±.7
28.8
±3.7
P
vs
22 20.5
±3.0
7.5
±1.1
p=.077 854.9
±32.8
31.6
±.8
p=.632 23.4
±3.7
p=.267
Non
P
21 15.0
±2.5
5.7
±.9
%p=.071 832.8
±31.8
31.6
±.7
18.3
±2.8
Sham = S
Hormones = E, P, E&P 
Ovariectomized = OV, no hormones 
Estrogen = E, E&P 
Non Estrogen = OV, P 
Progesterone = P, E&P 
Non progesterone = OV, E
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TABLE 4.1 C PHASE I - MACRONUTRIENT 
FOOD CHOICES IN KCAL
Treatment Sham Ovariec-
tomized
OV +17(3 
Estradiol
OV +17(3 
Estradiol 
and Pro­
gesterone
OV + 
Proges­
terone
ANOVA 
p value
n 12 10 11 12 10
Total 
Intake of 
Carbo­
hydrate 
(Calories)
368.6 ±
43.1
(a.b)
542.2 ± 
55.4
(a)
372.1 ±
40.6
(a,b)
314.8 ± 
36.2
<b)
413.2 ±
33.6
(a.b)
p=.007
% of total 45.5%
(a,b)
59.4%
(a)
47.5%
(a.b)
38.0%
(b)
47.8%
(a.b)
p=.027
Total 
Intake of 
Protein 
(Calories)
34.4± 6.2 
(a)
84.6 ±
22.8
(a.b)
87.8 
± 17.5 
(a.b)
132 ± 
16.1 
(b)
66.3 ± 
16.8 
(a.b)
p=.001
% of total 4.2%
(a)
9.3%
(a,b)
11.7%
(a.b)
16.2%
(b)
7.6%
(a.b)
p=.001
Total 
Intake of 
Fat
(Calories)
428.0 ± 
58.6
271.5 ± 
41.8
313.3 ± 
35.5
384.4 ± 
41.6
403.6 ± 
57.5
p=.144
% of total 50.3% 31.3% 40.8% 45.8% 44.7% p=.117
Values are m eans ± SE. Means in the sam e row with the different superscripts 
are significantly different from each other by Scheffe’s S procedure for post- 
hoc comparisons (p=.05)
% is for this 10 day period
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calories from fat. However, a  P effect was observed on total fat intake 
compared to NonP (Total Table 4.1 D). Additionally, when fat % group 
contrasts (Table 4.1 D) were conducted, all hormone treatm ents significantly 
increased, fat intake compared to OV which did not receive hormones (Figure 
2.0, 3.0 page 209-210). These findings were confirmed by factorial analysis 
(ANOVA factorial p194). A significant P effect on FAT consumption was 
evident which m eans that P alone had a  greater effect on FAT intake than E 
alone or E combined with P.
TOTAL PROTEIN
E&P treated animals consumed three times as much protein as the S 
animals (Total & % Table 4.1C). In both total and percent group contrasts, S 
consum ed significantly less protein than H, and E consumed significantly more 
protein than NonE (Table 4.1 D).
TOTAL CARBOHYDRATE
E&P treatment consumed less CHO compared to the OV group in both 
total and percent (Table 4.1 C). Similarly, hormone treatments also decreased  
the total intake of CHO in rats a s  contrasted with ovariectomized animals not 
receiving hormones (Total & % Table 4.1 D). Significant differences were also 
observed in E vs. NonE and P vs NonP (Total & %). Also, factorial analysis 
provides evidence that both estrogen and progesterone significantly affect 
CHO intake (4 group ANOVA factorial p195).
DISCUSSION OF PHASE I 
In phase I, the effect of estrogen on decreased body weight gain was 
evident with all statistical methods of analysis. The question of the effects of
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TABLE 4.1 D PHA SE I - G RO U P CO N TRA STS FOR 
TOTAL CARBOHYDRATE, PROTEIN AND FAT
Treat
ment
n Carbohydrate* p value Protein
tc p value Fat* p value
9 9 9
9 % % 9 % % 9 % %
S 12 369.0 45.5 p=.970 34.4 4.3 p=.015 428.0 50.3 p=.263
vs ±43.1 ±5.3 ±6.23 ±.8 ±58.6 ±5.3
H 33 363.7
±36.8
4.1
±2.4
%p=.890 97.4
±16.8
12.1 
±1.3
%p=.001 367.0
±44.9
43.8
±2.7
%p=.197
OV 10 542.0 59.4 p=.001 84.6 9.3 p=.583 272.0 31.3 p=.104
vs ±55.4 ±4.0 ±22.8 ±2.4 ±41.8 ±5.2
H 33 363.7
±36.8
14.0
±2.4
%p=.006 97.4
±16.8
12.1
±1.3
%p=.496 367.0
±44.9
43.8
±2.7
%p=.044
E 23 342.2 42.5 p=.03 110.9 14.0 p=.042 350.0 43.4 p=.818
vs ±27.1 ±2.9 ±12.5 ±1.6 ±28.0 ±3.3
Non 20 478.0 53.6 %p=.019 75.5 8.4 %p=.008 338.0 38.0 %p=,719
E ±34.8 ±14.1 ±13.9 ±6.5 ±37.8 ±3.9
P 22 359.6 42.4 p - 03 102.2 12.3 p=.434 393.0 45.3 p=.043
vs ±26.6 ±3.2 ±3.4 ±1.6 ±33.8 ±3.5
Non 21 453.1 53.2 %p=.022 86.2 10.5 %p=.396 293.0 36.3 % p-.057
P ±38.1 ±2.9 ±13.9 ±7.8 ±26.9 ±3.5
Sham = S
Hormones = E, P, E&P 
Ovariectomized = OV, no hormones 
Estrogen = E, E&P 
Non Estrogen = OV, P 
Progesterone = P E&P 
Non progesterone = OV, E
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exogenous female sex hormones on additional body weight was answered. 
Estrogen replacement curbed the body weight gain which occurred as the 
result of the ovariectomy. The significant differences in body weight were not 
based on caloric intake although a trend for an estrogen effect was observed. 
This raised the question of cause and effect which led to the calculation of 
caloric conversion ratios. Estrogen appeared to cause a  decrease in the 
efficiency rate at which calories are converted into body weight which is 
supported by Stem et. at. (1974), and Storlein et al., (1979) OV converted 
calories more readily into body weight than all hormone treatments. Non E 
treated animals converted more efficiently than those implanted with estrogen.
Hormones may also affect the choice of macronutrients. Animals 
implanted with P consumed significantly more FAT than Non P implanted 
animals. When grouped together, H treated animals consumed more FAT 
than animals in the OV treatment group which received no hormones. This 
supports the hypothesis that FAT intake is higher in the luteal phase of the 
normally cycling female when P levels are elevated. The combination of E&P 
appeared to motivate PRO consumption when compared to S, which ag rees 
with Wurtman, et al. (1992). Factorial analysis revealed that E in the presence 
of P is more effective in stimulating PRO consumption than either hormone 
individually. With group contrasts, hormonally treated animals and those 
implanted specifically with E chose more P than S and Non E treatments. The 
compensation or preference for calories from another macronutrient group by 
the OV animals, was from CHO. They chose more CHO than the E&P treated 
animals. In both total and percent in group contrasts, H, E and P suppressed  
CHO consumption to a  greater degree than OV, Non E and Non P
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respectively. These data imply that hormone replacement may suppress the 
craving for highly refined carbohydrate snack foods.
ft has been known for years that exogenous estrogens exert anorectic 
effects in rodents (Wade, 1976; Wade, Gray, & Bartness, 1985). Reduced food 
intake has been observed following the preovulatory surge of estradiol in 
younger animals that occurs either at proestrus or at the end of the follicular 
phase, depending on the species. In addition, the anorectic effects of 
estrogens (Kemnitz, et al. 1989; Haarbo, et al, 1991; Geary et al, 1994) have 
also been emphasized in ovariectomized animals in which estrogen 
replacement therapies reduce the effect of removal of the ovaries. In rats, 
generally estradiol decreases the intake and increases the expenditure of 
energy, which results in decreased body fat stores in the younger rat models. 
Progesterone reverses nearly all of these effects of estradiol and thus, 
promotes fat storage in rats (Poucher, Tobin, 1985). In a  series of 
experiments, Gray & Wade, (1981) reported increased food intake, body 
weight, and carcass adiposity in OV rats treated with progesterone but not in 
OV rats treated with estradiol benzoate. However, it must be noted that in 
P hase I in the present study, the group without ovariectomy and no exogenous 
hormones (S) responded similarly to the progesterone group. The above 
studies agree with the findings of the present study in the postbreeder rat in 
body weight but not in caloric intake and adiposity. No significant differences 
were observed in body composition in the present study in the older models.
The young female Sprague-Dawley rat model has been used 
extensively in much of the previously reported work on gonadal female sex 
hormones. In earlier studies in younger rats (Gray & Greenwood, 1984) the
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injection of progesterone alone, to OV had no additional effect on food intake 
or body weight beyond that observed in OV only (Blaustein & Wade, 1977; 
W ade & Gray, 1979). This agrees with the present study. Additionally, in his 
review of effects of gonadal hormones, Wade & Schneider (1992) reported 
that administration of progesterone to either estrogen-primed or gonadally 
intact adult rats led to increased food intake and an increased rate of body 
weight gain. This could parallel the luteal phase in the normally cycling female 
(Dalvitt-McPhillips, 1983). Estrogen alone or estrogen combined with 
progesterone a s  shown in the follicular phase in the cycling female 
suppressed body weight gain. An increased level of maturity combined with 
hormonal status may provide the differences observed in the present study. 
Additional research should be conducted on the aging model to examine what 
has earlier been implicated as a  reflection of gonadal influence of food intake 
and body weight.
Fluctuations in the rate of conversion of caloric intake into body weight 
may be seen  under the influence of exogenous female sex hormones both in 
the rodent and the human female and in future studies. The Sprague-Dawley 
rat appears to be a  valuable model in preliminary work to show trends and 
param eters not scientifically measurable in the human. Other aging strains 
and species of animals should also be tested.
Galletti and Klopper (1964) found that when mature female rats were 
given 3.14 mg of progesterone daily for 20 days they showed a  greater body 
weight gain than controls. C arcass analysis revealed this extra weight to be 
due to an increased fat deposition. Immature females did not gain weight 
faster than controls and showed no enhanced fat deposition. They reported
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that when adult female rats were castrated they gained weight faster than 
intact animals but treating such castrated animals with progesterone did not 
cause an additional weight increase beyond the OV effect The average daily 
weight gain in the P treated animals was 2.33g daily compared to the intact 
controls which gained 1.56g body weight per day. The additional body weight 
in the postbreeder OV and P treated animals in the present study reveal the 
sam e results for body weight; however, no significant differences in adiposity 
were observed.
Differences have also been examined in lean compared to obese rats. 
Gray and Greenwood (1984) injected 5 pg of estradiol benzoate (EB) in OV 
rats for five days, which resulted in decreases in the rate of body weight gain in 
both lean and obese Zucker rats. Additionally, EB administration resulted in 
significant induction of progestin binding sites in both neural and adipose 
tissues. However, EB treatment significantly decreased lipoprotein lipase 
activity in adipose tissue from lean but not obese Zucker rats. Their research 
shows that the presence of receptor sites for estrogens and the receptivity of 
the sites for progestins can be demonstrated in both adipose and uterine 
tissues. This suggests that the enzymatic changes that are observed in these 
tissues following hormone administration may be receptor mediated and that 
the original state of lean compared to obese may reveal very different results. 
These mechanisms may also help to explain the results of the present study 
with regard to differences observed in E and P treatments.
The effects of estrogenic stimulation (not progesterone) on diet 
selection were examined by Badness & Waldbillig (1984) on intact, OV and E 
treated animals. The FAT, PRO and CHO levels of laboratory chow were
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manipulated. OV treatment was associated with the nearly exclusive choice of 
higher caloric intake which was decreased in the E treated animals. Total 
caloric intake and body weight did not vary across the estrus (follicular) cycle. 
However diet selection did vary. Fat intake increased; CHO and to a  lesser 
extent, protein intake decreased during estrus when estrogen levels are 
elevated. An opposite diet selection occurred during diestrus (luteal). OV 
treated animals (no endogenous E & P )  chose progressive increases in CHO 
and protein intake, with concurrent decreases in fat consumption. The E 
treated animals partially reversed this diet selection profile demonstrating 
estrogenic reduction in CHO intake with standard high-CHO commercial diets.
In addition, an increase in fat intake during estrogenic stimulation was found. 
This supports the results of the present study with regard to food intake and 
body weight patterns in the OV and E treatments a s  a reflection of estrus.
The mechanistic effects of cyclic estradiol replacement on satiety and 
choiecystokinin (CCK-8) with subsequent resulting body weight gain in 
ovariectomized rats (Geary, et. al, 1994) were recently reported. Estradiol 
significantly increased CCK-8’s  inhibitory effect on sucrose intake. In contrast, 
progesterone alone or in combination with estradiol did not consistently 
influence the satiating potency of CCK-8. Potentiation of the satiating effect of 
CCK released from the small intestine by ingested food may be one of the 
mechanisms by which food intake decreases during the period of high 
estrogen concentration in the estrus cycle. During the 10 week study the 
ovariectomized rats treated only with the sesam e oil vehicle gained about 60 g 
more than the estradiol-treated rats. These results are supported by treatment
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and body weight data found in Phase I of the present study and may help to 
explain estrogen mechanisms.
The physiological phenomena which affected the outcomes in the aging 
female rat in phase I of this study with no significant differences in caloric 
intake (Figure 3.0) are not currently known. In Phase I, all animals received the 
sam e three macronutrient food choices. Estrogen replacement caused  
reduced weight gain, however, progesterone failed to suppress body weight 
gain compared to E treated animals. Additionally, ovariectomy and hormone 
treatm ents significantly altered preferences for macronutrient food choices.
Contrary to previously reported studies (Wade, 1976; W ade & Gray 
1979), the increase in body weight in the present study was not accom panied 
by additional caloric intake in Phase I. However a  trend was observed 
(p=.052) for lower caloric intake in the E treatment. Progesterone, which did 
not significantly increase body weight and food intake in the intact female rat 
(Wade & Gray, 1979) was found to increase body weight in the aging model in 
phase I when compared to estradiol treated animals. This supports the 
conclusions of other previous studies in the younger model (Hervey & Hervey, 
1967) which suggests that both ovariectomy and progesterone increase food 
intake and body weight. Galleti and Klopper (1964) reported that progesterone 
appears to lead to the laying down of fat, and that this can come about in one 
of three ways. Either the animals take in more food, or make more body fat out 
of the sam e amount of food by more efficient use of foodstuffs or else energy 
output is reduced by the sedative effect of progesterone. This view (of 
progesterone effects) in immature animals is supported by the fact that a 
progesterone effect was also observed in mature animals in Phase I and Total
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Study analysis in the present research. Possibly the effect of progesterone on 
weight gain in Phase I in adult female animals arises from the suppression of 
estrus at which time the animals are very active.
The obvious question becomes, was increased caloric expenditure a 
factor? Although the effects of female sex hormones on body weight in young 
rats are rather well documented (Hervey & Hervey, 1967; Wade, 1976; W ade 
& Gray, 1979), there is little information in the literature detailing the 
m echanism s through which these hormones act on the regulation of energy 
balance. According to previous reports, estradiol increases energy 
expenditure by playing a  role in increasing physical activity (Rodier, 1971; 
W ade & Gray, 1979). Richard (1986) has suggested that when food intake is 
kept constant, ovarian hormones affect energy balance by altering energy 
expenditure. In the current study, exercise was not measured. However, 
empirical observations indicate that an increase in body weight gain may be 
due to decreased activity, lack of endogenous hormones or hormone induced 
lethargy. A pronounced lethargy and hostility were observed in P treated 
animals. Voluntary exercise in the aging female rat should be m easured in 
future research studies.
The mechanisms responsible for hormonally induced increases in food 
intake in ovariectomized rodents are also poorly understood. Tarttelin (1973) 
has shown that the effect of the ovariectomy diminishes after 4 weeks. This 
provides evidence of a  potential existing mechanism that results in altered 
caloric conversion ratios shown in the present study. The reported increase in 
food intake observed after ovariectomy (Hervey & Hervey, 1967) is probably 
due to the removal of the circulating estrogens which are known to have an
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anorectic effect. The most interesting concepts surround a  m essenger system 
which sends information from the digestive system to the brain. Neural 
m essengers and the mechanisms involved are currently under investigation to 
determine hormonal effects on food intake regulation in the female rat 
influenced by exogenous female sex hormones (Geary, et al, 1994; Butera, 
1995 personal communication). No conclusive evidence has been published. 
The significant differences in caloric conversion ratios in the present study 
suggest that there may be metabolic alterations stimulated by exogenous 
female sex hormones yet unreported.
In a  review of known or hypothesized potential mechanisms, Wade and 
Schneider (1992) reported that a  transience could be related to estradiol- 
induced shifts in a  hypothetical weight set-point. Changes in food intake 
would in this case  persist only until body weight is brought into line with a  new 
regulated level (Harris, 1990). A more useful working hypothesis may be that 
ovarian steroids act centrally or peripherally to perturb the balance betw een 
the storage and mobilization of metabolic fuels (e.g., via changes in autonomic 
activity, insulin and counter-regulatory hormones, adiopocyte enzyme 
activities, hepatic fuel metabolism, etc.). Food intake could change in 
response to changes in fuel availability that result from these alterations in fuel 
partitioning. Once a  new equilibrium is established, body fuel stores would 
then stabilize at a  new level, and fuel availability (and, consequently, food 
intake) would revert to the previous values. The questions must then be, is this 
phenomenon inevitable in mid life or following an ovariectomy? Can or should 
it be manipulated? Perhaps the current practice of injecting replacement 
hormone into females immediately following the hysterectomy helps to prevent
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this added body weight in the human female. That investigation in the human 
has not been reported (Hayes, personal communication, 1995).
Ovarian steroids affect other food-related behaviors in rats. 
Ovariectomy causes a transient increase in the hoarding of food, and 
treatment with estradiol suppresses food hoarding in ovariectimized rats 
(Coling & Herberg, 1982). Various laboratories have used different protocols 
and different macronutrient sources, generally presented with sucrose in water 
bottles. It is conceivable that ovarian steroids primarily affect hedonic 
responses of rats to taste stimuli, affecting the animals’ response to differences 
in the relative palatability of the available macronutrients. Indeed, ovarian 
steroids have significant effects on rats’ preferences for nonnutritive sweet and 
bitter tastes, and on electrophysiological responses to tastes in the brain stem 
which is a major relay for taste information. Experimental manipulations of 
circulating gonadal steroid levels indicate that many of these changes in 
energy balance with reproductive status are due to the actions of these  
hormones, both in the brain and on nonneural peripheral tissues (DiLorenzo & 
Monroe, 1989; Wade & Zucker, 1969, 1970; Zucker, 1969). Little else is 
known about the neural circuitry mediating the actions of estradiol on food 
intake (Butera, personal communication, 1995).
There are numerous interconnected neural structures which contain 
estrogen receptors and which: 1) receive the chemo-sensory and visceral 
inputs; 2) integrate this information with other sensory cues; and 3) modulate 
the autonomic, hormonal, and behavioral responses to this information (Wade 
& Schneider, 1992). These structures within the brain include the area  
postrema and the nucleus of the solitary tracts, the mid brain central gray, the
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lateral parabrachial nucleus, the central nucleus of the amygdala, the bed 
nucleus of the stria terminallis, the lateral hypothalamus, the paraventricular 
nucleus, and the ventromedial hypothalamus (Loewy, 1990; Pfaff & Keiner, 
1973; Simerly, et al, 1990).
Psychologists, physiologists, biochemists and molecular biologists are 
attempting to m easure and report these mechanisms. W ade (1987) stated that 
one strategy would be to manipulate energy balance with estradiol treatments 
and m easure changes in neuronal function, such as c-fos activity, in brain 
regions known to be associated with regulation of feeding and body weight. 
Indeed, estradiol treatment has been shown to alter c-fos expression in rat 
brain (Hoffman, et al, 1990; Insel, 1990). An obvious problem with this 
approach is that ovarian steroids act in the brain to affect a wide variety of 
behaviors and physiological responses, not just those affecting energy 
balance. In addition, there is substantial anatomical overlap of the neural 
system s controlling energy balance and other hormone-sensitive functions, 
making it difficult to relate hormone-induced neuronal changes to any 
particular behavior or physiological endpoint (Wade & Blaustein, 1978). 
However, it might be possible to avoid, or at least minimize, this problem by 
using nonsteroidal antiestrogens. These compounds (e.g., tamoxifen, 
nafoxidine, MER-25) block most of the neuroendocrine actions of estradiol, 
including running wheel activity, estrus behavior, maternal behavior, and 
gonadotrophin secretion (Andieh, et al, 1987; Bowman, et al, 1983; Gerall, et 
al, 1973; Komisaruk& Beyer, 1972; Labhsetwar, 1970; Roy, et al, 1979; Roy & 
Wade, 1975, 1977; Wade & Blaustein, 1978). On the other hand, nonsteroidal 
antiestrogens mimic the actions of estradiol and reduce food intake and body
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weight in ovariectomized rats; they are completely devoid of antagonistic 
activity on these m easures (Bowman, et al, 1981, 1982; Donohoe & Stevens, 
1982; Gray & Wade, 1981; Roy & Wade, 1977; Wade & Blaustein, 1978).
Although estradiol-induced decreases in food intake undoubtedly 
contribute to the observed decreased body weight gain, pair-feeding 
experiments indicate that behavioral changes are neither necessary nor 
sufficient to cause weight loss. Estradiol-treated rats fail to gain weight even if 
they do not undereat (Kennedy, 1953; Thomas, et al, 1986; Wade, 1974; 
Zucker, 1972). However, in another study the hypophagia normally seen  
during estradiol treatment was not sufficient to cause weight losses in vehicle- 
treated, ovariectomized rats (Wade and Gray, 1979). Finally, the majority of 
the studies reported confirm that ovarictomized rats gain weight and fatten 
whether or not they are permitted to overeat (Bartness & Waldbillig, 1984; 
Landau & Zucker, 1976; Mook, et al, 1972; Roy & Wade, 1977; Thomas, et al, 
1986). Thus, it is clear that estradiol and ovariectomy both have significant 
effects on the postingestive handling and utilization of metabolic fuels. In the 
present study, significant differences in treatment effects of caloric conversions 
ratios are evidence of these phenomonen in the aging rat model.
Earlier research reported on younger animals by Wade, Gray and 
Bartness (1985) indicated that exogenous female sex hormones, in addition to 
the well-known actions on reproductive physiology and behavior, have been 
reported to affect a  wide variety of nonreproductive functions, including the 
metabolic processes that regulate energy balance, body weight, and body 
composition. They have reported that among female rats there are significant 
fluctuations in behavioral and physiological controls of energy balance with
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changes in reproductive conditions such as puberty, ovulatory cycles, 
pregnancy, lactation, and reproductive state. In addition, they have shown 
with experimental manipulations of circulating gonadal hormones that many of 
these changes in energy balance with reproductive status are due to the 
actions of female sex hormones, both in the brain and on non-neural 
peripheral tissues. This work in the mature rat model remains to be done.
The following are some examples of how ovarian steroids act in som e 
metabolically important organs, such as liver and adipose tissue, to adjust the 
metabolism and partitioning of calories. After food is absorbed from the gut, 
most of it enters the splanchnic circulation and is carried to the liver. 
Substrates from other sources (e.g., fatty acids and glycerol from adipose 
tissue, amino acids from muscle) are also carried to the liver. These fuels may 
simply pass through the liver on their way to other organs or they can be 
oxidized, stored a s  glycogen, or converted to other forms (e.g., 
gluconeogenesis, lipogenesis, ketogenesis).
Ovarian steroids have a  number of important effects on hepatic 
handling of metabolic fuels. For example, ovariectomy increases hepatic 
gluconeogenesis and reduces tissue glycogen content, and these changes 
are reversed by treatment with estradiol alone (Ahmed-Sorour & Bailey, 1981; 
Matute & Kalkhoff, 1973; Sladek, 1974). These effects in both human and rats 
could be due to direct hepatic actions of estradiol, because the liver is known 
to be a  target tissue for estrogens (Aten, et al, 1980; Eisenfled, et al, 1977). In 
addition, estradiol could act indirectly by modulating hepatic responsiveness 
to glucoregulatory hormones, or by altering the secretion of these horm ones 
via direct or indirect actions on the pancreas (Ahmed-Sorour & Bailey, 1980;
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Bailey & Ahmed-Sorour, 1980; Faure, et al, 1979; Mandour, et al, 1977; 
Storlien, et al, 1979; Tesone, et al, 1979; Thomas, e t al, 1986).
Manipulations of ovarian steroid levels also affect hepatic lipid 
metabolism. Ovariectomy decreased hepatic lipogenesis and triglyceride and 
lipoprotein production; sustained estradiol replacement therapy reverses 
these changes. However, careful examination of the time-course of these 
effects also indicates that estradiol treatment had biphasic effects on hepatic 
lipid metabolism (Edens & Wade, 1983). In the short term, estradiol inhibits 
hepatic lipogenesis and triglyceride release, but with longer treatment times, 
these functions are stimulated (Eisenfeld, et al, 1977; Gray & Greenwood, 
1982; Kenagy, et al, 1981; Kim & Kalkhoff, 1975, 1978; Ramirez, 1980). 
Therefore, it is not really clear from the existing literature, how the relatively 
rapid (day-to-day, hour-to-hour) changes in circulating levels of ovarian 
steroids that are seen across ovulatory cycles affect hepatic lipid metabolism 
in rats. Clearly cholesterol, LDL, and HDL were affected in the PEPI subjects 
who were postmenopausal females taking exogenous female sex horm ones 
(PEPI Writing Group, 1995).
Ovarian steroids have striking effects on the storage of calories in 
adipose tissue. They do this by altering the activities of the enzymes that 
control both the uptake and release of metabolic fuels by adipocytes. In rats, 
ovariectomy has been shown to increase body fat stores w hereas treatment of 
ovarictomized animals with estradiol decreases body weight and fat content 
(Leshner & Collier, 1973; Wade, Gray, and Bartness, 1985; W ade & Gray, 
1979). Percentage of body composition is not indicated, but should be 
reported in future studies.
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Estradiol probably acts both centrally and peripherally to alter adipose 
tissue fuel metabolism. Rat adipose tissues contain steroid-specific, high- 
affinity, limited capacity receptors for both estrogens and progestins that are  
similar to the receptors in other steroid target tissues (Gray, et al, 1981; Gray & 
Wade, 1979; Pedersen, et al, 1991; Wade & Gray, 1979). These findings 
support the possibility that estradiol could act directly on adipocytes to alter 
enzyme activities (Wade & Schneider, 1992).
It is conceivable that estradiol might act on other peripheral tissues, 
such a s  the liver, to alter adipose tissue enzyme activities indirectly (Wade & 
Gray, 1979). For example, estradiol can act directly on the liver to modulate 
the production and release of certain apoproteins which act as  cofactors for 
adipose tissue lipoprotein lipase (Kim & Kalkhoff, 1978).
The m echanisms in the brain have been more extensively examined. 
Estradiol may act in the brain to modulate adipose tissue metabolism via either 
hormonal (Wade & Schneider, 1992) or autonomic outputs. Cutting the 
sympathetic nerves to retroperitoneal white adipose tissue significantly 
attenuates the estradiol-induced fat pad weight loss (Lazzarini & Wade, 1988 
a). This reduction of fat pad responsiveness to estradiol is not due to a 
decrease in estrogen receptor concentration. Instead estradiol seem s to 
increase the activity of the sympathetic nerves to the retroperitoneal fat pads, 
but not those to the heart (Lazzarini & Wade, 1988b). An estradiol-induced 
increase in release of catecholamines from sympathetic terminals would 
stimulate lipolysis. It is likely that estradiol acts centrally to stimulate 
sympathetic activity, since many of the neural a reas that control autonomic 
activity are also target sites for estradiol (Lowey, 1990; Pfaff & Keiner, 1973;
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Simerly, 1990). Thus, it appears that estradiol enhances lipolysis by acting 
both in the brain to stimulate sympathetic activity (and consequently 
norepinepherine release in adipose tissue) and in adipose tissue to increase 
lipolytic sensitivity to catecholamines (Benoit, et ai, 1982; Hansen, et al, 1980; 
Lacasa, et al, 1991; Lazzarini & Wade, 1988a).
Estradiol may affect adipose tissue physiology indirectly, via the actions 
of other hormones. Estradiol alters the secretion of hormones, which may 
have important effects on metabolism and adipose tissue (Faure, et al, 1983; 
Storlien, et al, 1979; Wade & Gray, 1979). It is unlikely that estradiol-induced 
changes in insulin secretion play a critical role in the effects of estradiol on 
energy balance. Estradiol treatment increases circulating levels of insulin, but 
this should increase, rather than decrease body fat stores. In addition, the 
actions of ovariectomy and estradiol replacement on body weight are not 
impaired in streptozotocin-diabetic rats given controlled amounts of insulin 
(Faure & Sutter-Dub, 1979; Faure, et al, 1983; Mandour, et al, 1977; Storlien, 
et al, 1979; Thomas, et al, 1986).
Estradiol increases the expenditure of metabolic energy via changes in 
both regulatory behaviors and metabolic processes. Ovariectomy decreases 
and estradiol treatment increases metabolic rate and therm ogenesis in rats. 
This estradiol-induced increase in heat production is accompanied by a  rise in 
dry heat loss, so that changes in core temperature are absorbed, or at least 
inconsistent. That is, the extra heat is dissipated as fast a s  it is generated, and 
estradiol increases heat flux without affecting the body tem perature 
substantially (Wade & Schneider, 1992).
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Although thermoregulatory mechanisms often signal the beginning of 
menopause, very little is known about the effects of ovarian steroids on energy 
balance in mature women. Food intake and metabolism are known to vary 
with reproductive condition, including menstrual cycles, pregnancy and 
m enopause (Wade & Schneider, 1992). Virtually nothing is known about the 
effects of exogenous human female sex hormones on energy balance. We 
know only that in women of a  wide variance of ages who are taking 
exogenous female sex hormones, body weight changes occur. More research 
clearly needs to be conducted.
During hormonal shifts throughout the life cycle, females are often 
aware of changes which can be felt physiologically in feelings of fullness, due 
to edem a and perceived permanent additional weight gain (personal 
communication, Hayes, 1993). Whether this is a  temporary state or a metabolic 
alteration is not known. This study sought to m easure body weight shifts a s  
influenced by female sex hormones. The female rat model w as chosen 
because the controlled environment allows more accurate m easures of body 
weight and food intake m easurements than can be obtained in free living 
subjects keeping dietary records. The application of animal data to human 
physiology is often questioned. However, the rat model chosen for this study 
reflects many of the parameters shown in the literature to directly parallel the 
human female a s  suggested by Wade & Schneider (1992). The present study 
also shows a  strong correlation of the rat to the human. The results of the PEPI 
study should relate additional information on the hormonal effects on human 
body weight when it is released in 1996 (The PEPI Writing Group, 1995).
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RESULTS OF PHASE II: OVERVIEW
The availability of sweet and nonsweet CHO sources allowed for the 
additional investigation of hormonal effects. Body weight differences in 
hormonal treatm ents between Phase I and Phase II utilizing the sam e animals 
provided new information with regard to the effects of progesterone and 
provided evidence of regulatory mechanisms. Four food cups containing three 
macronutrient food choices were presented to the four OV groups. The sham  
rats which were used for comparison, continued with the three foods cups. The 
CHO source was divided into sweet and nonsweet components. The caloric 
content of the sweet food choice was 4 times higher in simple sugars than the 
nonsweet. The nonsweet carbohydrate sources were maltodextrin, cornstarch 
and cellulose which are classified as complex carbohydrate food choices 
(carbohydrate formulations Table 3.4). Protein and fat sources were the sam e 
formulation a s  in phase I. The sham group was not included in the following 
tables reported in this chapter. The tables which indicate 5 group contrasts 
and percentages along ANOVA factorials, and 5 group summary graphs can 
be found in the appendix.
BODY WEIGHT
Body weight gain in both absolute and relative m easures (total and %) 
w as greater (Table 4.2A, 5 group ANOVA p196, Figure 5.0 p212) in the OV 
animals than the E&P and P. Ovariectomized animals gained more body 
weight than hormone treated animals (Table 4.2 B total & % 4 group ANOVA 
contrasts 5 group ANOVA p196). P treated animals gained less than Non P 
(total & % 5 group p196, factorial, 197).
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TABLE 4.2A  PHASE II - BODY WEIGHT GAIN AND TOTAL
CALORIC INTAKE
Treatment Ovariec-
tomized
OV + 176 
Estradiol
OV + 17B 
Estradiol 
and Pro­
gesterone
OV + 
Proges­
terone
ANOVA 
p value
Number of
Animals
<n=)
10 11 12 10
Total 
Weight 
Gain (g)
15.3±3.4
(a)
7.3 ±2.1 
(a.b)
4.6 ± 1.4
(b)
4.2 ± 2 .7  
(b)
p=0.009
% gain 5.3%(a) 2.8%(a,b) 1,7%(b) 1.4%(b) p=0.013
Total
Caloric
Intake
953.5 ± 
66.4
822.7 ± 
44.8
838.1 ± 
23.6
871.7 ± 
39.2
p=0.188
% of total 34.1% 33.0% 31.6% 31.8%
Caloric
Conversion
Ratio
15.6±3.2
(a)
7.9±2.1
(a,b)
5.5±1.7 
(a.b)
4.3±3.1
(b)
p=.016
Values are m eans ± SE. Means in the sam e row with the different superscripts 
are significantly different from each other by Scheffe’s S procedure for post- 
hoc comparisons
% of gain is for this 10 day period 
% of total caloric intake shows total for phase
91
TABLE 4.2B  PHA SE II - GROUP CONTRASTS FOR TOTAL 
BODY W EIGHT GAIN AND TOTAL CALORIC INTAKE
Treat
ment
n Total Weight 
Gain*
p value Total Calorie 
Intake*
p value Caloric
Conversion
Ratios
p value
g g
g % % g % %
OV
vs
10 15.3
±3.4
5.3
±1.2
p=.001 954.0
±66.4
34.0 
±1.2
p=.045 15.6±3.2 p=.0024
H 33 5.3
±2.1
2.0
±.4
%p=.002 843.1
±35.9
32.2
±.6
%p=.059 5.9±2.3
E
vs
23 5.9
±1.2
2.3
±.5
p=.122 831.0
±24.2
32.3
±.7
p=.073 7.9±2.1 p=.173
Non
E
20 9.7
±2.5
3.3
±.8
%p=.127 913.0
±38.7
32.9
±.8
%p=.81 9.9±3.2
P
vs
22 4.4
±1.4
1.5
±.5
p=.007 853.8
±21.7
31.9
±.6
p=.473 4.3±3.1 p=.010
Non
P
21 11.1
±2.1
4.0
±.7
%p=.006 884.0
±41.1
33.4
±.8
%p=.486 11.8±2.6
*Mean ± SEM, a.05
Hormones = E, P, E&P 
Ovariectomized = OV, no hormones 
Estrogen = E, E&P 
Non Estrogen = OV, P 
Progesterone = P E&P 
Non progesterone = OV, E
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CALORIC INTAKE
There were no differences in of total caloric intake across the treatments 
(Table 4.2A, 4 group ANOVA factorial p196). However, in total caloric group 
contrasts, OV with no hormone consumed higher levels of calories than 
hormonally treated animals (Total Table 4.2B, 5 group p197).
CALORIC CONVERSION
Caloric conversion ratio (Figure 7.0 p214) was less in the P treated 
animals compared to OV animals (Total Table 4.2A). In group contrasts, OV 
conversion of calories into body weight was higher than in H treated animals, 
and P was lower than Non P (Total Table 4.2B). A progesterone effect on 
caloric conversion ratio was also shown with factorial analysis (4 group 
ANOVA factorial p197).
FAT
No main effects were observed for fat intake (total & %) among the 
treatment groups (Table 4.2 C). However, hormonally treated animals ate a 
greater percentage of fat than OV as revealed by group contrasts and E 
implanted rats consumed a higher % of fat than Non E {% Table 4.2D). Total 
calories comparing FAT, CHO, and PRO are shown in Figure 6.0 p213.
PROTEIN
Total protein consumption (Figure 6.0 p213) was higher in the OV and 
E&P than in P treated animals (Total & % Table 4.2C). Group contrasts also 
revealed that protein intake was higher with the OV than the hormonally 
treated animals (Total Tabie 4.2D). A E&P effect was shown on increased 
protein consumption (4 group ANOVA factorial p197).
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TABLE 4.2C  PHA SE II - MACRONUTRIENT 
FOOD CH O ICES IN KCAL
Treatment Ovariec-
tomized
OV +1713 
Estradiol
OV + 178 
Estradiol and 
Pro­
gesterone
OV + 
Proges­
terone
ANOVA 
p value
Number
of
Animals
(n=)
10 11 12 10
Total In­
take of 
Carbo­
hydrate 
(Calories)
524.2 ± 48.9 
(a)
324.1 ± 45 .4  
(b)
310.4 ± 33 .3  
(b)
395.9±51.8 
(a.b)
p=.007
% of total 56.5% 39.8% 37.0% 47.6% p=.054
Total 
Intake of 
Protein 
(Calories)
78.3 ± 9.4 
(a)
49.6 ± 9.5 
(a.b)
85.0 ± 10.5 
(a)
33.9 ± 3.0 
(b)
p=.001
% of total 8.6%(a,b) 6.2%(a,b) 10.1%(a) 4.0%(b) p=.004
Total 
Intake of 
Fat
(Calories)
351.0 ± 75.7 448.0 ± 60.7 443.5 ± 37.7 441.8± 83.8 p=.683
% of total 34.9% 53.9% 53.0% 48.4% p=.084
Values are m eans ± SE. Means in the sam e row with the different superscripts 
are significantly different from each other by Scheffe’s  S procedure for post- 
hoc comparisons 
% of gain is for this 10 day period 
% of total caloric intake shows total for phase
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TABLE 4.2D  PHASE II - G RO U P CO N TRA STS FOR 
TOTAL CARBOHYDRATE, PROTEIN AND FAT
Treat
ment
n Carbo­
hydrate
p value Protein p value Fat p value
g g g
9 % % g % % g % %
OV 10 524.0 56.5 p=.001 78.3 8.6 p=.042 351.0 34.9 p=.228
vs ±48.9 ±5.4 ±9.4 ±1.2 ±75.7 ±5.1
H 33 340.9 41.1 %p=.020 57.7 7.0 %p=.058 445.0 51.9 %p=.015
±43.5 ±3.0 ±7.7 ±.7 ±60.7 ±3.2
E 23 317.0 38.3 p=.003 68.0 8.3 p=,216 446.0 53.4 p=.450
vs ±27.2 ±3.2 ±7.9 ±.9 ±34.2 ±3.6
Non 20 460.0 52.0 %p=.013 56.1 6.3 %p=.278 397.0 41.7 %p=.042
E ±37.6 ±4.3 ±7.0 ±.8 ±55.9 ±4.5
P 22 349.3 41.7 p=.120 61.8 7.3 p=.616 443.0 50.9 p=.508
vs ±30.4 ±3.7 ±8.0 ±1.0 ±42.1 ±3.9
Non 21 419.4 47.8 %p=.153 63.3 7.4 %p=.581 402.0 44.9 %p=,418
P ±39.4 ±4.2 ±7.3 ±.9 ±48.1 ±4.4
Hormones = E, P, E&P 
Ovariectomized = OV, no hormones 
Estrogen = E, E&P 
Non Estrogen = OV, P 
Progesterone = P E&P 
Non progesterone = OV, E
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TABLE 4 .2E  PH A SE II - CALORIC INTAKE O F SW EET AND 
N O N SW EET CARBOHYDRATE
Treatment Ovariec-
tomized
OV + 17fB 
Estradiol
OV+ 1713 
Estradiol 
and Pro­
gesterone
OV + Pro­
gesterone
ANOVA 
p value
Number of 
Animals (n)
10 11 12 10
SW vs. Non/SW ♦
Sw eet
Carbohydrate
277 ± 26 167 ±21 226 ± 30 164 ± 2 9 p=.017
% 29.2% 21.1% 26.6% 19.9% p=.1678
Nonsweet
Carbohydrate
247 ± 55 
(a)
158 ± 3 9  
(a >b)
85 ± 1 4  
(b)
232 ±4 
(a,b)
p=.015
% 27.3% 18.7% 10.3% 27.6% p=.022
Values are m eans ± SE. Means in the sam e row with the different superscripts 
are significantly different from each other by Scheffe’s S procedure for post- 
hoc comparisons.
♦ E&P intake was significantly different in SW/CHO vs. NON/SW CHO p=.001.
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TABLE 4 .2F  PH A SE II - G RO U P CO N TRA STS CALORIC 
INTAKE O F SW EET AND NONSW EET CARBOHYDRATES
Treat
ment
n SW Carbo-hydrate p value NSW
Carbohydrate
p value
9 9 g
SEM % % g % %
OV 10 277.2 29.2 p=.127 247.1 27.8 p=.0552
vs ±25.8 ±2.5 ±54.7 ±6.3
H 33 185.6
±26.7
22.6
±3.0
%p=.120 157.9
±30.9
18.8
±3.6
%p=.058
E 23 166.5 21.1 p-,253 157.5 18.7 p=,004
vs ±27.2 ±3.2 ±39.4 ±4.4
Non 20 220.7 24.6 %p=. 189 202.3 27.5 %p=.006
E ±27.5 ±3.2 ±47.2 ±5.3
P 22 164.4 19.9 p=.264 231.6 27.6 p=.616
vs ±29.8 ±3.9 ±8.0 ±4.7
Non 21 221.8 25.7 %p=.301 202.3 22.9 %p=,581
P ±47.1 ±2.9 ±94.2 ±5.4
Hormones = E, P, E&P 
Ovariectomized = OV, no hormones 
Estrogen = E, E&P 
Non Estrogen = OV, P 
Progesterone = P E&P 
Non progesterone = OV, E
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CARBOHYDRATE
Macronutrient analysis in phase II (Table 4.2 C-E Figure 6.0 p213), a s in 
phase I, revealed that both E and E&P treatments decreased total CHO intake 
compared to OV (Total Table 4.2C). CHO intake was higher in the OV than in 
hormonally treated animals when using group contrasts (Total & % Table 
4.2D). Estrogen implanted animals consumed less CHO than Non E treated 
animals (Total & % Table 4.2D). E combined with P had a greater effect than 
either separately (4 group ANOVA factorial p198).
SWEET & NONSWEET CARBOHYDRATE
Sweet vs. Nonsweet CHO was significantly different in E&P treated 
animals (Table 4.2E). Sweet carbohydrate consumption was significantly 
higher in the OV than the H treated animals in group contrasts (Total Table 4.2 
F). There was an E&P effect which m eans that E&P combined stimulated more 
SW/CHO intake than E or P separately (4 group ANOVA factorial p198).
E&P treatment group had an intake of nonsweet CHO which was one 
third of the level consumed by the OV animals (Total & % Table 4.2E). 
Estrogen treatment group had a  significantly lower intake of nonsweet CHO 
than the Non E treated animals (Table 4.2F). An E effect was observed (4 
group ANOVA factorial p 198).
DISCUSSION OF PHASE II 
The purpose of phase II was to continue to examine hormonal effects for 
another ten days on body weight, macronutrients and especially “tease  out” 
the type of carbohydrate intake, sweet or nonsweet, a s  affected by exogenous 
female hormones. The effect of estrogen, continued as observed in Phase I, 
but all the other groups and especially the progesterone treated anim als
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adapted and did not continue to gain weight the sam e (Figure 17.0) a s  in 
Phase I. This is important information because currently progesterone is 
perceived to cause body weight gain and this can be a  major reason fem ales 
do not comply with HRT prescriptions given by the physician (Lemer, 1995). 
E&P represents the typical hormone treatment therapy prescribed by 
physicians. In HRT, the progesterone is added to decrease the likelihood of 
reproductive cancer.
When Phase II is compared to Phase I, body weight in four group 
analysis with both total and % analysis revealed increased body weight in the 
OV animals compared to P. OV gained 3 times more body weight than the P 
treated animals. Progesterone treated animals gained an average of only .4 g 
of body weight per day compared to 1.5 g in the OV treatment. Group contrasts 
confirmed these effects with higher body weight in OV compared to H, and 
Non P compared to P.
In Phase II as in Phase I, no significant differences were observed in 
caloric intake. The only caloric consumption differences were observed in OV 
animals which was significantly higher than H when group contrasts were 
examined. With the significant differences in body weight and the absence of 
significant differences in caloric intake among the treatment groups, the 
evidence in Phase II showing hormonal effects on caloric conversion ratios 
was strengthened. OV animals required fewer calories to gain a  gram of body 
weight than did the P treated animals. When grouped, OV body weights were 
higher than H and Non P were higher than P. This provides evidence that 
hormone treatment suppresses the additional body weight gain of the OV and 
that specifically progesterone in Phase II suppressed body weight gain,
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contrary to the results observed in Phase I. It should also be noted that the S 
group responded similarly to the P group in Phase II with dramatically different 
caloric conversion ratios contrasted to Phase I. This slowing of body weight 
gain may be a natural response to elevated body weight gain following 
surgery in Phase I.
Hormones also continued to affect food choices with significant 
differences in macronutrient consumption in Phase II. Macronutrient choices 
revealed that the percent of fat intake was higher in the H and E than in the OV 
and NonE treatments. This agrees with the hypothesis that FAT consumption 
is higher during the luteal phase. Protein intake was higher in OV and E&P 
compared to H and P, confirming an estrogen effect on PRO consumption. 
Total CHO intake was higher in the OV than in the E&P and P with an estrogen 
effect revealed by factorial analysis. In group contrasts OV consum ed more 
total CHO than H and NonE consumed more total CHO than E. With regard to 
consumption patterns for SW/CHO, E&P had a  greater effect when combined 
than either hormone had separately. OV consumed more SW/CHO than H. 
More NSW/CHO was consumed by NonE than E. Additionally, E&P 
consum ed significantly more SW/CHO than NSW/CHO. However, the rats 
were clearly able to discriminate and combine both SW and NSW.
The examination of the hypothesis of hormonal effects on food intake 
and body weight revealed a  different and unexpected result in phase II. The 
reason for the decrease in body weight gain in phase II in the female was 
further examined. One reason may be due to the regulation m echanism 
termed “set point”, which serves as a  thermostat or regulator around which 
upper and lower limits of body weight are maintained reported by Fantino &
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Brinnel (1986). This set point regulation mechanism has also been observed 
in the human female (Harris, 1990).
Calories appear to be converted into body weight at a  higher rate in OV 
animals (postmenopausal model) compared to the S animals (prem enopausal 
model) with intact ovaries. Differences were observed in caloric intake among 
the five groups (Figure 6.0). Comparisons of the percentages of fat 
consumption of the four groups shows fat consumption to be lower in the OV 
compared to H and higher in the E treated animals when compared to NonE in 
agreem ent to Geiselman's et al. findings (1981). The high caloric conversion 
ratio of the OV group is evident in Figure 7.0. This study provides evidence that 
the high CHO intake of the OV group may have contributed to increased body 
weight gain. This information agrees with a  recent report from the Center for 
Genetics, Nutrition, and Health in Washington, D.C., (Simopoulos, 1994) 
which shows that a  high carbohydrate diet or conversely a  low fat diet can be 
fattening, which also supports the research conducted by Tarttelin and Gorski 
(1973).
The unexplained weight gain in 25 to 30 % of the aging population 
(Leibel, 1995) is a subject widely discussed in the popular and professional 
press. Insulin resistance may provide a further explanation of increased body 
weight with high carbohydrate consumption in phase II (Simopolous, 1994).
Abnormalities in carbohydrate and lipid metabolism evident in 
hyperinsulinemia have been investigated by Reaven (1988). He has 
concluded that the possibility exists that resistance to insulin-stimulated 
glucose uptake and hyperinsulinemia are involved in the etiology and clinical 
course of three major related diseases; non-insulin dependent diabetes,
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hypertension and coronary disease. In addition to these conditions, obesity, 
particularly truncal obesity, has been shown to be associated with insulin 
resistance and hyperinsulinemia, increased very-low density lipoprotein 
triglyceride, decreased high-density lipoprotein triglyceride, decreased high- 
density lipoprotein cholesterol and hypertension. Reaven has termed this 
state a s  “syndrome X". The current hypothesis, however, is that syndrome X 
and obesity, whether genetically determined or acquired, might act through 
insulin resistance to cause metabolic abnormalities (Reaven, 1988). From a 
physiological standpoint, it is important to know if insulin resistance is the first 
abnormality from which the others follow. Other factors that modulate insulin 
action should also be studied.
The increased body weight with high CHO consumption may be due to 
an increase in insulin resistance in the OV animals. Treatment with 
exogenous hormones (E and E&P) in the present study resulted in an altered 
rate of weight gain, variation in the intake % of calories consumed a s  CHO and 
the subsequent impact on the caloric conversion ratio. This comparison is also 
indicative of the important role of E and P in the above processes a s  it relates 
to macronutrient selection. It should be mentioned that this research by no 
m eans demonstrates that insulin resistance was confirmed in the OV anim als 
or that E and P are the only hormones involved, a s  many other factors are  
changed with the ovariectomy.
Simopoulos, (1994a) recent research reveals that insulin resistance 
can occur in the preobese state. Typically insulin is not m easured a s  an 
indication of irregular body weight gain in the human, neither was it m easured 
a s  an indicator of body weight changes in this study. However, a  growing
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body of evidence has recently reported that with aging, adult onset diabetes is 
increasing and that 25 to 30 % of the population may suffer from insulin 
resistance (Leibel, 1995). This figure also parallels the percentage of the 
population known to be obese (Atkinson, 1990). Ovariectomy may affect 
insulin resistance and possibly the greater consumption of CHO. The concepts 
of metabolic param eters in obesity correlated to insulin resistance should be 
examined in greater detail in future research.
The environment also has an impact on insulin resistance in the form of 
stress, drugs, smoking, alcohol, diet and inactivity. The effects of these 
environmental factors have been investigated and results indicate that in the 
predisposed individual, saturated fats decrease insulin sensitivity and that 
alcohol raises blood pressure and triglycerides. W hereas regular physical 
exercise improves insulin sensitivity (decreases insulin resistance), reduces 
blood sugar and lipid levels, lowers blood pressure, reduces body fat, and 
leads to weight loss. Subgroups of individuals at high risk in whom markers of 
the predisposition exist, should be identified (Reaven, 1988) by m easuring 
insulin resistance. Some genotypes may be more sensitive to environmental 
influences than others. Based on a  cardiovascular d isease study by Borkman 
et al. (1993) and assuming that dietary fatty acid intake influences the 
composition of muscle membrane phospholipids, the highly refined 
carbohydrate current food supply provides the perfect environmental influence 
in which genetically predisposed individuals gain excess body weight. The 
relationship to insulin resistance is indicated but not currently proven.
Results of the food choice and caloric regulation data in the present 
study may be highly relevant for the human condition. For example, low fat
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cookies are perceived to be a  low calorie food choice, but they truly are not 
low in calories. These food choices are high in calories in the form of simple 
sugars. With this perception and a  CHO appetite an entire box of diet cookies 
can be consum ed by a  postmenopausal woman with high caloric intake and 
increased body weight. Even if excess calories are not consumed, a  diet high 
in simple sugars could theoretically lead to obesity (Reaven, 1988), contrary to 
recent perceptions. In phase II surprisingly, a higher fat intake was observed 
with lower body weight in the E&P treated rats. A recent report (Allred, 1995) 
states “A low fat or low-calorie food is low in neither if multiple servings are  
consumed and excess caloric intake occurs."
In the past, cyclical variations in food intake and body weight in females, 
synchronous with the ovarian cycle, have been well documented. These 
findings are reflected in research in humans (Pliner & Flemming, 1983), in 
monkeys (Rosenblatt, et.al., 1980), and in numerous rodents such a s  the rat 
(Brobeck, Wheatland, & Strominger, 1947; Wade and Gray, 1979), ham ster 
(Miceli & Fleming, 1983; Morin & Flemming, 1978) and guinea pig (Czaja, 
Butera, & McCaffrey, 1983; Czaja & Roy, 1975). In all these species food 
intake and body weight are minimal at estrus, increase, reaching a  maximum 
during diestrus, and then decrease until the next diestrus. The dependence of 
these  cycles on female sex hormones is attested to by their disappearance 
after ovariectomy and their restoration by appropriate hormonal treatment. 
Ovariectomy in younger female rats (Landau & Zucker, 1976; Wade, 1974), 
mice (Blaustein, Gentry, Roy, & Wade, 1976) and hamsters (Miceli & Fleming, 
1983) increases food intake and permanent body weight increase. C arcass 
analyses have indicated that body weight changes represent changes in fat
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m ass within age and treatment groups (Galleti & Klopper, 1964; Gray & Wade, 
1981; Leshner & Collier, 1973; Pallier, Aubert, & Lemonnier, 1980; Wade, 
1976), total protein, and water content (Gavin, Gray, & Johnson, 1983). Data 
reflecting original percent body composition are needed in future research at 
the beginning and end of each phase.
The fluctuation in body weight observed in phase II needs further 
investigation. The addition to the literature of the progesterone effect on 
lowered body weight in the aging model is a  new contribution.
RESULTS OF PHASE III: OVERVIEW
The objective in phase III was to determine hormonal effects on 
chocolate choices and the subsequent impact on caloric regulation and body 
weight beyond the observations in phase II by adding 4 caloric levels of 
chocolate to the existing macronutrient choices. This gave the animals 8 food 
cups from which to choose: the four macronutrients from phase II plus the four 
choices of chocolate. Chocolate choices included: high fat/ high sugar; high 
fat/ low sugar; low fat/ high sugar; and low fat/ low sugar. Hormonal effects on 
chocolate choices and macronutrient preferences were observed. The weight 
gain was not significantly different in this phase among OV, E, P, and E&P 
which received the chocolate food choices however body weight was 
significantly different from S which received the 3 macronutrient choices 
throughout the entire study. The addition of another group, S receiving all 
food choices, would have allowed the investigation of surgery vs. food choices 
but due to death rates early in the study, this group was eliminated.. Statistical 
analysis of the 4 groups compared to 5 groups yielded different results.
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An interesting finding of phase III was that caloric intake was chosen 
from the nutrient deficient chocolate choice to the exclusion of the more 
nutrient dense FAT, CHO, and PRO food cups, which were complete diet 
choices that included all the macronutrients in the recommended amounts. 
Results also revealed that the sweet/nonsweet carbohydrate food choices 
were ignored in preference to the chocolate flavored choices. Caloric intake 
from macronutrients FAT, PRO, and CHO was calculated both separately and 
with those found in the chocolate food cups for comparative analysis.
BODY WEIGHT
No significant differences were observed in total body weight gain when 
excluding the S groups for the statistical analysis (Table 4.3A). The S group 
continued to gain weight at a  rate similar to phase II, while not being given the 
chocolate choices (5 group % S vs H p199). There were no group contrast 
differences in body weight (Table 4.3B). Body weight gain increased across all 
treatments in phase III compared to phase II for ovariectomized rats regardless 
of the type of hormone replacement. Weight gain among the treatment groups 
in this phase was not significantly different. Four group ANOVA is shown in the 
tables in the text. Five group analyses, percentages, and factorials appear in 
the appendix. Body weight was significantly different when S w as included 
(Total & % 5 group ANOVA p 199).
TOTAL CALORIC INTAKE
No significant differences were observed in total caloric intake among 
treatm ents a s  affected by exogenous female sex hormones (Total Table 4.3A). 
There were no total contrast differences in caloric intake (Table 4.3B). Total
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TABLE 4.3A  PHASE III - BODY WEIGHT GAIN AND TOTAL
CALORIC INTAKE
Treatment Ovariec-
tomized
OV +1713 
Estradiol
OV+17IB 
Estradiol 
and Pro- 
gesteron 
e
OV + 
Proges­
terone
ANOVA 
p value
Number of 
Animals(n)
10 11 12 10
Total Weight 
Gain (g)
21.7 ± 
2.6
26.2 ± 
3.1
25.3 ± 
2.7
25.9 ± 
3.5
p=.708
% gain 7.1% 9.6% 8.8% 8.5% p=.351
Total Caloric 
Intake
942± 56 898±30 977± 44 988± 57 p=.516
% of total 33.7% 36.0% 36.8% 36.0%
Caloric
Conversion
Ratio
22.7±2.0 29.2±3.2 25.3±2.1 26.2±3.7 p=.450
Values are  m eans ± SE. Means in the sam e row with the different superscripts 
are  significantly different from each other by Scheffe’s S procedure for post- 
hoc comparisons 
% of gain is for this 10 day period
% of total caloric intake shows total for phase (including chocolate)
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TABLE 4.3B  PHASE III - G RO U P CO N TRA STS FOR BODY 
WEIGHT GAIN AND TOTAL CALORIC INTAKE
Treat
ment
n Body Weight Gain* p value Total Calorie 
Intake*
p value
g g
9 % % kcai % %
OV
vs
10 21.7
±2.6
7.1
±.7
p=.251 942.1
±56.0
33.8
±1.1
p=.815
H 33 25.8 9.0 %p=.268 955.0 36.4 %p=.794
±3.1 ±.6 ±25.0 ±.6
E 23 25.8 9.2 p=.515 940.0 36.6 p=.578
vs ±2.0 ±.7 ±27.6 ±.6
Non E 20 23.8 7.8 %p=.526 965.2 34.9 %p=.457
±2.2 ±.7 ±39.4 ±.9
P 22 25.6 8.6 p=.577 983.4 36.5 p=.184
vs ±2.1 ±.7 ±34.3 ±.8
Non P 21 24.0
±2.1
8.4
±.7
%p=.563 919.1
±30.5
35.0
±.7
%p=.145
*Mean ± SEM, a.05
Hormone = E, P, E&P 
Ovariectomized = OV, no hormone 
Estrogen = E, E&P 
Non Estrogen = OV, P 
Progesterone = P, E&P 
Non progesterone = OV, E
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calories reflect intake from all sources. Caloric intake was significantly different 
when S was included (Total & 5 group ANOVA p 199).
CALORIC CONVERSION RATIO
No significant differences were observed among OV treated animals, 
with or without exogenous hormone replacement treatment (Total Table 4.3A). 
Caloric conversion ratios were not significantly different when S w as included. 
TOTAL FAT
No significant differences were observed in % or total fat among the 
groups (Table 4.3C). There were no group contrast differences in fat intake 
(Table 4.3D). However, it should be noted that high fat, high sugar chocolate 
intake contributed the major portion of high fat intake in the caloric 
consumption profile (Total & % Table 4.3E ). No significant differences were 
observed in 5 group analysis.
TOTAL PROTEIN
No significant differences were observed in protein intake (Table 4.3C). 
Factorial analysis revealed an interaction effect of E&P which m eans that with 
regard to protein intake, the presence of E with P had a  greater effect than 
either alone (4 group ANOVA factorial p200).
TOTAL CARBOHYDRATE
For the first time in the thirty day study there were no significant 
differences in total CHO intake for both total and % (Table 4.3C). There were 
no differences in CHO in group contrasts analysis (Table 4.3D). In this phase 
of the study neither the estrogen nor progesterone treatments affected the 
carbohydrate consumption. No significant differences were observed in N/SW 
CHO or in SW/CHO.
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TABLE 4 .3C  PHA SE III - MACRONUTRIENT 
FOOD CH O ICES AND CHOCOLATE
Treatment Ovariec-
tomized
OV+1713
Estradioi
OV +176 
Estradiol 
and Pro­
gesterone
OV + Pro­
gesterone
ANOVA 
p value
Number of
Animals
(n)
10 11 12 10
Intake of 
Carbohy­
drates 
(Calories)
432.7
±37.0
441.9
±38.1
389.7
±23.8
431.9
±58.9
p=.814
% of total 46.8% 43.8% 45.3% 44.1% ]D=.965
Intake of
Protein
(Calories)
72.1
±16.9
34.2
±7.7
74.2
±10.8
49.2
±11.5
p=.062
% of total 7.5% 4.0% 8.1% 4.8% p=.087
Intake of 
Fat
(Calories)
437.3
±51.2
474.3
±59.1
463.2
±37.5
507.0
±72.8
p=.858
% of total 45.7% 52.1% 46.6% 51.1% p=.708
Values are m eans ± SE.
% of gain is for this 10 day period
% of total caloric intake shows total for phase (includes chocolate)
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TABLE 4.3D  PHA SE III - G RO U P CO N TRA STS FOR 
CARBOHYDRATE, PROTEIN AND FAT
Treat
ment
n CHO
Intake
kcal
p Value PRO
Intake
kcal
p Value Fat
Intake
kcal
P
Value
9 9 9.
9 % % 9 % % 9 ' % %
OV 10 432.7 46.8 p=.819 72.1 7.5 p=.174 437.3 45.7 p=.612
vs ±37.7 ±4.2 ±16.9 ±1.7 ±51.2 ±4.3
H 33 420.0 44.5 %p=.716 53.3 5.7 %p=.153 480.2 49.8 %p=.596
±42.9 ±2.5 ±10.0 ±.7 ±56.5 ±2.7
E 23 416.9 44.6 p=.698 54.2 6.2 p=.592 468.5 49.2 p=.994
vs ±25.3 ±2.6 ±7.8 ±1.0 ±35.6 ±2.9
Non 20 432.3 45.5 %p=.647 60.6 6.1 %p=.479 472.2 48.4 %p=.972
E ±34.0 ±3.4 ±10.3 ±1.0 ±44.1 ±3.6
P 22 437.4 44.8 p=.547 62.2 6.6 p=.477 483.1 48.6 P-.698
vs ±28.9 ±2.7 ±8.2 ±1.0 ±38.2 ±2.9
Non 21 410.2 45.2 %p=.562 53.1 5.7 %p=.424 456.7 49.1 %p=.629
P ±29.8 ±3.3 ±19.7 ±1.0 ±38.6 ±3.6
*Mean ± SEM, a.05
Hormone -  E, P, E&P 
Ovariectomized = OV, no hormone 
Estrogen = E, E&P 
Non E = OV, P 
Progesterone = P, E&P 
Non progesterone = OV, E
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TABLE 4.3E  PH A SE III - MACRONUTRIENT FOOD 
CH O ICES C O N TRA STS O F CHOCOLATE CH O ICES*
Treatment Ovariec-
tomized
OV+1713
Estradiol
OV + 178 
Estradiol + 
Proges­
terone
OV +
Proges-
terone
p value
High Fat/ 
High
330.0 ± 65.4 271.9 ± 38.3 400.4 ± 41 .8 346.3 ±49.1 p=.302
S ugar 
Choco­
late cal.
(599) (48.9g) (71.9g) (62.2g)
% 33.9±5.5 31.3 ±5.2 40.8±3.9 34.7±3.4 p=.483
High Fat/ 32.1 ± 8 .7 13.9 ±3.9 53.3±12.1 41.3± 10.9 p=.036
Low
S ugar
(a,b) (a) (b) (a,b)
Chocolate
cal.
(6.2g) (2.7g) (10.3g) (8.0g)
% 3.2±0.7 1.5±.4 5.3±1.1 4.3±1.1 p=.024
Low Fat/ 
High
54.9 ± 21 .4 42.2 ± 8.5 46.6 ± 12.1 33.7 ± 10.0 p=.757
Sugar
Chocolate
cal.
(20.7g) (15.9g) (17.6g) (12.7g)
% 6.2±2.6 4.6±0.9 4.6±1.1 3.7±1.1 p=.729
Low Fat/ 
Low
22.8 ± 4.7 27.1 ±5.3 20.7 ± 2.8 27.0 ± 5.5 p=.757
Sugar
Chocolate
cal.
(19.2g) (22.8g) (17.4g) (22.7g)
% 2.6±0.6 3.0±0.5 2.2±0.3 3.0±0.7 p=.675
*AII chocolate combined:
Total kcal 439.8. 355.1 521.0 448.4
% Total kcal 46.7% 39.5% 53.3% 45.4%
Values are m eans ± SE. Means in the sam e row with the different superscripts 
are significantly different from each other by Scheffe’s  S procedure for post- 
hoc comparisons 
% of gain is for this 10 day period
% of total caloric intake shows total for phase (chocolate only)
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TOTAL CHOCOLATE
All groups that were given chocolate demonstrated a  preference for 
High Fat/ High sugar chocolate, consuming from 272 to 400 kcal of this food 
choice. All other chocolate choices were ingested in smaller amounts. E&P 
consum ed higher levels of HF/LS than E (Total & % Table 4.3E). P consum ed 
higher levels of the HF/LS than the Non P (Total & % ). The effect of P was a 
greater than E or E&P on HF/LS chocolate intake (4 group ANOVA factorial 
p200). During this phase, 40 - 53% of calories consum ed cam e from the 
chocolate food choices.
DISCUSSION OF PHASE III 
The overriding effect of chocolate on food choice, body weight gain and 
caloric regulation in Phase III was a  new contribution in this research. The 
paste form was similar to the consistency of bonbons. Much higher levels of 
chocolate consumption than previously expected were recorded. Careful 
observation of the data revealed that the rats increased their preference for the 
chocolate food cups across all treatment groups, and did so to the exclusion of 
the more macronutrient dense selections, FAT, CHO and PRO. These three 
macronutrient food choices had been carefully planned and balanced to 
provide all essential vitamins and minerals but were dramatically excluded in 
preference to chocolate. The S group did not receive the chocolate choices 
but served a s  a  comparison group of endogenous hormonal effects on FAT, 
CHO, and PRO in the normally cycling rat of the sam e age. When the S group 
w as included for comparison, the following significant differences were 
observed: body weight, caloric intake, and caloric conversion ratio differences. 
Therefore, not surprisingly, in group contrasts, S was significantly different
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than H. Figures 8.0 through 10.0 (pp 215-217) give the reader a  review of the 
five group comparisons. The tables and analyses in this section for Phase III 
reflect four group comparisons in total and percent. Body weight, caloric 
intake, and caloric conversion ratios in the four groups were not significantly 
different.
Macronutrient choices as influenced by hormones were evident but no 
differences were observed in the SW/NSW CHO profile in the analyses in 
phase III. Factorial analysis provided additional information with regard to the 
E&P effect of protein consumption. This indicates that the combination of 
hormones has a  more powerful influence on protein consumption than when 
estrogen and progesterone are administered separately. To parallel the 
evidence from the current study with the human female; estrus compares to the 
follicular phase when estrogen levels are endogenously higher and diestrus 
com pares to the luteal phase when progesterone levels are elevated. The 
reader will recall that E&P is typically prescribed for women with a  uterus and 
E alone to those who have had a hysterectomy.
The question: do hormones affect chocolate consumption was clearly 
answered. The overriding effect of HF/HS chocolate on macronutrient choices 
in the OV retired breeder female rat was quite evident. The suppressing effect 
of estrogen on body weight in Phase I and the suppressing effect of 
progesterone on body weight in phase II was “wiped out” in phase III when 
chocolate was presented a s  a  food choice. The only significant differences in 
chocolate consumption in phase III were the preferences for HF/LS in the E&P 
vs E treatments and the group contrasts in P vs. NonP. In this case, the fat in 
the chocolate (HF/LS) seem ed to be a greater attraction than the sucrose to
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the E&P group. When E and P effects (for HF/LS) were compared in factorial 
analysis the P effect was greater than either the E&P combined or the E alone. 
In a  broader sense, this may indicate that females on a continuous combined 
regimen of estrogen (Premarin®) and progesterone (Provera®) may 
experience a  greater attraction to chocolate, regardless of sw eet flavor 
sources. And that when P levels are higher (in the luteal phase or when 
cyclical hormone replacement is prescribed, E for 12 days and E&P for 12 
days), FAT and chocolate are more important than sucrose. Chocolate and fat 
may be craved (in contrast to sugar) when both E and P are elevated (in 
diestrus in the rat) (luteal phase in the cycling female) and when progesterone 
is taken in hormone replacement therapy.
This indicates that the progesterone effect relates more to fat choice 
than to sucrose preference. This progesterone effect was further em phasized 
in group analysis in both total and percent. P treated animals preferred the 
HF/LS in significantly greater quantities than Non P treated animals. This 
shows that the rat can discriminate between sweet flavors when they are 
combined with chocolate and FAT. This potential parallel to the human adds 
merit to the use of the Sprague-Dawley rat in this type of research. The 
human literature strongly reports the progesterone effect of chocolate and FAT 
choices in the luteal phase when progesterone levels are high. This may help 
explain the hypothesis of preferred (craved) fat and chocolate intake just prior 
to menstruation.
The increase in total chocolate calories em phasizes the attraction to 
chocolate compared to the more nutrient dense foods. They were clearly 
ignored in preference to chocolate. It is presumed that the S group would
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also have chosen chocolate had the choice been given and that chocolate 
would also have increased the S body weight. Further research should be 
conducted to determine if the surgical effect of the removal of the ovaries 
affected these food choices or altered metabolic conversion rates.
This evidence challenges the Bowen and Grunberg (1990) hypothesis 
which reported increased sweet preference in the luteal phase with 
documented progesterone levels. However, the reader will recall that their 
sw eet choices also included fat and chocolate. This evidence agrees with the 
earlier work by Abraham (1984) who reported cravings for chocolate in the 
luteal phase. Pliner and Fleming (1983) also found that both body weight and 
food intake were significantly higher during the luteal phase than during the 
follicular phase in menstruating women. In a later study (1983) they also 
reported decreased sucrose preference both before and after a  sucrose load 
during the luteal phase but not in the follicular phase.
Aaron’s work (1975) which supports these findings reported greater 
p leasantness of the sweet taste in the follicular phase which lowered during 
the luteal phase when progesterone levels were higher and estradiol and 
estrone were lower. Without regard for the hormonal phase, Smith and Sauder 
(1969) stated that 85% of those who craved chocolates also included 
them selves in the group that craved sweets. The current data clearly indicate 
that eating behavior research should always reveal the stage in the menstrual 
cycle or source of exogenous hormones when reporting food intake data in the 
future.
These results also emphasize the importance of studying not only sugar 
preference but also fat preference. When the evidence from the three phases
116
is combined, the ‘leasing out” of the sweet, fat and chocolate components are 
possible. In phase I , H (E and P) consumed a significantly higher % of dietary 
FAT than OV. And P treated animals consumed significantly more total FAT 
than NonP. Evidence from phase II clearly indicates a  sweet preference (3 
times higher) in the E&P treated animals over nonsweet carbohydrate. And in 
Phase III, the study shows that the high fat/low sugar chocolate is preferred by 
the E&P animals in contrast to E. This indicates that in the aging female rat, 
FAT and chocolate may be preferentially chosen over the sweet when both 
estrogen and progesterone levels are elevated. This also provides evidence 
of the value of using the sam e rats over the 30 day study under the influence of 
the sam e hormones with three different food choice patterns. Through varying 
the macronutrients in phase I we were able to discern hormonal effects on the 
choice of FAT, CHO or PRO. In phase II we were able to further discriminate 
between the sweet and nonsweet. Then in phase III we were able to separate  
the hormonal effects further with the four caloric levels of chocolate by 
separating high and low fat levels with saccharin and sucrose and observing 
the P effect of FAT and chocolate over sucrose.
Flavor, palatability and the opioid effect of chocolate are  likely 
contributing factors (Drenowski, 1985). Data on the preferred HF/HS type of 
chocolate were also observed (Giraudo, et al., 1993). The rats chose the more 
palatable chocolate choices a s  is typically seen in the human population. No 
definitive evidence in animals or humans was reported to explain the 
preference for chocolate. Discriminatory palatability differences in the 
Sprague-Dawley rat have been shown in earlier taste tests in rats (Hamilton, 
et al., 1995). Addition research is needed to investigate the excessively high
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levels {40-53% during the 10 day study) of chocolate intake in all 
ovariectomized animals.
This paste form of chocolate in four caloric levels may be a new addition 
to the eating behavior taste research arena. The paste form used w as quite 
palatable, easy  to manage, and the most acceptable form of chocolate chosen 
by rats in a  pilot study when chocolate chips, chocolate bars, chocolate syrup 
and the paste form were compared.
No female rat studies comparing chocolate consumption under 
hormonal influence have been reported. However, earlier studies m easuring 
other param eters have reported the use of chocolate in the Sprague-Dawley 
rat (Runyan et al, 1990, Richard et al, 1982). In one such study, cocoa powder 
was fed to male and female Sprague-Dawley rats in a  multi-generational study 
to examine toxicity and carcinogenicity (likelihood of cancer). No evidence of 
carcinogenicity was reported in either gender (Tarka, et al., 1991).
Few recent human chocolate eating behavior studies have been 
conducted which m easure hormonal influences. One human study m easuring 
fat, carbohydrate and chocolate indicated increasing preferences for chocolate 
a s  body weight increased and obesity advanced over time (Drewnowski, et al., 
1985). Increased body weight was positively correlated to food preferences 
for fats, sw eets and chocolate. In another study, Hetherington & Macdiarmid 
(1995) m easured responses to three different presentations of chocolate in 
two groups of females: overeaters and moderate eaters. Three conditions of 
presentation were (a) a  fixed amount of milk chocolate; (b) ad lib access to 
milk chocolate; and (c) a  self-selected amount of the individual's most 
preferred form of chocolate. The results revealed that variables associated
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with the excitation of appetite were higher in overeaters and variables 
associated with the inhibition of appetite were lower in the overeaters relative 
to the controls. This study suggests that investigations of individuals who eat 
certain foods to excess can help define normative and aberrant eating 
behavior. This is an important contribution in eating behavior research. 
However, actual levels of chocolate intake were not reported. The 
m easurem ent of hormonal profiles in future female studies should be 
documented and correlated to food intake parameters.
Interestingly, in the present study with chocolate consumption in phase 
III, rats increased caloric intake compared to phase II, and no significant 
differences were observed in body weight gain and total caloric intake within 
this 10 day period in the four groups receiving chocolate choices. Also, no 
differences were observed in overall FAT, CHO, and PRO intake which 
included the fat and carbohydrate from the chocolate choices. The actual 
intake of the nutrient rich FAT, CHO, and PRO food choices was decreased as 
fat and carbohydrate were consumed from the HF/HS chocolate choice.
Choices from the chocolate food cups which were consumed in large 
quantities (40-53% of caloric intake) were nutrient deficient. This m eans that 
the rats were not consuming a nutritionally balanced diet. With respect to 
micronutrients, they were getting about one-half the daily NRC 
recommendations (Reeves et al, 1993). While this is not critical for a ten day 
study period, on a  long term basis the animals may become seriously 
deficient, depending on individual requirements. Aging human fem ales may 
also choose nutrient deficient snack foods to the exclusion of more nutrient
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dense foods that could help combat osteoporosis, B-vitamin deficiencies and 
other nutrient related diseases.
Often in the human, the additional chocolate is eaten for dessert. To 
date we do not have conclusive evidence in the aging female a s  to whether 
this is added a s  excess caloric intake or is chosen a s  the major portion of the 
diet in preference to nutrient dense foods as was observed with the female rat. 
However, the rats did increase total caloric intake by 9.24% from phase II to 
phase III when the caloric preference included chocolate. Both the rat and the 
human female may choose chocolate in preference to more nutrient dense  
foods when the choice in available with subsequent body weight increase and 
negative health benefits.
RESULTS: ACROSS ALL PHASES
The following results are reported for both five and four group analysis. 
Data in tables are based on 5 group ANOVA. All percentages, contrasts and 
factorials are in the appendixes. There are limitations in the interpretation of 
these data across all phases. One weakness is that the sam e animals were 
used throughout the 3 phases in the 30 day study. Ideally animals would have 
been sacrificed at the conclusion of each phase.
BODY WEIGHT
Five Group Analysis: Total body weight was higher in the OV and P 
animals compared to the S over the 3 phases in both total and %(Table 
4.4A).Group contrasts revealed that in averages over the 30 days, S was lower 
than H, OV was higher than H, E was lower than Non E (Total & % Table 4.4B).
Four Group Analysis: The total body weight was higher in the OV 
animals compared to H and E was significantly lower than Non E (4 group
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Total & % ANOVA contrasts p 201). An estrogen effect was observed (4 group 
ANOVA factorial p202) which means that E had a  greater effect on decreased  
body weight than E&P or P alone.
TOTAL CALORIES
Five Group Analysis: The average in total caloric intake over the three 
phases for S was lower than the averages for E, E&P, P, and OV (Total & % 
Table 4.4A). S was lower than H (total) and E revealed a  trend of a  lower 
average caloric intake than Non E in group contrasts (Table 4.4B).
Four Group Analysis: ANOVA showed no significant differences in the 
caloric intake across the phases (4 group ANOVA).
CALORIC CONVERSION RATIO
Five Group Analysis: S was lower than P and OV (Total & % Table 4.4 
A). S was lower than H, and E was lower than Non E (Total Table 4.4B) in 
group contrasts. An effect was observed in factorial analysis (p203).
Four Group Analysis: A trend, P..058, was observed in 4 groups (p202).
E was lower than Non E (Total 4 group ANOVA p202).
TOTAL FAT
Five Group Analysis: Total fat intake was not significantly different 
(Table 4.4C). OV was lower in percentage (not total) of fat consumed than H 
across all phases (Table 4.4D) (Figure 14 & 16 p221-223).
Four Group Analysis: No differences were observed.
TOTAL PROTEIN
Five Group Analysis: S and P consumed less protein than E&P (Total & 
% Table 4.4C). S consumed less protein than H (Total Table 4.4D).
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TABLE 4.4A  TOTAL STUDY - BODY WEIGHT GAIN AND 
TOTAL CALORIC INTAKE AND CONVERSION RATIOS
Treatment Sham Ovariec-
tomized
OV +1713 
Estradiol
OV + 176  
Estradiol 
and Pro­
gesterone
OV + Pro­
gesterone
ANOV
A
P
value
Number of 
Ani-mals (n)
12 10 11 12 10
Total 
Weight 
Gain (g)
27.3± 4.4 
(a)
61.4 ± 6.5
( b )
39.9± 5.2 
( a , b )
44.6 ± 3.2 
( a ,b )
57.7 ± 6.0 
( b )
p=.001
% gain 10% (a) 23% (b) 16%(a,b) 16.7%(a,b) 21% (b) T3 II o o
Total 
Caloric 
intake (kcal)
2184±69
(a)
2794±144 
( b )
2493 ±83 
( b )
2650 ± 93 
( b )
2743±100
( b )
p=.001
Conversion 
Ratio •
12.2 ± 
1.8(a)
22.1 ± 2 .8  
( b )
16.0±.2.0
(a,b)
16.8 ±1.1 
(a,b)
21.0 ± 2 .0  
( b )
p=.003
Values are m eans ± SE. Means in the sam e row with the different superscripts 
are significantly different from each other by Schefte’s  S procedure for post- 
hoc comparisons
• Conversion ratio is body weight increase divided by total caloric intake over 
30 days x 1000 or g wt. gained/1000 kcal consumed
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TABLE 4 .4B  TOTAL STUDY - G RO U P CO N TRA STS O F 
BODY WEIGHT GAIN AND TOTAL CALORIC INTAKE
Treat n Total Weight 
Gain*
p value Total
Calorie
Intake*
p value Conversion
Ratio
p value
9 kcal
9 % % Mean±SEM Mean±SEM
S
vs
12 27.3
±4.4
10.4
±1.8
p=.001 2184 ± 7 0 p= .002 12.2±1.8 p=.008
H 33 47.0
±4.8
17.6
±1.1
%p=.001 2627 ± 47 17.8±2.0
Ov
vs
10 61.4
±6.5
23.1
±2.4
p=.024 2794 ± 144 p -  .165 22.1 ±2.3 p=.063
H 33 47.0
±4.8
17.6
±1.1
%p=.024 2627 ± 47 17.8±2.0
E
vs
23 42.3
±2.8
16.2
±1.2
p=.001 2582 ± 61 p= .053 16.3±1.0 p=.008
N oE 20 60.5
±4.4
21.9
±1.6
%p=.005 2769 ± 90 21.9±1.5
P
vs
22 50.6
±3.4
18.6
±1.2
p=.917 2692 ± 67 p= .599 18.7±1.1 p=.920
N oP 21 50.1
±4.7
19.2
±1.8
%p=.998 2636 ± 86 18.9±1.6
*Mean ± SEM, a.05
Sham = S
Hormones = E, P, E&P 
Ovariectomized = OV, no hormones 
Estrogen = E, E&P 
No Estrogen = OV, P 
Progesterone = P E&P 
No progesterone = OV, E
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TABLE 4 .4C  TOTAL STUDY - MACRONUTRIENT 
FOOD CHOICES IN KCAL
Treatment Sham Ovariec-
tomized
OV + 17B 
Estradiol
OV + 17fB 
Estradiol 
and Pro­
gesterone
OV + 
Proges­
terone
ANOVA 
p value
Number of
Animals
(n)
12 10 11 12 10
Intake of 
Carbohy­
drates 
(Calories)
811 ±90
(a)
1499± 112 
(b)
1086± 117 
(a.b)
1067± 65 
(a,b)
1241±131 
(a,b)
p=.001
% of total 38.0% 53.9% 43.6% 40.4% 46.1% p=.082
Intake of
Protein
(Calories)
118±17 
(a)
235 ± 31 
(a,b)
172 ± 3 0  
(a,b)
291 ± 30 
(b)
149 ± 2 8  
(a)
p=.001
% of total 5.5%(b) 8.6%(a,b) 7.1%(a,b) 11.2%(a) 5.4%(b) p=.003
Intake of 
Fat
(Calories)
1255±137 1060± 130 1236±142 1291 ±101 1352±197 p=.701
% of total 56.5% 37.5% 49.3% 48.3% 48.5% p=.088
Values are m eans ± SE. Means in the sam e row with the different superscripts 
are significantly different from each other by Scheff6’s  S procedure for post- 
hoc comparisons
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TABLE 4.4D  G RO U P CONTRASTS O F TOTAL STUDY 
M ACRONUTRIENT FOOD CH O ICES INTAKE
Tmt n Intake of
Carbohydrate★
p value Intake of 
Protein*
p value Intake of 
Fat*
p value
total total total
total % % total % % total % %
S
vs
12 811
±90
38.0
±4.7
p=.008 118
±17
5.5
±.8
p=.007 1255
±137
56.5
±5.1
p=.812
H 33 1126
±104
43.2
±2.2
%p=.057 208
±29
8.1
±.8
%p=.061 1291
±147
48.7
±2.5
%p=.961
OV
vs
10 1499
±112
53.9
±3.5
p=.004 235
±31
8.6
±1.2
p=.352 1060
±130
37.5
±3.8
p=.176
H 33 1126
±104
43.2
±2.2
%p=.036 208
±29
8.1
±.8
%p=.396 1291
±147
48.7
±2.5
%p=.046
E
vs
23 1057
±64
42.0
±2.4
p=.007 227
±24
9.3
±1.1
p=.164 1298
±87
48.8
±2.8
p=.692
Non
E
20 1410
±84
50.0
±3.1
p=.051 199
±23
7.0
±.8
%p=.194 1161
±117
43.0
±3.6
%p=.716
P
vs
22 1146
±70
43.0
±2.7
p=.192 227
±27
8.6
±1.1
p=.541 1319
±102
48.4
±3.0
p=.232
NonP 21 1283
±92
48.5
±2.9
%p=.212 202
±22
7.8
±.9
%p=.612 1152
±96
43.7
±3.3
%p=.295
*Mean ± SEM, a.05
Sham = S
Hormones = E, P, E&P 
Ovariectomized = OV, no hormones 
Estrogen = E, E&P 
Non Estrogen = OV, P 
Progesterone = P, E&P 
Non progesterone = OV, E
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Four Group Analysis: E&P animals consumed more protein than both E 
and P treatment groups (Total p203). An E&P effect was observed (4 group 
ANOVA factorial p 203). This m eans that the presence of estrogen with 
progesterone had a  more significant impact on protein consumption than 
estrogen or progesterone alone.
TOTAL CARBOHYDRATE
Five Group Analysis: Carbohydrate intake was lower in S than OV 
(Total Table 4.4C). S consumed less than H (total), OV consumed more than 
H (total & %), E consumed less than Non E (total), (Table 4.4D).
Four Group Analysis: OV was higher than H, and E was lower than Non 
E (Total 4 group ANOVA p203). An estrogen effect was shown on 
carbohydrate intake (4 group ANOVA factorial p204). This m eans that the 
presence of estrogen alone had a  more significant impact on lowered CHO 
intake than P or E&P.
POSTMORTEM ANALYSIS 
TOTAL BODY COMPOSITION
Total body composition was compared using a percentage basis to 
correct for the larger and smaller rats (Table 4.4E). No significant differences 
for the percentage of body fat were observed by the ether extraction method. 
No differences in percentage of moisture were determined in m easures of 
carcass homogenate taken in a  drying oven (Table 4.4E). Neither were there 
percentage differences observed in total body composition from protein. 
(Table 4.4E).
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CHOLESTEROL
Levels of serum cholesterol in the S treatment were lower (Table 4.4F) 
than the H treated animals (5 group ANOVA group contrasts p226).
HDL CHOLESTEROL
Additionally levels of serum HDL Cholesterol were lower (Table 4.4F) in 
S than H (5 group ANOVA group contrasts p228).
CHOLESTEROL-HDL RATIO
No significant differences in total cholesterol to HDL ratios were 
observed among treatm ents (p225-226).
SERUM ESTROGEN
No significant differences in serum estrogen levels were observed 
(Table 4.4G).
SERUM PROGESTERONE
A significant difference was observed in serum progesterone (Total 
Table 4.4G, and 4 group ANOVA p205).
SERUM TESTOSTERONE
No significant differences were observed in 5 group serum testosterone 
levels (Table 4.4G, 4 group ANOVA p205). Group contrasts revealed 
differences in 4 groups analysis. P vs. NonP revealed significant differences 
in testosterone levels (Total 4 group ANOVA p205).
WEIGHT OF HEART
No significant differences in heart weight were observed among the 
treatm ents (Table 4.4H).
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TABLE 4 .4E  TOTAL STUDY - BODY COM POSITION
Treatment Sham Ovariec-
tomized
OV+17B
Estradiol
OV + 173 
Estradiol 
and Pro­
gesterone
OV + 
Proges­
terone
ANOVA 
p value
Number of 
Animals(n)
12 8 10 11 11
Fat (%) 8.21± .37 8.22 ± .72 9.10 ± .7 8 10.0± .48 8.95 ± .39 p=.141
Protein (%) 9.77 ± .15 9.29 ± .25 10.07±.71 9.3 ± .23 9.00 ± .1 9 p=.240
Water (%) 80.30±.52 81.30±.58 79.60±1.42 79.20±.63 80.40±.22 p=.466
Values are m eans ± SE.
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TABLE 4 .4F  TOTAL STUDY - CHOLESTEROL AND HIGH 
DENSITY LIPO PRO TEIN  C H O LESTER O L
Treatment Sham Ovariec-
tomized
OV + 170 
Estradiol
OV +1713 
Estradiol 
and Pro- 
gesteron 
e
OV + Pro-
gesteron
e
ANOV
A
p value
Number of 
Animals (n)
12 10 11 12 10
Cholesterol
mg/dl
82.3
±5.1
105
± 5 .6
102.0
± 7 .6
110.0
± 7 .9
101.0
±11.7
p=.116
Group
Contrasts (a )v (b r (b)* (b)* (b)* p=.014
HDL
Cholesterol
mg/dl
71.8
± 4 .5
80.8
± 5 .0
87.7
± 7 .7
93.6
± 7 .6
84.4
+9.0
p=.216
Group
Contrasts a) V (b)* (b)* (b)* (b)* p=.034
Values are m eans ± SE. Means in the sam e row with the different superscripts 
are significantly different from each other by Scheffe’s  S procedure for post- 
hoc comparisons, 
v * Denotes group contrasts.
Group means: CHOL: S: (82.3±5.1), OV (104.5±8.2)
HDL-C: S:(71.8±4.5), OV (86.6±7.3)
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TABLE 4.4G  HORMONE LEVELS BY 
RADIOAM M UNOASSAY
Treatment Sham Ovariec-
tomized
OV +
178
Estradiol
OV+17R 
Estradiol 
plus Pro­
gesterone
OV + 
Proges­
terone
ANOVA 
p value
Number of 
Animals (n)
12 11 10 11 11
Estradiol 141.0
± 46 .6
79.0
± 24 .7
142.0
± 21 .2
140.0 
± 18.6
109.0 
± 29.6
p=.521
Progesterone 10.1
± 2 .2
4.9 
± 1.7
4.2
±.9
11.0
± 2 .8
18.7
± 6 .3
p=.033
Testosterone .97 ± .46 .08 ± .08 .37 ± .29 .05 ± .03 .65 ± .32 p=.139
Group contrasts (a.b) (b) (b) (a) (a) p=.050
Values are  m eans ± SE. Means in the sam e row with the different superscripts 
are significantly different from each other by Scheffe's S procedure for post- 
hoc comparisons
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WEIGHT OF LIVER
S had lower liver weights than E&P and P (Total Table 4.4H). S and OV 
also had lower liver weights than H (Table 4.4I).
WEIGHT OF UTERUS
Five Group Analysis: OV and P were lower than E&P, E, and S (Total 
Table 4.4H). S was higher than H, OV was lower than H, E ( total Table 4.4I 
p204).
Four Group Analysis: Both OV and P were lower than E&P and E (Total 
p233). OV uterine weights were lower than H and E was higher than Non E 
(Total p206). An estrogen effect on uterine weights was observed (4 group 
ANOVA factorial p206).
FAT PERCENTAGE OF LIVER
Five Group Analysis: Percentage fat (% Table 4.4J ) in the E group was 
lower than Non E,
Four Group Analysis: An E effect was observed in liver fat content (% 4 
group ANOVA factorial, p207).
WEIGHT TO LENGTH RATIO
Five Group Analysis: E treated animals had a lower (Total Table 4.4 K) 
weight to length ratio than Non E.
Four Group Analysis: An E effect was observed in weight to length ratios 
(4 group ANOVA factorial, p 207).
DISCUSSION OF THE TOTAL STUDY 
These data for the total study across all phases indicate that exogenous 
female sex hormones affect caloric conversion ratios in retired breeder female 
rats given novel food choices. And that over time the rats treated with
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TABLE 4.4H  TOTAL STUDY - WEIGHT O F O RG A NS
Treatment Sham Ovariecto-
mized
OV +1713 
Estradiol
OV +1713
Estradiol
and
Progester­
one
OV +
Progester­
one
ANOVA 
p Value
Number of 
Animals (n)
12 10 11 12 10
Weight of 
Uterus (g)
.74
± .05
.24
± .03
.62 
± .05
.61
± .05
.40
± .0 4
p=.001
Weight of 
Heart (g)
1.17 
± .04
1.27 
± .07
1.2
± .0 3
1.21 
± .07
1.29
± .0 5
p -4 5 8
Weight of 
Liver (g)
9.15
± .23
9.85
±.19
10.40
±.32
10.50
±.24
10.60
±.37
p=.002
Values are m eans ± SE. Means in the sam e row with different superscripts 
are significantly different from each other by Scheffe’s S procedure for post- 
hoc comparisons.
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TABLE 4.41 TOTAL STUDY G RO U P 
CO N TRA STS FO R W EIGHT O F O RG A N S
Treat­
ment
n Weight
of
Uterus
P
value
Weight
of
Heart
P
value
Weight
of
Liver
P
value
Weight
of
Bone
P
value
Mean ± 
SEM
Mean ± 
SEM
Mean ± 
SEM
Mean ± 
SEM
S vs 12 .738 ± 
.049
p=.001 1.17 ± 
.04
p=.254 9.15 ± 
.23
p=.001 1.19 ± 
.05
p=.355
H 33 .545 ± 
.046
1.23 ± 
.05
10.50 ± 
.31
1.14 ± 
.04
OV vs 10 .242 ± 
.026
p=.001 1.27 ± 
.07
p=.625 9.85 ± 
.186
p=.052 1.17 ± 
.05
p=.589
H 33 .545 ± 
.046
1.23 ± 
.05
10.50 ± 
.31
1.14 ± 
.04
E vs 23 .616 ± 
.047
p=.001 1.21 ± 
.06
p=.174 10.50 ± 
.28
p=.488 1.13 ± 
.04
p=.431
Non E 20 .322 ± 
.035
1.28 ± 
.06
10.20 ± 
.28
1.17 ± 
.05
P vs 22 .508 ± 
.046
p=.091 1.25 ± 
.06
p=.713 10.60 ± 
.31
p=.096 1.17 ± 
.05
p=.483
Non P 21 .430 ± 
.037
1.24 ± 
.05
10.10 ± 
.25
1.13 ± 
.05
Sham = S
Hormones = E, P, E&P 
Ovariectomized = OV, no hormones 
Estrogen = E, E&P 
No Estrogen = OV, P 
Progesterone = P E&P 
No progesterone = OV, E
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TABLE 4.4J % FAT CONTENT OF THE LIVERS
Treatment Sham Ovariec-
tomized
OV +17(3 
Estradiol
OV+ 1713 
Estradiol 
and Pro- 
gesteron 
e
OV + 
Proges­
terone
ANOVA
p value
Number of 
Animals (n)
12 10 10 11 12
Fat (%) 1.4±.2 1.9 ± .3 1.3 ± .2 1,2±  .1 2.1 ± .4 p=.086
Group
contrasts ml w <b) w w p=.010
Values are m eans ± SE. Means in the sam e row with the different superscripts 
are significantly different from each other by Scheffe’s  S procedure for post- 
hoc comparisons. It should also be noted that factorial analysis shows 
significant effects of estrogen at (p=.02).
Group means: E: (1.3± .5), lower than NonE (2.0 ± .4) in group contrasts.
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TABLE 4.4K  TOTAL STUDY - WEIGHT TO LENGTH
R A T IO S
Treatment Sham Ovariec-
tomized
OV +1713 
Estradiol
OV+ 1713 
Estradiol 
and Pro­
gesterone
OV + 
Proges­
terone
ANOVA 
p value
Number of 
Animals (n)
12 10 11 12 10
Weight to 
Length 
Ratio g/cm 
A
16.7
± .4
18.3
± .5
16.8
±.4
17.2
± .4
18.3
± .4
p=.015
Group
Contrasts (a) (b) (b) ___ p=.004
Values are m eans ± SE. Means in the sam e row with the different 
superscripts are  significantly different from each other by Scheffe’s  S 
procedure for post-hoc comparisons
A Weight to length ratio is length in centimeters divided by weight in grams 
Group means: E: (17±.4) lower than NonE (18.3±.5).
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exogenous female sex hormones regulate body weight. Evidence of this 
regulation phenomonen is the caloric conversion ratio for phase II which w as 
lower than for phase I and phase III. In order to examine these param eters 
separately in an aging model over time the combined effects of the 30 day 
study also seem  worthy of consideration. Eating behavior literature typically 
reflects this type of data collection. Therefore, the following report relates the 
statistical analysis of all three phases combined.
The carryover effect from phase to phase of the body weight param eter 
and subsequent effects on body composition should be noted. The effect can 
be moderated by considering the % weight gain and growth rates in the 
animals. In future studies, the collection of body weight data from the day the 
hormones were implanted is recommended. Significant body weight 
differences may also be due to growth rates (Figure 17.0) and interactions with 
exogenous hormones. A recent study addressing body weight changes, 
indicates that children had significantly greater percentages in body weight 
changes than their adult parents, which indicates that caloric conversion ratio 
differences can be age related (Epstein et. al., 1995). Growth hormone which 
has recently been approved by FDA for human use in this country could be 
m easured in future studies. The future measurement of insulin is also
r
recommended. The observations within each phase have already been 
presented. The results at the end of the study are a  summary of the hormonal 
effects for the 30 day period (Figures 1.0-17.0 pp 208-224).
The estrogen effect on body weight as observed by Wade & Schneider 
(1992) was found only by factorial analysis when the results were combined 
over the 30 day study. When Sham is removed for four group analysis E is
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significantly lower than the OV treatment. Body weight was higher in the OV 
and P treatments in both total and percent when compared with the sham  in 
five group analysis. As previously stated, this may reflect chocolate choices not 
allowed by the S group and E effects on suppressed body weight. Group 
contrasts with five groups reveal H to be significantly higher than S, And in 
both four and five group analysis OV was higher than H and Non E higher than 
E. The application to hormonal effects on body weight in the human forms a 
nice parallel. The endogenous estrogen pool representative of the 
prem enopausal female appears to keep body weight at lower levels. Once 
surgical or natural m enopause occurs, the natural endogenous source in 
removed. Exogenous estrogen appears to keep body weight gain lower 
compared to the increased body weight gain in the OV female with no 
exogenous supplemental hormonal therapy.
The more interesting concept in the aging model is the evidence that 
under hormonal influence, calories are converted into body weight at varying 
degrees a s  shown in significant differences in caloric conversion ratios. The 
higher the caloric conversion ratio, the fewer kcal are required to gain a gram 
of body weight. Calories in this case  are more efficiently converted. Both OV 
and P conversion ratios were significantly higher than S. Factorial analysis 
also revealed an estrogen effect on lower caloric conversion ratios. Group 
contrasts confirmed the aging human model implications; ovariectomized 
animals given hormone supplements had significantly higher caloric 
conversion ratios than S. Non E conversion ratios were higher than E. 
Estrogen would appear to suppress caloric conversion into body weight in 
both the ovariectomized and normally cycling females.
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Macronutrient choices were significantly different but not in ways which 
were expected. An interesting new concept was that hormone treated animals 
chose higher percentage levels of FAT than OV with significantly lower body 
weights. PRO was chosen by the E&P group in significantly higher levels than 
the S and P which was confirmed by factorial analysis. Group contrasts 
identified higher levels of PRO intake in H treated animals compared to S. 
This may be of value if the PRO intake is chosen in the form of red meat in the 
bleeding postmenopausal female who may be deficient in heme iron.
CHO was consumed in greater quantities in the OV animals compared 
to S. In this study higher levels of CHO in the OV animals resulted in 
significantly higher body weight gain. Estrogen had a  greater influence alone 
than P or combined E&P in suppressing CHO intake. When grouped, with 
regard to CHO consumption, OV was significantly higher than H, Non E higher 
than E and H w as higher than S. The hormonally untreated postm enopausal 
female model may consume higher quantities of highly refined carbohydrate 
snack foods, convert calories into body weight more efficiently and ultimately 
gain more body weight than those who receive exogenous female sex 
hormones.
The evidence of hormonal effects on body weight gain, macronutrient 
food choices and caloric regulation was observed early in the study, when 
estrogen implanted animals gained significantly less body weight than the 
progesterone and OV animals. Further, the additional body weight gain effects 
of progesterone were of short duration, which may occur at the onset on 
m enopause or immediately following surgical removal of the ovaries. 
Progesterone effects of increased fat and chocolate intake are often observed
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in the younger female in the luteal phase followed by periods of fasting during 
the m enses or follicular phase (Dalvitt-McPhillips, 1983). This adds strength to 
the argument that the Sprague-Dawley female rat is a  good model to study in 
examining human pharmaceutical and physiological questions. Earlier 
studies in the intact female rat have shown greater caloric intake and body 
weight in the diestrus phase when progesterone levels are elevated (Gray & 
Greenwood, 1983). These data also agree with the estrogen effect observed in 
younger rats in earlier studies which reflects decreased body weight gain and 
the trend to lower caloric intake in estrus when estrogen is elevated (Wade, 
1975, 1976). The more meaningful interpretation of these physiological 
endocrine param eters to the aging female may be that the declining estrogen 
pool seen during this period of life (Wing, 1992) may contribute to metabolic 
alterations leading to the additional body weight observed in the aging rat 
model in this study.
The rats in this study may have adapted a s  evidenced by reduced body 
weight possibly via a  setpoint mechanism over time. In phase II, the second 
ten day period, the rate of gain decreased for S, E&P and P when compared to 
the first 10 days of the study for phase I. Body weight increased again in 
phase III when chocolate was available. In this study, higher CHO both a s  a  
total and percentage of calories consumed was identified with ovariectomy 
and increased caloric conversion to body weight gain. Increased fat intake 
both as a  total and percentage of calories consumed was observed in 
treatment groups with decreased body weight gain and lower caloric 
conversion ratios. These concepts are clearly contradictory to current 
hypotheses that low fat diets produce decreased body weight gain. The
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evidence shown by the changes in caloric conversion ratios could indicate 
physiological and metabolic mechanisms which should be investigated in 
future research.
Before these conclusions can be considered for potential theoretical 
change, the potential w eaknesses which could have affected in these results 
should be discussed. Inclusion of the sham group in statistical analyses must 
be addressed because the more palatable novel food choices were never 
offered to this group. The sham group was only offered the three nutrient 
dense food choices FAT, CHO and PRO throughout the study. This group 
served a s  a  comparison and represented the normally cycling female. Future 
studies should include a  sham group which received all food choices. This 
was the original design of the study, but due to the high death rate following 
the two surgeries early in the study, one group was unfortunately eliminated. 
Therefore the sam e three macronutrient food choices ingested throughout the 
study could have affected the body weight data. There is a  strong likelihood 
that the sham group did not gain at the sam e rate due to the difference in food 
choices. The other obvious factor is the difference in surgical processes which 
left the ovaries in tact in the sham animals. Sham body weight was less than 
other treatments in all other phases except for phase I when all groups 
received the sam e food choices. They did not receive the sam e SW/NSW 
CHO and chocolate options in phases II and III, respectively, a s  the other 
groups. This design and information may skew the results when the sham is 
compared to the other treatment groups. The other four groups of 
ovariectomized animals who had access to the more palatable choices 
showed clear preferences when the options were available in phase III. This
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has marked implications for examining behavioral food choice mechanisms. 
To extrapolate this evidence to the human model may indicate that when more 
palatable food choices are available, these may be chosen to the exclusion of 
other well balanced, nutrient dense foods that may not be a s  delicious but are 
nourishing and essential to good health. This concept agrees with the work of 
Rolls (1993) in the study of sensory specific satiety.
Caloric intake from the three macronutrient choices was significantly 
different in group contrasts between the sham and the hormone treated 
animals with a  trend toward significance when estrogen and nonestrogen 
were compared. No caloric intake differences were shown when only the four 
treatment groups were individually compared. When macronutrient food 
choices were observed and compared, carbohydrate, protein and fat 
consumption were shown to be influenced by the hormone treatments. CHO 
w as preferred by OV. Protein choice was almost twice as high for E&P 
compared to the P, and a  progesterone treatment effect on FAT consumption 
during the 30 day study period.
In the total study exogenous hormones were clear indicators of body 
weight differences between S and OV, with regard to caloric intake. Caloric 
conversion for S was lower than the for OV and P groups. Two additional 
param eters that possibly played a  role in this study which should be m easured 
in future research are; the hormonal effects on increased voluntary exercise 
and hormonally induced lethargy.
Due to the biases potentially created by the sham receiving the three 
food choices throughout the study, the four OV groups should be discussed. 
When the four OV groups were compared, E treatment resulted in lower caloric
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conversion of food intake into body weight than in the Non E treated animals. 
Differences of caloric conversion ratio and body weight to length ratio both 
revealed a  trend between the OV and hormonally treated rats. The differences 
in weight to length ratios may relate to the rate of growth in the rat model. 
Exogenous female sex hormones may alter length growth rates in rats. 
Exogenous hormone treatments may increase involuntary activity, voluntary 
exercise, or metabolic differences and should be examined in future research. 
These effects separately or combined may have influenced the data used to 
calculate the rate at which calories are converted into body weight. Obviously, 
in the four OV groups, ovariectomy results in the absence of endogenous 
estrogen influence. Exogenous estrogen prevented the increased body weight 
which was observed in the OV, P and S (endogenous) rats in phase I in this 
study and in the OV and P in the total study (Galletti & Klopper, 1964; Gray & 
Greenwood, 1984). Tracking the effects over longer periods of time in the 
aging model may provide additional information.
At the conclusion of the study, animals were sacrificed and the post 
mortem results were analyzed. The following could have affected the statistical 
outcomes and should be mentioned. NonE treated animals were significantly 
longer at the conclusion of the study than the E treated animals which could 
affect body weight data. Liver weights were significantly higher in the E&P and 
P treated animals than S indicating the need for further analysis into the 
hepatic markers related to exogenous female sex hormones.
The significantly different uterine weights confirm the bioactivity of the 
exogenous hormone implants. This important marker was shown in 
significantly different uterine weights with atrophy of the uterus clearly seen  in
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the OV group. E and E&P implants were equally effective in approaching 
maintenance of pre-ovariectomy uterine weights. P alone could only partially 
maintain uterine weight. Thus estrogen was the most critical hormone in 
preventing atrophy of the uterus in the ovariectomized rat. The additional 
biomarker used to a sse ss  the activity of the implants was radioimmunoassay 
of the serum to m easure progesterone, estradiol and testosterone. Serum 
progesterone levels were significantly higher in the animals implanted with 
progesterone. Testosterone levels were higher in animals with progesterone 
implants. Estradiol levels were not found to be significantly different. 
Biological evidence of uterine weights clearly reveals that estradiol levels 
were also different, however a  more sensitive form of RIA analysis should be 
used in the future to m easure this hormone.
Surprisingly, body fat distribution did not vary across the treatments. In 
fact, total body composition (%) analysis revealed no significant differences in 
fat, water and protein among the five treatment groups. Mean body 
composition data, obtained upon sacrifice, showed 9% of the total weight as 
fat, 11% a s  protein, SO % as  body water. The rats consum ed almost half of 
their caloric intake from fat, but deposited only 9% of it in body fat stores a s  
shown in total body composition analysis. This information is contrary to earlier 
reports by Wade and Gray (1979) in which adiposity was m easured in terms of 
lipoprotein lipase activity and correlated to increases in body fat storage. A 
potential w eakness in the use of lipoprotein lipase a s  a marker of changes on 
body fat composition is that lipoprotein lipase activity may increase 
proportionately a s  body weight increases and may not necessarily reflect 
differences in % body composition. Earlier studies reported lipoprotein lipase
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increased with increased body weight in the absence of m easures for protein 
and water which were not measured in proportional body composition. 
Therefore the body fat composition (%) reported in W ade’s  earlier studies may 
not be different and therefore flawed in reporting. If increases in body fat as a 
percent of total body composition were reported by Wade, the results might 
present a  different picture. Similar results to those found in the present study 
might be shown. Preliminary and concluding body composition data by DEXA 
should be m easured in future studies but were not possible in the present 
study. The methods of measuring total and % body fat increases should be 
examined.
Body composition analysis was questioned by Clark and Tarttelin 
(1982). They report conflicting results from chemical analysis for example, 
comparing intact rats, to the weight of body fat in OV rats a s  a percentage of 
body weight. To examine the differences, Sprague-Dawley rats were 
ovariectomized at three ages: 3 days, 4 weeks and 7 weeks and were 
subsequently sacrificed at four ages, 7, 9, 12 and 15 weeks for chemical 
analysis of carcass and skin. Chemical compositions were analyzed at % wet 
weight and a s  component weights by two-way analysis of variance. 
Ovariectomy increased overall body weight without causing obesity. The 
weight gain of the OV rat was mainly due to true growth response. OV 
treatment increased fat reserves but slowed the growth of other body 
components including the skeleton. E treatment reversed this process. 
Clearly body composition data must be examined with the sam e age, species 
and treatment to provide comparable data. Earlier studies have reported 
increased (Leshner & Collier, 1973; De Smet, 1953), decreased (Galleti &
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Kloper, 1964, Rebuffe-Scrive, 1987), and unchanged body fat end points 
(Bogart, Lasley & Mayer, 1944; Holt, Keeton, and Vennesland, 1936; Nyda, 
deMajo, & Lewis, 1948; Reed, Anderson, & Mendel, 1932). Data in the 
postbreeder female which has been ovariectomized and implanted with 
female sex hormones were not evident in the literature.
Body composition can also be influenced by the availability of 
calorically consistent food choices. It should also be noted that in earlier 
studies (Wade & Gray, 1979; Wade & Schneider, 1992) animals were not 
offered choices of macronutrients or food choices of sweet, nonsweet and 
chocolate. The food choices in their studies consisted of lab chow and sucrose 
in water. Body weights were different and therefore body composition in the 
younger rat could also have been affected. The present study indicates that 
the aging female model changes in body weight but that the ratios in total 
body composition analysis of fat to protein and body fluids remain consistent 
across the treatments.
Total study caloric conversion ratios of food intake to body weight were 
shown to be lower in the sham than the other treatment groups (Figure 12.0). 
The effect of estrogen was first seen in phase I in the E group. These animals 
gained less weight per calorie than the other hormonal treatments. This 
evidence indicates that the OV and P implanted animals convert calories into 
body weight at a  higher efficiency rate than the S and E treatment groups 
(Figure 12.0). The significance shown in the sham group is clearly influenced 
by the phase III data in which the S group was not given chocolate choices. 
There appeared to be differences in body weight, although calorie levels were 
not significantly different. These differences can also be described a s  the ratio
145
at which feed is converted to body weight. The caloric conversion ratios 
provide evidence that calories are converted into body weight at differing rates 
possibly due to changes in basal metabolic rate, hormonally induced lethargy 
or activity levels which were not measured in the present study. This concept 
requires further investigation. The data leading to caloric conversion ratios 
reported in this paper on the postbreeder female rat is not consistent with 
evidence reported by W ade and Schneider (1992) in a  review of gonadal 
influence on body weight and adiposity. Their previously reported data from 
younger rats implanted with female sex hormones, indicated that the research 
contained in this report would constitute a  valuable contribution in the body of 
knowledge with regard to the aging female rat model (Wade, personal 
communication, 1995). An earlier study (Roy & Wade, 1977) adds strength to 
the findings of the current study, food intake had to be restricted to 80% of the 
norm to keep weight stable in the estrogen deficient rats. This suggests that 
these animals may have had similar caloric conversion ratios to the animals in 
this research.
The current information suggests that when comparing research data 
on different age animal models (e.g. neonatal vs 4 months vs 10 months), the 
age and reproductive status may reflect different metabolic implications which 
affect eating behavior and body weight. Similar results may be seen  in studies 
with other aging animal models. In the human, Wing (1992) has reported that 
additional weight gain occurs a s  a  result of aging. The term “aging" 
encom passes many biological alterations. Most param eters m easured in 
younger rats compared to the postbreeder rat reveals a  different profile. Wing’s 
suggestions in the human female may be true in the aging female rat.
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The question of declining estrogen as correlated to body weight gain 
during the life span may become clearer when tests for estrogen are less 
expensive and more commonly used. Currently LH and FSH are m easured as 
indicators of the menopausal state. Additional research should be conducted 
to m easure body composition changes a s  body weight increases are 
observed in the aging process. Additionally, the percent body weight gain 
shown a s  adipose tissue compared to muscle tissue (% lean body mass) in 
the female taking hormone replacement needs further investigation.
In review, the impact of hormonal differences on the caloric intake and 
body weight gain for the total study can be viewed in Figure 11, the 
subsequent resulting caloric conversion ratios in Figure 12. Figure 13 
indicates different patterns of body weight gain over the three phases. Figure 
14.0 reveals influence of hormonal treatments on the percent of total caloric 
intake from FAT, CHO, and PRO. The higher total and % of fat intake is most 
obvious in this chart. Total kcal intake from each of the three phases is shown 
in Figure 15.0. Total caloric intake from all sources in Figure 16.0 clearly 
demonstrates the overwhelming effect of chocolate in phase III. Figure 17 
allows the reader to view a line graph of body weight over the 30 day study. 
Phase II begins on day 11 and Phase III in day 21.
»
In future studies the measurement of pre and post markers of total body 
composition (% fat, protein and water) would be of great value in measuring 
effects of exogenous female sex hormones. Differences have been observed 
in the total body weight between treatments with no significant differences in % 
body composition. Differences have also observed hormonal effects in 
macronutrient choices and different caloric conversion ratios. Total dietary fat
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was high across all treatments (37.5 - 56.5%). Across all phases the OV group 
(which consumed the lowest percentage of calories from fat) gained the most 
BW. The total percentage of fat in body composition analysis was S 8.2%, OV 
8.22%, E 9.46%, E&P 10%, P 8.64% (p=.0945). Therefore, the higher 
percentage of fat intake from macronutrient food choice was not converted 
proportionately into percentage of body fat stores.
Therefore the extensive body of research and current reports in the 
popular press which indicate that the lowering of fat intake will result in 
decreased body weight are not in evidence from this research. This “low fat 
concept” is so widespread that the higher fat intake a s  seen  in the sham  
treatment group with lower body weight and the lower fat intake seen  in the 
ovariectomized animals with the greatest weight gain could easily have been  
thrown out a s  false data. However, this contribution to the literature is 
meaningful and should be discussed. The possibilities which explain this 
phenomenon may include: (a) fat is a  satiating macronutrient and therefore 
suppresses the desire to consume additional food, (b) gut motility of foods 
containing higher levels of fat decreases the rate of digestion and provides a 
longer period of absorption and assimilation, (c) high fat foods may create a 
pleasure factor in eating behavior param eters that overrides other factors not 
met by low fat food items, and, (d) the biochemistry of appetite through 
systemic m essenger signals whether hepatic or neural or otherwise, may be 
more or less efficient under the influence of certain hormones.
There is an extensive body of literature on the effects of estrogen on 
feeding behavior, but the relevance of these studies to the control of energy 
balance has yet to be fully established. According to Wade and Schneider
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(1992) there is a  complete absence of any unifying consensus a s  to how 
estrogen modulates feeding behavior and body weight, although several 
hypotheses have been proposed. One hypothesis tested is that estrogens 
produce anorexia by directly affecting the mechanisms that normally terminate 
meals. It has been suggested that estrogen promotes the effectiveness of 
various peripheral short-term satiety signals by trigeminal (Beretter & Barker, 
1976) pancreatic and/or gastrointestinal action (Bailey & Matty, 1972; 
Blaustein & Wade, 1977; Lichtenberger, Nance, & Gorski, 1976; Nance, 1983; 
W ade & Gray , 1979), or direct action on the metabolism of adipocytes (Wade 
& Gray, 1979). The current study is in direct opposition to these reports 
because there were clearly body weight differences when ANOVA of caloric 
intake revealed no significant differences.
Additionally, numerous arguments speak against Wade and 
Schneider’s  (1992) hypothesis (Geary, et al, 1994; Nance, 1983; Ramirez, 
1980). Other authors have suggested that the effects of estrogen on feeding 
behavior result from a hormone-dependent shift in the long-term control of the 
energy balance, which fixes the level of regulated body weight or fat stores. 
Redick et al. (1973) were the first to suggest that estradiol does not suppress 
food intake directly, but dictates a  low level of body weight gain. Such a 
mechanism would correspond to a  shift-down of the setpoint of body weight 
regulation and, a s  a  consequence, feeding would be secondarily suppressed  
in animals which have excess weight a s  a  regulatory attempt to readjust body 
weight to a  lower regulated level. While this hypothesis has been repeatedly 
evaluated (Landau & Zucker, 1976; Nance, 1983; Fantino & Brinnel, 1986; 
Leibel, et al, 1995) and strengthened by numerous experimental arguments, it
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has never been directly verified. Indeed the very nature of body weight 
setpoint is not known (Mrosovsky & Powley, 1977; Toates, 1983; Wade & 
Zucker, 1970a), so hormone-induced variations have never been directly 
appreciated.
Additionally, the elegantly designed method of evaluating the body 
weight setpoint in rats through food hoarding behavior during a  period of 
reduced body weight (Fantino & Brinnel, 1986) provides strong evidence that 
physiological mechanisms are strongly in place. In the wild, hoarding 
behavior is a  specific response in rodents, occurring mainly in autumn, and 
this response is useful in improving their long-term energy balance (Anderson 
& Krebs, 1978; Launay, 1975). Fantino and Brinnel (1986) reported that in 
female rats a s  well as in male, the m ass of food hoarded during extended 
three-hour experimental sessions increases when body weight decreases. 
Fantino m easured body weight, food intake and food hoarding behavior in 
female rats fed ad lib and correlated these m easures with the ovarian cycle. 
All three param eters fluctuated synchronously with the 4 day cycle with estrus 
(two days prior to ovulation) and diestrus (two days following ovulation). But 
he detected that the critical level of body weight for the onset of hoarding 
behavior was 13.2 g lower at estrus than at diestrus. His research provides 
direct evidence in the rat of the estrogen effect of fluctuation of the body weight 
setpoint with the ovarian cycle under hormonal influence.
The question of additional body weight gain a s  related to total body 
composition in this model is of interest. The absence of percent change in 
body fat stores may provide new information in the aging rat model and in the 
future, help to explain shifts in body fat disposition in tine human. Women may
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comment, "I weigh the sam e at 50 as I did at 30, but my clothes don’t fit the 
sam e way.” Percentage of fat to lean muscle tissue and percent moisture may 
actually not be different a s  shown in the present experiment. Shifts in waist to 
hip ratios, and upper body and lower body weight may occur (Haarbo, et al., 
1991). The shifts in location of body fat stores may be perceived as body 
weight gain if m easures are obtained by triceps skin folds in the upper body in 
the aging model (Folsom, et al., 1989). These m easures should not be 
compared to the younger model to reflect body weight gain. Shifts to upper 
body adiposity and waist to hip m easurements are evident in the aging human 
female (Brezezinski & Wurtman, 1993; Armellini, et al., 1990; Peiris, et al., 
1989). Methods of measuring the validity of these param eters are currently 
under evaluation but have not yet been approved by FDA for human use in the 
medical setting (Troisi, et al., 1995). Evaluation and m easurem ent of body 
weight and body composition changes over time will be included in future 
human research.
Exogenous female sex hormones are among the highest selling 
pharmaceutical agents in the industry (Wallis, 1995). Postm enopausal 
fem ales are currently choosing hormone replacement therapy to combat the 
negative symptoms of m enopause and as a  protective therapy against 
osteoporosis and cardiovascular disease. This is the reason that the two most 
prevalent, estrogen (17 p estradiol) and progesterone were chosen for this 
study to examine subsequent physiological effects (Richard, 1986; Butera & 
Beikirich, 1989). The estrogen group was chosen to reflect the follicular phase 
in the normally cycling female, estrogen replacement therapy in the female 
who has had a  hysterectomy or the estrogen phase in hormone replacem ent
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therapy. The estrogen and progesterone group was chosen to reflect current 
hormone replacement therapy and mid cycle hormonal profiles in the normally 
cycling female. And the progesterone treatment group was observed to show 
exclusive effects of progesterone. Progesterone is often prescribed to combat 
uncontrolled vaginal bleeding, prevent miscarriages, or as hormone 
replacement for women whose genetic patterns reflect a  likelihood for 
reproductive cancer (Notelovitz & Tonnessen, 1993). Dosages and reasons 
physicians prescribe exogenous female sex hormones vary.
Body weight and food intake are major concerns during this period in 
the life of a  female. Often the comment is heard, “I am eating the sam e amount 
but gaining additional weight.” This perception has not been addressed in 
depth by the medical community but has initiated major monetary 
expenditures ($33 billion, [Atkinson, 1990] previously cited) in the population. 
The obese are not the only ones who invest in weight loss programs. The 
investment to lose an extra 10 to 20 pounds of additional body weight is an 
expense incurred by a  large segment of the weight conscious population. The 
body weight fluctuations which result in either permanent or temporary body 
weight gain may be affected by female sex hormones a s  shown in this study. 
Low fat food items are expensive and not effective in achieving the desired 
result (Allred, 1995). When excess calories are consumed in the form of simple 
sugars, these simple sugars may initiate additional caloric ingestion. 
(Geiselman, et al., 1981; Simopoulos, 1994b). The data observed in the 
current study (Figures 13 and 14) agrees with reports by Rolls (1992): that 
caloric intake is more important in body weight gain than fat grams consumed.
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In earlier research on rats, a  high rate of weight gain seen  in the 
ovariectomy has been prevented or reversed by injection of estradiol (Landau 
& Zucker, 1976; Wade & Zucker, 1970b) or by unilateral implants of estradiol 
benzoate in the ventromedial hypothalamus (Nunez, Gray, & W ade 1980; 
W ade & Gray, 1979). The present study supports the information in these 
reports. In several younger species, endogenous as well a s exogenous 
estrogens have revealed a  suppressive effect on both body weight gain and 
food intake (Czaja, Butera, & McCaffrey, 1983) which is not reflected in the 
current study. The earlier reports and the current results can explain why body 
weight is minimal at estrus, when circulating estradiol is maximal (Czaja, 
Butera, & McCaffrey, 1983; Morin & Fleming, 1978) but does not explain the 
non significant food intake results and subsequent differences in caloric 
conversion ratios.
Accordingly, the simplistic concept which has been reported in weight 
loss programs that the ingestion of 3,500 additional calories will produce a 
pound of body weight gain or that the deprivation of 3,500 calories will cause  a  
pound of decrease in body weight may not be true in all cases. There may be 
metabolic effects of aging during the menopausal years which can be directly 
correlated to the decline in endogenous female sex hormones such a s
r
estrogen with subsequent variations in the way calories are converted into 
body weight. This research shows that in the aging female rat, the absence of 
endogenous estrogen creates the condition whereby calories are  converted 
into body weight at a  higher ratio.
Body weight has become an important consideration in the quality of life 
in the female. Genetics and lifestyle changes currently seen in the population
153
may contribute to differences observed in the human. Undefined levels of 
hormonal therapy designed to relieve the symptoms of m enopause (hot 
flashes, vaginal dryness, night sweats) may create problems. Currently, 
laboratory documentation of endogenous levels prior to the prescribing of 
exogenous levels is not the normal clinical procedure. Perhaps this 
assessm ent should be considered in the future in symptomatic individuals 
before the decision is m ade on whether to prescribe 10 mg. or 2.5 mg of 
Provera early in m enopause or immediately following surgery when body 
weight seem s to be affected most by progesterone (eg. Phase I). In addition 
dosages of exogenous female sex hormones may need to be individually 
determined through laboratory analysis in the future. Currently, women are 
prescribed levels of exogenous female sex hormones in dosages which apply 
to the larger population and often based on patterns established in Europe. 
This protocol may not be appropriate for all women. Perhaps individual 
analysis and cultural differences should be considered in future research. 
Current discomforts and body weight gain may be dose related and affect 
compliance problems (OB/GYN physicians, personal communication, 1995). 
Recent reports reveal that the earlier indicated 8% lifetime compliance rate 
may be declining.
The findings reported in this document in female postbreeder rats may 
provide preliminary data to design research studies in the human. Clearly, the 
human model is the best model for the study of the human. Human female 
caloric conversion ratios should be examined in postm enopausal fem ales 
taking various sources and dosages of hormone replacement therapy. There 
are clearly body weight and caloric fluctuations in the ovariectomized post
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breeder ra t There may also be differences in the postmenopausal human 
female. Exogenous female sex hormones are probably here to stay, a s  they 
improve the quality of life in the postmenopausal female. More information is 
needed, and additional research should be conducted.
The fluctuations shown in body weights observed in phase I and II of 
this research reveal increased body weight gain with subsequent decrease in 
the rate of gain a s  was reported by Fantino & Brinnel (1986). The complex 
molecular mechanisms by which discrete ingestive behavior, continuous 
energy expenditure, and dynamic energy storage in adipose tissue are 
integrated remain unknown. The demonstration that "leptin” (Haalas, et. al., 
1995) can reduce food intake and body weight in obese and lean mice 
provides further evidence for the hypothesis that a  circulating protein-based 
signal, generated in adipose tissue, acts on control neuronal networks and 
plays an important role in the regulation of feeding behavior and energy 
balance. The failure to achieve these results in other genetic strains is 
consistent with the hypothesis that a  genetic defect in some renders them 
unable to appropriately respond. Perhaps this may occur as a  result of a 
defect in the receptor or postreceptor signaling pathway (Campfield, et. al., 
1995). Several lines of evidence argue for circulating signals that act in the 
brain to regulate feeding behavior and energy balance. Future research to 
examine aging and gender differences will be needed to interface exogenous 
female sex hormones and the affects of leptin. The altered caloric conversion 
ratios in the present study may be evidence that female sex hormones play a  
role and should be included in future investigations.
CHAPTER 5: SUMMARY CONCLUSIONS & IMPLICATIONS
The focus of this research was the body weight implications of the 
relationship between macronutrient food choices and exogenous female sex 
hormones. The body weight consequences of changes in physiological status 
through the ovariectomy with and without hormone replacement were 
examined. C hanges in macronutrient preference, caloric conversion ratios, 
and additionally the measurement of body composition and post mortem 
param eters were also examined. Contempory models of the regulation of 
energy balance investigate and emphasize the physiological signals that 
control energy intake. These results reflect the outcome of those signals.
The female rat model was chosen to obtain data on body weight, caloric 
regulation, and macronutrient choices in a controlled environment. This 
sequence of studies using the postbreeder rat model (to examine a  
postm enopausal and normally cycling female) provided an arena in which to 
examine questions that could otherwise not be investigated and answered in 
free living human subjects. Following is a  summary of the conclusions from 
the present study:
PHASE I:
1. Exogenous estrogen in ovariectomized rats caused a  significant 
decrease in body weight gain without significant differences in 
caloric intake (there was a  trend toward lower caloric intake in the 
estrogen treated rats).
2. Caloric conversion ratios (grams of body weight gain divided by 
caloric intake x 1000) revealed an estrogen effect and were lower for 
H vs. OV (total) and E vs. Non E (total) among the groups.
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3. Exogenous female sex hormones affect macronutrient choices with 
statistical analysis a s  group contrasts: (a) Higher levels of FAT (total) 
were consumed by P vs. NonP treated animals (confirmed by 
factorial analysis) and H vs. OV (%), (b) Higher levels of PRO were 
consumed by H vs. S (total & %) and E vs. Non E (total & %), (c) 
Higher levels of CHO were consumed by OV vs. H (total & %), Non E 
vs. E (total & %) and Non P vs. P (total & % ) (all CHO results 
confirmed by factorial).
PHASE II:
1. There may be time related metabolic differences in the conversion of 
calories into body weight after the ovariectomy. Decreased body 
weight gain in phase II compared to phase I for the S and P groups 
may indicate set point (age, gender) adjustments over time.
2. Caloric conversion ratios were lower for H than for OV and P vs. Non 
P. The physiological effects of ovariectomy without supplemental 
hormones may produce a  carbohydrate appetite a s  demonstrated by 
increased caloric intake from both sw eet and nonsw eet 
carbohydrate. E&P chose 3 times more SW than NSW.
3. Exogenous female sex hormones affect macronutrient choices with 
statistical analysis a s  group contrasts: (a) More FAT was consum ed 
by H vs. Non H {%), and E vs. Non E (%), (b) More PRO was 
consumed by OV vs. H (total & %), (c) More CHO w as consumed by 
OV vs. H (total & %), Non E vs. E (total & %, factorial E effect), (d) 
More SW/CHO was consumed by OV vs. H (total), (e) More
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NSW/CHO was consumed by Non E vs. E (total & %) (also factorial 
E effect).
PHASE III
1. The chocolate novel food choices in phase III produced a higher rate 
of body weight gain. Access to chocolate eliminated both the 
reduced rate of weight gain caused by exogenous estrogen in 
Phase I and Phase II and the set point adjustment or adaptation with 
subsequent reduced conversion of calories into body weight in the 
progesterone group observed in phase II.
2. Caloric intake was significantly lower (total) in the Sham (which did 
not receive chocolate) than the OV treatments (caloric conversion 
ratios were not significantly different in 5 group compared to 4 group 
analysis). A sham group receiving chocolate should be included in 
future research.
3. Chocolate (a choice only in phase III) was consumed at 40% to 53% 
of total caloric intake in ovariectomized animals with or without HRT 
to the exclusion of the nutrient dense macronutrient food choices. P 
vs. NonP preferred higher levels of HF/LS chocolate which indicates 
that in the luteal phase chocolate and FAT may be chosen in 
preference to sucrose.
TOTAL STUDY:
1. Exogenous estrogen prevented the increased body weight which 
w as observed in the OV, P and S rats in phase I in this study and in 
the OV and P in the total study. Overall body weight gain for the 30 
days was greatest in animals with no estrogen, the OV and P
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treatments. The P group (as well as the S) adjusted in phase II with 
lower rate of body weight gain equal to that of the E group. In P hase  
III, the S group did not receive chocolate while the P group 
increased body weight gain with chocolate a s  a  choice. Body weight 
gain was higher according to group contrasts in H than S (total & %), 
OV was higher than H (total & %) and Non E was higher than E (total 
& %). Ovariectomy without hormone replacement was shown to be 
the greatest indicator in increased body weight. Therefore in 
m enopause or with surgical removal of the ovaries, HRT is indicated 
for suppression of increased body weight gain.
2. An estrogen effect was observed for caloric conversion ratios. 
Caloric conversion ratios were lower for S vs. H (total) and E vs. 
NonE (total). Total caloric intake was higher in the OV treatm ents 
when compared to the S (total) with a  trend toward lower caloric 
intake with E.
3. In the aging female, palatable chocolate choices may be preferred 
over a nutritious balanced diet. E&P preferred SW over NSW/CHO. 
Exogenous female sex hormones according to group contrasts 
affected macronutrient choices: (a) More FAT was consumed by H 
vs. OV (%), (b) More PRO was consumed by H vs. S (total), (c) More 
CHO was consumed by H vs. S (total), OV vs. H (total &%), and 
NonE vs. E (total).
4. The OV rats consuming the highest caloric levels of carbohydrates 
(total & %) gained the most body weight. Of the OV treatments, those
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receiving hormones (H) consumed the highest levels of fat {%) and 
gained the least amount of body weight (total & %).
5. Typical regimes of hormone replacement (E or E&P) therapy do not 
produce increased body weight gain in the aging female rat. 
Hormonal effects on changes in caloric conversion ratios could 
indicate physiological and metabolic mechanisms which should be 
investigated in future research.
POST MORTEM:
1. Variations in percent of fat intake (40% to 60%) did not result in 
treatment differences in body composition. Mean body composition 
was 80% body water, 10 % fat, 10 % protein across all groups at the 
conclusion of the 30 day study.
2. Cholesterol and HDL cholesterol levels were lower (total) in the 
normally cycling rats (S) which produce endogenous hormones as 
opposed to the OV rats implanted with exogenous female sex 
hormones.
3. Uterine weights confirmed estrogen bioactivity and serum levels of 
progesterone verified the release of progesterone from the implants. 
Livers of the H treated animals weighed significantly more than S 
(total) or OV (total) and the (percent) fat content of the livers of the E 
treated animals was significantly higher than Non E. This may 
indicate a metabolic or hepatic influence on all of the results.
The caloric conversion ratios observed in this study may project future 
research results in the human female taking hormone replacement therapy. 
The body weight fluctuations in the first two phases may also reflect the
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metabolic implications of the ovariectomy and the effort by the body to stabilize 
at a  set-point. This physiological metabolic alteration may cdcbe a  temporary 
weight gain that will stabilize in the human a s  observed in rats in phase II 
compared to phase I of the present study. In the human, the perim enopausal 
period (often 1 to 3 years) following the initial decline in estrogen may be the 
most critical period regarding body weight gain.
Historically it has been assum ed that fat is associated with satiety and 
weight gain. However, the story may be different for hum ans under the 
influence of hormonal fluctuations. The role of carbohydrates (chow vs. 
balanced macronutrient food cups) in the study of appetite and hunger has 
received relatively little attention in the animal feeding literature. It has been 
assum ed that all carbohydrates are satiating (Geiselman, et al., 1981). 
However, Geiselman and her colleagues (1987) have shown that 
carbohydrates do not always produce satiety. Instead, carbohydrates (simple 
sugars) appear to stimulate appetite and physiological hunger. This 
information is of particular significance in this research. The group that gained 
the most body weight also consumed the highest levels of both sweet and 
non/sweet carbohydrates. Fat intake was found to be elevated in the groups 
implanted with exogenous female sex hormones that gained less body weight.
The information from the present study should be accompanied by the 
following warnings. If novel food choices containing sweets, fats and 
chocolates are presented immediately following ovariectomy or natural 
m enopause, body weight may be altered and conversion ratios of food intake 
into body weight may also be increased. This research shows that timing and 
age with the free choice for chocolate may be a  major risk factor. The animals
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chose chocolate to the exclusion of other balanced macronutrient food choices 
in the diet. Poor nutrition in m enopause may confound hormonal effects and 
add additional body weight. This body weight increase in the past may have 
been blamed on the hormones, when in fact, poor food choices may have 
been the culprit. These observations may go unnoticed in the aging human 
population. Taste responsivity reported by Rodin et al. (1976) and others is 
known to play a  major role in food choice. The novel flavor and the opioid 
effect of chocolate may contribute to increased intake and resulting body 
weight gain (Drewnowski et al., 1985).
A state of malnutrition can develop over time if this preference 
dominates to the exclusion of more nutritious foods. The aging female who 
lives alone may prefer the convenience and taste of sweet, fat and chocolate 
snack foods over more nutritious food choices that may be more labor intense 
to prepare but physiologically devastating to bone loss, cardiovascular health 
and obesity. A potential positive outcome of macronutrient selection was 
shown in the increased choice of protein in the H treated animals compared to 
S. This effect may be a  positive influence in the anemic postm enopausal 
female with break-through bleeding. If the protein is consumed a s  red meat 
she will consum e heme iron which will help to combat anemia. This research 
indicates that food choices may be affected by female sex hormones.
Empirically, body weight is different in the younger a s  opposed to the 
older human (Epstein, et. al., 1995). Lifestyles, intensity of exercise, and 
hormonal levels change with advancing years. The female sex horm ones 
naturally produced in the human body cannot be duplicated in content or in 
metabolic physiological effects. Exogenous female sex hormones may provide
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a  supplement that will provide cardioprotection, protect against bone loss and 
improve the quality of life in females in this century and beyond. This is an 
opportunity not afforded to our grandmothers.
The changes in caloric conversion ratios reflect what could be 
happening in the human population. Body weight may be easier to maintain 
with endogenous hormones production a s  observed in the normally cycling S. 
Ovariectomy without supplemental hormones may produce added body 
weight as observed in the OV treated animals. After m enopause or surgical 
removal of the ovaries, estrogen and E&P may help keep body weight at lower 
levels. Progesterone may create additional body weight that the body seeks 
(successfully temporally but unsuccessfully under the influence of poor 
nutrition) to lower through endogenous mechanisms not yet known.
The segm ent of the female population which motivated this research 
question is the female who reports additional cravings for chocolate during the 
luteal phase of the menstrual cycle when progesterone levels are elevated, 
the female taking oral contraceptives, and the postmenopausal female taking 
exogenous female sex hormones (Salhanic et., al.,1969). The progesterone 
treatment group tried to recover from the abrupt weight gain in Phase I. In 
phase II with essentially the sam e caloric intake the body changed the ratio at 
which calories were converted into body weight and the rate of gain was 
dramatically decreased. This looked hopeful, and yet under the influence of 
chocolate (a model for a  poor nutritional choice), an unbalanced diet (termed 
poor nutrition), body weight crept back up and caloric conversion ratios 
converted very efficiently into increased body weight gain.
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This pattern is also seen in the female in the human population. This is 
the physiological phenomonen which may have motivated the spending of the 
$33 billion dollars in weight loss reported by Dr. Richard Atkinson, current 
president of the Society for Clinical Nutrition (previously cited). Body weight 
increase is a  major problem in our country. Despite the difficulties with 
treatment, Dr. Xavier Pi-Sunyer current president of the North American 
Society for the Study of Obesity, reports that 25% of the men and 45% of 
women are trying to lose weight at any one time. And that one in three adults 
in the US is currently attempting to lose weight (Pi-Sunyer, 1995). The 
answ ers to control are not currently known.
According to this study, the effects of exogenous female sex horm ones 
on food intake and body weight gain in the aging female do not appear to 
contribute to the growing problem of obesity in this country. Typical regimes of 
hormone replacement (E or E&P) therapy do not produce increased body 
weight gain in the aging female rat. The perception that hormones cause  
excess body weight which would preclude the female from using HRT as  a 
preventive m easure against osteoporosis, cardiovascular disease and 
menopausal symptoms is not evident in these results. Hormonal effects on 
changes in caloric conversion ratios could indicate physiological and 
metabolic mechanisms which should be investigated in future research.
IMPLICATIONS FOR CLINICAL PRACTICE AND FUTURE RESEARCH
What do these results portend in terms of current body weight gain 
concepts reported across the television screens, popular press and taught in 
weight control clinics across the country? It may mean that there are metabolic 
regulators affecting body weight that go beyond merely counting calories. It
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may mean that during certain times of the month in the normally cycling 
female, or the aging postmenopausal female taking cyclical HRT, food intake 
is converted into body weight at different ratios. Or it may m ean that energy 
expenditure changes, or hormonally induced lethargy occurs or that a  totally 
different concept exists that has not yet been fully discovered and reported.
As this research applies to the female human population, it is the desire 
of this researcher to propose new individualized assessm ents of dosage  
levels of HRT to protect against osteoporosis, cardiovascular d isease and 
cancer. The risk assessm ents calculated with each female individually, based  
on her genetic predisposition to these d iseases prior to prescribing exogenous 
supplem ents seem s appropriate. She can then make decisions based on 
medical and scientific evidence. Negative symptoms of m enopause which 
impact compliance rates of HRT are typically not m easured in the human 
(Lemer, 1995). Further investigations are needed to m easure hormonal 
effects on macronutrient food choice, caloric regulation, chocolate intake and 
subsequent impacts on body weight and body composition in the human.
Additionally, of interest are current National Health and Nutrition 
Examination Survey (NHANES III) reports that show 31.3% of men and 34.7% 
of women were found to be obese. The percentages for those Americans 
under the poverty line are even worse. In addition the prevalence for obesity 
has doubled since 1900 and increased 30% from 1980 to 1990 (Pi-Sunyer, 
1995). There are those who would credit this national problem to decreased  
exercise and the “couch potato” syndrome. And yet, is there another 
unexplained hormonally influenced dimension which affects setpoint in body 
weight, causing calories to be converted into additional body weight at
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different ratios? One of those differences recently reported in Science termed 
the hypothesis "a chronobiological solution” to metabolic alterations that affect 
obesity and non-insulin dependent diabetes. The process involves “resetting" 
hormonal rhythms to treat illness (Roush, 1995).
We have shown hormonal differences in the rate at which caloric intake 
is converted into body weight. Is the presence or absence of estrogen the only 
reason? This question would follow: if abnormal differences are detected, 
how can corrections be made, and can the source of manipulation be 
eliminated? The intake of dietary fat is clearly not the total picture a s  many 
current nutritionists report. The answer involves more than “willpower.”
A recent answer to this question was revealed when researchers found 
that injections of the protein product of the mouse obesity gene caused both 
overweight and normal mice to lose weight. This new discovery called “leptin” 
is reported to provide dual action. It turns down the animals’ appetites and 
increases their energy use, causing them to bum more fat. The parallel to the 
recent research is that mice with the sam e diets, treated with leptin tost 50% 
more weight than did the untreated animals, suggesting that food intake alone 
did not account for the weight loss. Two answers were given, the protein 
reduces the lethargy (increases activity) and speeds slow metabolisms. 
(Halaas, et. al., 1995). If ovariectomy slows the metabolism and produces a 
lethargy resulting in increased body weight, does this indicate unreported 
potential production of leptin by the ovary? Could there be a  correlation 
between female sex hormones (estrogen and progesterone) and the rate at 
which the leptin is produced in the body. Does the prolactin hormone and 
resetting of chronological clocks play a role in the mechanisms of leptin and
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the way estrogen and progesterone affect body weight? The altering of 
circadian rhythms (which may impact all metabolic regulators) may be a 
solution to uncontrolled body weight gain, diabetes and other disease states 
(Roush, 1995). Clearly there are mechanisms which are currently active in the 
aging female rat that are not understood or reported.
Caloric regulation and eating patterns clearly need to be evaluated. Fat 
and protein intake may provide satiating factors that offset the uncontrolled 
consumption of highly refined, high carbohydrate snack foods. Total caloric 
intake a s  compared to the percentage of caloric intake derived from fat may be 
misinterpreted by many consumers. Increased dietary fat and protein levels in 
this study did not increase body weight proportionately. Rather, higher levels 
of carbohydrate intake were positively correlated to body weight gain and 
higher fat and protein intake to less body weight gain.
Why does the body choose to convert calories into body weight at 
different ratios? Is this evidence of the setpoint hypothesis? Is this system 
which has potentially worked well for centuries being altered by exogenous 
progestins, estrogens, m enopause or endogenous progesterone, which could 
cause  setpoint to be altered in unexpected, unpredicted and undesirable 
ways? Is all of this the result of a  biological “survival of the species” which 
provides additional energy during the luteal phase when the body is 
potentially preparing to support new life? This study contributes new 
information in an aging model into the investigation of female body weight 
gain, which will hopefully provide a  basis for more extensive investigation in 
the future and provide further information to this perplexing question. In clinics
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and future research studies that involve the aging female the following 
implications should be considered:
1. The hormonal phase (endogenous levels) in the normally cycling 
female may affect food intake and body weight data, and should 
therefore be measured and documented in all future research 
studies.
2. The postmenopausal woman could em erge a s  the model for 
examining female health parameters. The female postbreeder rat 
can provide preliminary data in a controlled environment.
3. There may be metabolic differences in the way calories are 
converted into body weight, which may be affected by both 
endogenous and exogenous female sex hormones.
4. Eating behavior, food choices and caloric regulation may be affected 
by endogenous and exogenous female sex hormones. Higher 
protein intake in the postmenopausal female with breakthrough 
bleeding can be of value if she is deficient in heme iron and 
consum es red meat.
5. Postmenopausal women on hormone replacement therapy may 
experience different caloric conversion ratios depending upon the 
nature, combination and dosage of the exogenous female sex 
hormones. Progesterone caused early higher rate of body weight 
gain which decreased with time. Therefore at the onset of 
m enopause or immediately following surgery when body weight 
gain most often occurs, progesterone should be prescribed in 
minimal dosages known to be protective against cancer.
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6. Various levels and sources of exogenous hormones in addition to 
various levels of endogenous female sex hormones may affect food 
intake and body weight and should therefore be monitored. 
Dosages should be individualized based on risk assessm ent ratios.
7. Body weight changes in menopause may occur a s  the estrogen pool 
declines. In the future, perimenopausal females could suppress 
midlife body weight gain by beginning HRT earlier.
8. New research is needed to "reset” the setpoint when stress, genetic 
or environmental factors violate or disturb this hypothesized 
metabolic mechanism (Roush, 1995).
9. Further research is needed to examine the effects of hormone 
replacement therapy on cardiovascular disease, cancer, diabetes 
mellitus and other related d iseases in the postmenopausal woman.
10. In the aging female model the absence of HRT with access to novel 
food choices and chocolate (with or without HRT) contributed most to 
body weight gain. The data from the present study indicate that 
hormone replacement therapy in levels typically prescribed to deter 
m enopausal conditions in midlife do not necessarily contribute to 
additional body weight gain.
The larger question encompassing all previously discussed param eters 
is: what determines body weight fluctuations? Body weight gain in
m enopause a s  it relates to hormonal profiles has been implied. This research 
does not agree with earlier findings in the younger rat model which show 
additional food intake resulting in additional body weight gain and a 
progesterone effect with an accompanying increase in percent body fat stores.
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A recent commentary on classics in obesity by Dr. George Bray (1995) 
examines the possibility that human beings might defy the first law of 
thermodynamics (termed “Luxuskonsumption") by being more of less efficient 
in the conversion of calories into body weight. In the early 1900’s male 
scientists studied the concept carefully using themselves a s  subjects with 
careful feeding and recording of body weight with differing results. Additional 
and more current studies show a  linear relationship in the degree of weight 
gain of overfeeding both male and female subjects (Forbes, et al.t 1986). 
However, the m easurement of endogenous female hormone levels, age and 
time is not evident in the reported results. These param eters may affect energy 
expenditure reported by Leibel et. al. (1995) and sympathetic activity 
modulating to variable degrees the nutrient partitioning between carbohydrate 
storage and metabolism and protein storage and catabolism with fat storage 
being the pathway consuming the residual surplus energy (Bray, 1995). This 
current research in the hormonal effects in the postbreeder female rat, reveals 
that these param eters should be m easured and documented in future 
research. Another analysis of “Luxuskonsumption” in the human female 
should be conducted to report documented hormonal effects.
The highly refined carbohydrate diet that is advertised and marketed so
t
convincingly across the globe is the sam e product that Dr. Paula Geiselman 
stated in 1987 would stimulate appetite. If the postbreeder female rat is a 
model that parallels what could be happening in the postm enopausal female, 
this research documents her findings. Highly refined carbohydrate foods may 
stimulate body weight gain and possibly appetite. The wide spread pattern of 
excess food consumption in a population motivated by convenience may
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contribute to the increase in insulin resistance and body weight gain. Satiety 
may not be achieved at the sam e level a s  with fat. The population consuming 
highly refined carbohydrate diets deficient in nutritious satiating foods with 
resulting obesity, should be further investigated. The increase in Type II 
diabetes and insulin resistance in this country with regard to the consumption 
of highly refined carbohydrate diets is a  growing concern. The question is: is a 
calorie a calorie in all physiological anatomical states. Is a calorie a  calorie 
with all foods or do some macronutrients convert at different rates? Age, 
surgical implications, metabolic mechanisms and hormonal effects on eating 
behavior may reach beyond the female taking exogenous female sex 
hormones.
Data from the recent PEPI trial and the Women’s  Health Initiative to be 
completed in the year 2005 (Healy, 1993) may provide new evidence to 
correlate current research findings in the human female. Perhaps this research 
can provide a small glimpse into what has been termed a major health 
problem, the uncontrolled increase of body weight in this country in a  growing 
segm ent of the population. The larger segm ent of the population who maintain 
healthy life style patterns should be commended.
The effects of exogenous female sex hormones on food intake and 
body weight gain in the aging female do not appear to contribute to the 
growing problem of obesity in this country. Genetic and environmental 
influences on hormonal effects of changes in caloric conversion ratios (also 
termed luxuskonsumption) indicate physiological and metabolic m echanism s 
which should be investigated in future research.
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APPENDIX A PHASE I 
Phase I ANOVA(4-groups) Body weight
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Treatment 3 2952.500 984.167 9.240 .0001
Residual 39 4154.012 106.513
Dependent: Body Weight
P h ase  I ANOVA(4-groups) Body W eight %
Dependent: Wt % Ph1
Xj£jg<HII Sum s of S q u a res  ^ Sum of Squares Mean Square F-Value P-Value
| Treatment 3 373.914 124.638 8.779 .0001
| Residual 39 553.702 14.197
Phase I ANOVA(4-groups) Body WEIGHT %
Ovariec vs Hormones 
Effect: Treatment 
Dependent: Wt % Phi
Cell Weight
Estrogen vs No Estrogen 
Effect: Treatment 
Dependent: Wt % Ph1
Cell Weight
Ovariec 1.000 - Ovariec -.500
Ovar-E&P -.333 Ovar-E&P .500
Ovar-E -.333 Ovar-E .500
Ovar-P -.333 Ovar-P -.500
df 1
Sum of Squares 77.228 
Mean Square 77.228 
F-Value 5.440 
P-Value .0249
df 1
Sum of Squares 328.988 
Mean Square 328.988 
F-Value 23.172 
P-Value .0001
192
193
Phase I ANOVA(2x2 Factorial) Body weight
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 2562.836 2562.836 24.061 .0001
Progesterone 1 353.567 353.567 3.319 .0761
Estrogen * Progesterone 1 69.583 69.583 .653 .4238
Residual 39 4154.012 106.513
Dependent: Body Weight
ANOVA fo r  I n i t i a l  Body Wt
Type III Sums of Squares
Source df Sum of Squares Mean Squar e F-Value P-Value
Treatment 4 2223.235 555.809 1.056 .3881
Residual 50 26318.111 526.362
P h ase  I ANOVA(2x2 Factorial) Total C alories
Dependent: Total Calories
Type III Sums of Squares „ „ „  _ w , „ W1Source df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 83624.884 83624.884 3.949 .0540
Progesterone 1 4910.826 4910.826 .232 .6328
Estrogen * Progesterone 1 14382.587 14382.587 .679 .4149
Residual 39 825891.562 21176.707
P h ase  I ANOVA(4-groups) Caloric Conversion
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Treatment 3 3059.814 1019.938 8.740 .0001
Residual 39 4551.407 116.703
Dependent: Caloric Conversion
194
P hase I ANOVA (4-groups) Caloric Conversion
Ovariec va Hormones 
Effect: Treatment 
Dependent: Feed Efficiency
Cell Weight
df 1
Sum of Squares 665.768 
Mean Square 665.768 
F-Vatue 5.705 
P-Value .0219
Estrogen vs No Estrogen 
Effect: Treatment 
Dependent: Feed Efficiency
Cell Weight
C-Ovariec 1.000 C-Ovariec -.500
E-Ovar-E&P -.333 E-Ovar-E&P .500
D-Ovar-E -.333 D-Ovar-E .500
F-Ovar-P -.333 F-Ovar-P -.500
df 1
Sum of Squares 2713.328 
Mean Square 2713.328 
F-Value 23.250 
P-Value .0001
Phase I ANOVA(2x2 Factorial) Caloric Conversion
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 2713.328 2713.328 23.250 .0001
Progesterone 1 275.162 275.162 2.358 .1327
Estrogen * Progesterone 1 104.109 104.109 .892 .3507
Residual 39 4551.407 116.703
Dependent: Feed efficiency
P h ase  I ANOVA(2x2 Factorial) Fat
Dependent: FatType III 
Sum s of S q u a res
Source  df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 1370.862 1370.862 .065 .7999
Progesterone 1 110195.286 110195.286 5.237 .0276
Estrogen * Progesterone 1 9949.363 9949.363 .473 .4958
Residual 39 820674.081 21042.925
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Phase I ANOVA(2x2 Factorial) CHO
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 192654.016 192654.816 10.274 .0027
Progesterone 1 92706.323 92706.323 4.944 .0320
Estrogen * Progesterone 1 13725.693 13725.693 .732 .3975
Residual 39 731325.542 18751.937
Dependent: Carbohydrate
APPENDIX B PHASE II
Phase II ANOVA(5-groups) Body Weight
Type III Sums of Squares
Source _____________  df Sum of Squares Mean Square F-Value P-Value
TREATMENT 4 937.331 234.333 3.795 .0090
Residual 50 3087.778 61.756
Dependent: BODY WT
Phase II ANOVA(5-groups) Body Weight %
Type III Sums of Squares
Source______________________ df Sum ol Squares Mean Square F-Value P-Value
Treatment 4 111.394 27.848 3.576 .0122
Residual 50 389.412 7.788
Dependent: Wt % Ph2
P hase II ANOVA (5-groups) Body Weight %
Ovar vs Hormones 
Effect: Treatment 
Dependent: Wt % Ph2
Cell Weight
Prog vs No Prog 
Effect: Treatment 
Dependent: Wt % Ph2
Cell Weight
Ovariec 1.000 Ovariec -.500
Ovar-E&P -.333 Ovar-E&P .500
Ovar-E -.333 Ovar-E -.500
Ovar-P -.333 Ovar-P .500
df
Sum of Squares 
Mean Square 
F-Value 
P-Value
1
82.507
82.507 
10.594 
.0020
df
Sum of Squares 
Mean Square 
F-Value 
P-Value
1
67.785
67.785 
8.703 
.0048
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Phase II ANOVA(2x2 Factorial) Body weight
Type III Sums of Squares
Source______________________ df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 152.253 152.253 2.461 .1233
Progesterone 1 507.751 507.751 8.274 .0065
Estrogen * Progesterone 1 184.751 184.751 3.011 .0906
Residual 39 2393.278 61.366
Dependent: Body-WT
Phase II AN0VA(5-groups) Total Calories
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
TREATMENT 4 476458.703 119114.676 6.501 .0003
Residual 50 916171.149 18323.423
Dependent: TOTAL-CAL
Phase II ANOVA(2x2 Factorial) Caloric Conversion
Type III Sums of Squares
Source  df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 108.027 108.027 1.598 .2137
Progesterone 1 501.476 501.476 7.416 .0096
Est r ogen * Pr ogest er one 1 211.395 211.395 3.126 .0849
Residual 39 2637.060 67.617
Dependent: Caloric Conversion
Phase II ANOVA(2x2 Factorial) Protein
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 1344.946 1344.946 1.584 .2156
Progesterone 1 216.557 216.557 .255 .6163
Estrogen * Progesterone 1 16958.511 16958.511 19.979 .0001
Residual 39 33104.202 848.826
Dependent: Protein
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Phase II ANOVA(2x2 Factorial) CHO(SW&NSW)
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 216089.292 218089.292 10.259 .0027
Progesterone 1 53816,213 53616.213 2.532 .1197
Estrogen * Progesterone 1 35135.194 35135.194 1.653 .2062
Residual 39 829046.029 21257.590
Dependent: Total-CHO
Phase II ANOVA(2x2 Factorial) CHO/NSW
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 149382.849 149382.849 9.582 .0036
Progesterone 1 20846.903 20846.903 1.337 .2546
Estrogen * Progesterone 1 8779.832 8779.832 .563 .4575
Residual 39 608000.548 15589.758
Dependent: CHO/NSW
Phase II ANOVA(2x2 Factorial) CHO/SW
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 6480.634 6480.634 .832 .3674
Progesterone 1 7673.502 7673.502 .985 .3271
Estrogen * Progesterone 1 79042.356 79042.356 10.144 .0028
Residual 39 303888.087 7792.002
Dependent: CHO/SW
APPENDIX C PHA SE III 
Phase III ANOVA(5-groups) Body Weight
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Treatment 4 4744.030 1186.008 12.048 .0001
Residual 50 4921.970 98.439
Dependent: Ph3 Body Wt
Phase III ANOVA(5-groups) Body Weight %
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Treatment 4 567.626 141.907 12.905 .0001
Residual 50 549.802 10.996
Dependent: Wt % Ph3
Phase III ANOVA (5 groups) body weight %
Sham vs Hormone 
Effect: Treatment 
Dependent: Wt % Ph3
SHAM
Ovar-E&P
Ovar-E
Ovar-P
df 1
Sum of Squares 558.094 
Mean Square 558.094 
F-Value 50.754 
P-Value .0001
Phase III ANOVA(5-groups) Total Calories
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Treatment 4 733829.624 183457.406 9.161 .0001
Residual 50 1001249.381 20024.988
Dependent: Ph3 Total Cal
Cell Weight 
1.000 
-.333  
-.333  
-.333
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Phase III ANOVA(2x2 Factorial) Protein
Type III Sums of Squares
Source______________________ df Sum of Squares Mean Square_____ F-Value P-Value
Estrogen 1 444.814 444.814 .291 .5924
Progesterone 1 785.464 785.464 .515 .4774
Estrogen * Progesterone 1 10557.041 10557.041 6.916 .0122
Residual 39 59533.528 1526.501
Dependent: PROTEIN
Phase III ANOVA(2x2 Factorial) HF/LS
Type III Sums of Squares
Source______________________ df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 102.879 102.879 .104 .7494
Progesterone 1 6306.571 6306.571 6.345 .0160
Estrogen * Progesterone 1 2416.334 2416.334 2.431 .1270
Residual 39 38765.961 993.999
Dependent: HF/LS
APPENDIX D TOTAL STUDY
All Phases ANOVA(4-groups) Body Weight
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Treatment 3 3358.855 1119.618 3.849 .0166
Residual 39 11343.087 290.848
Dependent: Total Weight
All P hases ANOVA(4-groups) Body Weight
Ovariec vs Hormones 
Effect: Treatment 
Dependent: Total Weight
Cell Weight
Estrogen vs No Estrogen 
Effect: Treatment 
Dependent: Total Weight
Cell Weight
Ovariec 1.000 Ovariec -.500
Ovar-E&P -.333 Ovar-E&P .500
Ovar-E -.3 3 3 Ovar-E .500
Ovar-P -.333 Ovar-P -.500
df 1
Sum of Squares 1495.316 
Mean Square 1495.316 
F-Value 5.141 
P-Value .0290
df 1
Sum of Squares 3199.449 
Mean Square 3199.449 
F-Value 11.000 
P-Value .0020
ALL PHASES ANOVA (4 GROUPS) BODY WEIGHT%
Ovariec vs Hormones 
Effect: Treatment 
Dependent: TotlWt %
Cell Weight
Estrogen vs No Estrogen 
Effect: Treatment 
Dependent: TotlWt %
Cell Weight
Ovariec 1.000 Ovariec -.500
Ovar-E&P -.333 Ovar-E&P .500
Ovar-E -.333 Ovar-E .500
Ovar-P -.333 Ovar-P -.500
df 1
Sum of Squares 221.496 
Mean Square 221.496 
F-Value 5.311 
P-Value .0266
df 1
Sum of Squares 352.782 
Mean Square 352.782 
F-Value 8.459 
P-Value .0060
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All Phases ANOVA(2x2 Factorial) Total Body weight 
Type III Sums of Squares
Source______________________ df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 3579.215 3579.215 12.656 .0010
Progesterone 1 18.766 18.766 .066 .7981
Estrogen * Progesterone 1 99.631 99.631 .352 .5562
Residual 39 11029.767 282.815
Dependent: Total Weight
All Phases ANOVA(4-groups) Caloric Conversion
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Treatment 3 289.708 96.569 2.704 .0585
Residual 39 1392.639 35.709
Dependent: Feed Efficiency
ALL P hases ANOVA (4-groups) Caloric Conversion
Estrogen vs No Estrogen 
Effect: Treatment 
Dependent: Feed Efficiency
Ovariec
Ovar-E&P
Ovar-E
Ovar-P
df 1
Sum of Squares 281.835 
Mean Square 281.835 
F-Value 7.893 
P-Value .0077
Cell Weight 
- .500  
.500 
.500 
-.500
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All Phases ANOVA(2x2 Factorial) Caloric Conversion
Type III Sums of Squares
Source  df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 326.781 326.781 9.421 .0039
Progesterone 1 .072 .072 .002 .9639
Estrogen * Progesterone 1 2.645 2.645 .076 .7839
Residual 39 1352.763 34.666
Dependent: Feed Efficiency
All Phases ANOVA(4-groups) Total Protein
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Treatment 3 137560.651 45853.550 4.764 .0063
Residual 39 375344.564 9624.220
Dependent: Total Pro
Scheffe's S 
Effect: Treatment 
Dependent: Total Pro 
Significance level: .05
Vs.
Ovar-P
Ovar-E
Ovariec
Diff. Crit. diff. P-Value
Ovar-E 22.145 125.228 .9657
Ovariec 85.519 128.175 .2992
Ovar-E&P 141.865 122.719 .0175
Ovariec 63.374 125.228 .5411
Ovar-E&P 119.720 119.637 .0498
Ovar-E&P 56.346 122.719 .6190
S = Significantly different at this level.
All Phases ANOVA(2x2 Factorial) Total Protein
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 7417.964 7417.964 .700 .4078
Progesterone 1 1775.098 1775.098 .168 .6845
Estrogen * Progesterone 1 85279.127 85279.127 8.052 .0072
Residual 39 413074.880 10591.664
Dependent: Total Pro
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All Phases ANOVA(4-groups) Total CHO
Type III Sums of Squares
Source______________________ df Sum of Squares Mean Square F*Value P-Value
Treatment 3 1259774.125 419924.708 3.438 .0260
Residual 39 4763878.096 122150.720
Dependent: Total CHO
ALL PHASES ANOVA (4-groups) Total CHO
Ovariec vs Hormones 
Effect: Treatment 
Dependent: Total CHO
Cell Weight
Estrogen vs No Estrogen 
Effect: Treatment 
Dependent: Total CHO
Cell Weight
Ovariec 1.000 Ovariec -.500
Ovar-E&P -.333 Ovar-E&P .500
Ovar-E -.333 Ovar-E .500
Ovar-P -.333 Ovar-P -.500
df
Sum of Squares 
Mean Square 
F-Value 
P-Value
1
1036668.197
1036668.197 
8 .487  
.0059
df
Sum of Squares 
Mean Square 
F-Value 
P-Value
1
921529.914
921529.914 
7 .544 
.0091
All Phases ANOVA(2x2 Factorial) Total CHO
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 1259595.510 1259595.510 10.870 .0021
Progesterone 1 154576.336 154576.336 1.334 .2551
Estrogen * Progesterone 1 48634.523 48634.523 .420 .5209
Residual 39 4519195.579 115876.810
Dependent: Total CHO
APPENDIX E POST MORTEM
ANOVA(4-groups): Progesterone
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
TREAT 3 1437.465 479.155 3.304 .0304
Residual 38 5510.928 145.024
Dependent: PROG 
ANOVA (4-GROUPS): TESTOSTERONE
Progest vs No Progest 
Effect: TREAT 
Dependent: TEST
C-Ovariec
E-Ovar-E&P
D-Ovar-E
F-Ovar-P
df 1
Sum of Squares 2 .094 
Mean Square 2 .094 
F-Value 4.063 
P-Value .0508
ANOVA(4-groups): Wt of Uterus
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Treatment 3 1.053 .351 17.710 .0001
Residual 39 .773 .020
Dependent: Wt of Uterus
Cell Weight 
- .500  
.500 
-.500  
.500
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Scheffe's S 
Effect: Treatment 
Dependent: Wt of Uterus 
Significance level: .05
Vs. Diff. Crit. diff. P-Value
C-Ovariec
F-Ovar-P
E-Ovar-E&P
F-Ovar-P .160 .184 .1092
E-Ovar-E&P .372 .176 .0001
D-Ovar-E .376 .180 .0001
E-Ovar-E&P .212 .176 .0123
D-Ovar-E .216 .180 .0125
D-Ovar-E .004 .172 .9999
S
S
S
S
S = Significantly different at this level.
ANOVA (4-GROUPS) WT OF UTERUS
Ovariec vs Hormones 
Effect: Treatment 
Dependent: Wt of Uterus
Cell Weight
Estrogen vs No Estrogen 
Effect: Treatment 
Dependent: Wt of Uterus
Cell Weight
C-Ovariec 1.000 C-Ovarlec -.500
E-Ovar-E&P -.333 E-Ovar-E&P .500
D-Ovar-E -.333 D-Ovar-E .500
F-Ovar-P -.333 F-Ovar-P -.500
df
Sum of Squares 
Mean Square 
F-Value 
P-Value
1
.703
.703
35.443
.0001
df
Sum of Squares 
Mean Square 
F-Value 
P-Value
1
.925
.925
46.656
.0001
ANOVA(2x2 Factorial): Wt of Uterus
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 .925 .925 46.656 .0001
Progesterone 1 .072 .072 3.626 .0643
Estrogen * Progesterone 1 .065 .065 3.279 .0779
Residual 39 .773 .020
Dependent: Wt of Uterus
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ANOVA(2x2 Factorial): Fat % of Liver
Type III Sums of Squares
Source df Sum of Squa... Mean Squa... F-Value P-Value
Estrogen 1 4.955 4.955 6.310 .0163
Progesterone 1 .083 .083 .105 .7471
Estrogen * Progestero... 1 .267 '.267 .340 .5634
Residual 39 30.625 .785
Dependent: %FAT OF LIVER
ANOVA(2x2 Factorial): Weight/Length ratio
Type III Sums of Squares
Source  df Sum of Squares Mean Square F-Value P-Value
Estrogen 1 17.434 17.434 8.577 .0057
Progesterone 1 .651 .651 .320 .5748
Estrogen * Progesterone 1 .487 .487 .240 .6272
Residual 39 79.277 2.033
Dependent: W/L ratio
APPENDIX F SUMMARY FIGURES
Phase I Weight Gain and Total Caloric Intake
3 0 i
| □  Total calories (x100) BBody Weight (g)
Figure 1.0 Phase I Weight Gain and Total Caloric Intake 
Treatment: 1. Sham, 2, No hormone, 3. Estrogen, 4. Estrogen and 
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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Phase I Carbohydrate, Fat, Protein Intake
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Figure 2.0 Phase I Carbohydrate, Fat, Protein Intake
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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Phase I % Fat Intake
60
1 2 3 4 5
Figure 3.0 Phase I % Fat Intake
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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Phase I Caloric Conversion Ratio
Figure 4.0 Phase I Caloric Conversion Ratio
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized
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Phase II: Total Caloric Intake and Body Weight Gain
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Figure 5.0 Phase II: Total Caloric Intake and Body Weight Gain 
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and 
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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Phase II Macronutrient Food Choices in kcal
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Figure 6.0 Phase II Macronutrient Food Choices in kcal
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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Phase II Caloric Conversion Ratio
Figure 7.0 Phase II Caloric Conversion Ratio
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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P h ase  III: Total C alories and  Body W eight
1 2 3 4 5
□ Total C alories (x100) H Body Weight
Figure 8.0 Phase III: Total Calories and Body Weight
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized
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Phase III: Macronutrient Composition and Chocolate 
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Figure 9.0 Phase III: Macronutrient Composition and Chocolate Intake 
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and 
Progesterone, 5. Progesterone. 2-5 were ovariectomized. Sham was not 
given chocolate sources.
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Phase III: Caloric Conversion Ratio
Figure 10.0 Phase III: Caloric Conversion Ratio
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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Total Study: Caloric Intake and Body Weight Gain
□ Caloric Intake X 100 h Body Wt. Gain (g)
Figure 11.0 Total study: Caloric Intake and Body Weight Gain 
Treatment 1. Sham, 2. Estrogen, 3. Estrogen with Progesterone, 4. 
Progesterone only, 5. Ovariectomized with no hormone. 2-5 were 
ovariectomized. Grams of body weight increase compared to caloric intake.
Group
Sham
Estrogen
Estrogen & Prog.
Progesterone
Ovariectomized
Grams consumed 
2184+69 
2493 ±83 
2650±93 
2743±100 
2794±144
Body Weight Gained (g):
27.3±4.3
39.9±5.19
44.63.19
57.7±5.96
61.4±6.54
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Total Study: Caloric Conversion Ratio
2 5
Figure 12.0 Total Study: Caloric Conversion Ratio
Treatment: 1. Sham (12), 2. No hormone (21) 3. Estrogen (15), 4. Estrogen
and Progesterone(16), 5. Progesterone (20). 2-5 were ovariectomized.
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Body W eight Increase  Over 3 P h ase s
□ Phase I Q Phase II □ Phase III
Figure 13.0 Body weight increases over three phases
Treatment: 1 Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone, 2-5 were ovariectomized.
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Total Study: Percent of Total Caloric Intake: 
Fat, Carbohydrate and Protein
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Figure 14.0 Total Study: Percent of total caloric intake: fat, carbohydrate, 
and protein
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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Total C aloric Intake over 3 P h ase s
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Figure 15.0 Total caloric intake over 3 phases
Treatment: 1 Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone, 2-5 were ovariectomized.
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Total Study Total Caloric Intake
3 0 0 0 i
2 5 0  0 *
■ P rote I n n a -O  o CHO/NSW B CHO/SW ■ H F/LS
■ LF/LS HLF/HS o HF/HS □ Fat
Figure 16.0 Total Study Total Caloric Intake 
Treatment: 1 Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone, 2-5 were ovariectomized. Macronutrient 
profile for macronutrients and chocolate choices.
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Body W eight Gain of Total S tudy
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Figure 17.0 Body weight gain of total study
Line graph of variation of 30 day, body weight gain. Phase I data starts on day 
I, Phase II data starts on 11, Phase III data starts on day 21.
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